WO2004111014A1 - Pyrimidine derivatives as modulators of atp-binding cassette transporters - Google Patents

Pyrimidine derivatives as modulators of atp-binding cassette transporters Download PDF

Info

Publication number
WO2004111014A1
WO2004111014A1 PCT/US2004/017673 US2004017673W WO2004111014A1 WO 2004111014 A1 WO2004111014 A1 WO 2004111014A1 US 2004017673 W US2004017673 W US 2004017673W WO 2004111014 A1 WO2004111014 A1 WO 2004111014A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
independently
optionally
ring
conr
Prior art date
Application number
PCT/US2004/017673
Other languages
French (fr)
Inventor
Lewis R. Makings
Ashvani K. Singh
Mark T. Miller
Sarah S. Hadida Ruah
Peter Grootenhuis
Matthew Hamilton
Anna R. Hazelwood
Liming Huang
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to AT04754303T priority Critical patent/ATE440825T1/en
Priority to DE602004022819T priority patent/DE602004022819D1/en
Priority to EP04754303A priority patent/EP1646615B1/en
Priority to US10/862,909 priority patent/US8642609B2/en
Publication of WO2004111014A1 publication Critical patent/WO2004111014A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to modulators of ATP-Binding Cassette
  • ABC Cystic Fibrosis Transmembrane Regulator
  • CFTR Cystic Fibrosis Transmembrane Regulator
  • ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions.
  • ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities.
  • Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents.
  • MRPl multidrug resistance protein
  • 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
  • ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
  • CFTR cAMP/ATP-mediated anion channel
  • CFTR is expressed in a variety of cells types, including absorptive and secratory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + -ATPaSe pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • COPD chronic obstructive pulmonary disease
  • COPD dry eye disease
  • Sjogren's Syndrome a chronic obstructive pulmonary disease
  • COPD is characterized by airflow limitation that is progressive and not fully reversible. The airflow limitation is due to mucus hypersecretion, emphysema, and bronchiolitis.
  • Activators of mutant or wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD.
  • Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles.
  • causes of dry eye include age, Lasik eye surgery, arthritis, medications, chemical/thermal burns, allergies, and diseases, such as Cystic Fibrosis and Sjogrens's syndrome.
  • CFTR CFTR Activated corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease.
  • Sjogrens's syndrome is an autoimmune disease in which the immune system attacks moisture- producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
  • ⁇ F508-CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane.
  • insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced.
  • this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery has been shown to be the underlying basis not only for CF disease, but for a wide range of other isolated and inherited diseases.
  • the diseases associated with the first class of ER malfunction are Cystic fibrosis (due to misfolded ⁇ F508-CFTR as discussed above), Hereditary emphysema (due to al- antitrypsin; non Piz variants), Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses (due to Lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ - Hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), Polyendoc
  • the diseases associated with the latter class of ER malfunction are Glycanosis, CDG type 1, Hereditary emphysema (due to ⁇ l-Antitrypsin (PiZ variant), Congenital hyperthyroidism, Osteogenesis imperfecta (due to Type I, II, IV procollagen), Hereditary hypofibrinogenemia (due to Fibrinogen), ACT deficiency (due to ⁇ l-Antichymotrypsin), Diabetes insipidus (DI), Neurophyseal DI (due to Vasopvessin hormone/V2-receptor), Neprogenic DI (due to Aquaporin II), Charcot-Marie Tooth syndrome (due to Peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy,
  • CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport.
  • the mechanism involves elevation of cAMP and stimulation of CFTR.
  • Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
  • Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
  • ETEC enterotoxogenic E-coli
  • Common viral causes of diarrhea include rotavirus and coronavirus.
  • Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
  • Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease. [0021] Accordingly, there is a need for modulators of an ABC transporter activity, and compositions thereof, that can be used to modulate the activity of the ABC transporter in the cell membrane of a mammal.
  • These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1,
  • the present invention relates to compounds of formula I useful as modulators of ABC transporter activity:
  • G 1 0, -R A , -OR A , SR A , or NR A R B , wherein R A and R B are each independently V-R v , or R A and R B , taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -O-, -NR'CONR'-, -OCONR'-, -NR 1 NR', -NR'NR'CO-, -NR 1 CO
  • R 1 is absent or is Y-R ⁇ ;
  • Y is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO 2 -, -NR-, -SO 2 NR-, or -NRSO 2 -, and each occurrence of R ⁇ is independently R 5 , OR', SR', N(R 5 ) 2 , halogen, NO 2 , or CN, provided that when R 1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C 1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C 1- C 8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 hetero
  • R 2 and R 3 are each independently halogen or -T-R z , or R 2 and R 3 , taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R 2 and R 3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-R x , wherein x is O- 5;
  • T is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, -NRSO 2 -, -NRSO 2 NR-, and each occurrence of R z is independently R', halogen, NO 2 , or CN;
  • Q is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of Q are optionally and independnetly replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, -NRSO 2 -, -NRSO 2 NR-, and each occurrence of R x is independently R', halogen, NO 2 , or CN; L is G 2 -B-G 3 -Ar ⁇ wherein G 2 is absent, an optionally substituted Ci-C 6 alkylidene chain, or a C 3 -C 6 spiro
  • G 3 is absent or an optionally substituted Ci-C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO 2- , -NR'-, N(SO 2 R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R';
  • B is absent or is an optionally substituted C 6-I o aryl > a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a Ci-C 6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO 2- , -NR'-, -N(SO 2 R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ; and
  • Ar 1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar 1 is optionally substituted with m independent occurrences of WR W , wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C 6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -
  • G 1 0, -R A , -OR A , SR A , or NR A R B , wherein R A and R B are each independently V-R v , or R A and R B , taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 1 CO 2 -, -O-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-,
  • R taken together with the nitrogen atom are optionally and independently substituted by q occurrences of U-R u , wherein q is 0-5, U is a bond or is an optionally substituted Ci-C 6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, -NR 5 SO 2 NR'-, and each occurrence of R u is independently R 5 , halogen, NO 2 , or CN;
  • R 1 is absent or is Y-R ⁇ ; wherein Y is a bond or is an optionally substituted Ci-C 6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO 2 -, -NR-, -SO 2 NR-, or -NRSO 2 -, and each occurrence of R ⁇ is independently R', OR', SR', N(R') 2 , halogen, NO 2 , or CN, provided that when R 1 is present, it is always bonded to the nitrogen atom thiough a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C 1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C 1- C 8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or
  • R 2 and R 3 are each independently halogen or -T-R z , or R 2 and R 3 , taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R 2 and R 3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-R x , wherein x is 0- 5;
  • T is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, -NRSO 2 -, -NRSO 2 NR-, and each occurrence of R z is independently R', halogen, NO 2 , or CN;
  • Q is a bond or is an optionally substituted CpC 6 alkylidene chain wherein up to two methylene units of Q are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -O-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, -NRSO 2 -, -NRSO 2 NR-, and each occurrence of R x is independently R', halogen, NO 2 , or CN; wherein G 2 is absent, an optionally substituted C 1 -C 6 alkylidene chain, or a C 3 -C 6 spirocycloalkylidene ring, wherein one or two m
  • G 3 is absent or an optionally substituted Ci-C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO 2- , -NR'-, N(SO 2 R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
  • B is absent or is an optionally substituted C 6-1O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C 1 -C 6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO 2- , -NR'-, -N(SO 2 R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
  • Ar 1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar 1 is optionally substituted with m independent occurrences of WR W , wherein m is 0-5 and W is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -O-, -NRCONR-, -OCONR-, -NRNR, -NRCO-, -NRCO-, -S-,
  • ABS-transporter as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro.
  • binding domain as used herein means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et al., J. Gen. Physiol. (1998): 111(3), 477-90.
  • CFTR cystic fibrosis transmembrane regulator or a mutation thereof capable of regulator activity, including, but not limited to, ⁇ F508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
  • modulating means increasing or decreasing by a measurable amount.
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 4O 0 C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” "cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-20 aliphatic carbon atoms.
  • aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms.
  • cycloaliphatic refers to a monocyclic C 3 -C 8 hydrocarbon or bicyclic C 8 -C 12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • heteroaliphatic means aliphatic groups wherein one or two carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon.
  • Heteroaliphatic groups may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include “heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, or “heterocyclic” groups.
  • heterocycle means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom.
  • the "heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.
  • haloalkyl means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • halogen means F, Cl, Br, or I.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxy alkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring”.
  • aryl also refers to heteroaryl ring systems as defined hereinbelow.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents.
  • Optional substituents on the aliphatic group of R° are selected from NH 2 , NH(C 1-4 aliphatic), N(Ci. 4 aliphatic) 2 , halogen, Ci -4 aliphatic, OH, O(Ci -4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (Ci -4 aliphatic), 0 ⁇ aIoC 1-4 aliphatic), or haloC 1-4 aliphatic, wherein each of the foregoing C 1-4 aliphatic groups of R° is unsubstituted.
  • Optional substituents on the aliphatic group of R * are selected from NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, Ci -4 aliphatic, OH, 0(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (Ci -4 aliphatic), O(halo C 1-4 aliphatic), or halo(Ci. 4 aliphatic), wherein each of the foregoing C 1-4 aliphatic groups of R * is unsubstituted.
  • Optional substituents on the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(Ci -4 aliphatic), N(Ci -4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, 0(Ci -4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (Ci -4 aliphatic), O(halo Ci -4 aliphatic), or halo(C 1-4 aliphatic), wherein each of the foregoing Ci -4 aliphatic groups of R + is unsubstituted.
  • alkylidene chain refers to a straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
  • spirocycloalkylidene refers to a carbocyclic ring that may be fully saturated or have one or more units of unsaturation and has two points of attachment from the same ring carbon atom to the rest of the molecule.
  • two independent occurrences of R 0 are taken together together with the atom(s) to which each variable is bound to form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Exemplary rings that are formed when two independent occurrences of R 0 (or R + , or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R 0 (or R + , or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R°) 2 , where both occurrences of R 0 are taken together with the nitrogen atom to form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R° (or R + , or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for example where a phenyl group is substituted with two occurrences of OR 0
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each, asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • G 1 0, -R A , - OR ⁇ , SR A , or NR A R B .
  • the bond between the nitrogen atom and C-G 1 can be a single or double bond (as represented by the dotted line), depending upon the G 1 substituent.
  • G 1 O
  • the bond between the nitrogen atom and the carbon atom of C-G 1 is a single bond, and thus R 1 will be present.
  • the present invention provides compounds having any one of the following general structures I- A, I-B, I-C, I-D and I- E, as depicted below.
  • compounds of the invention have the structure of general formula I-A. In other embodiments, compounds of the invention have the structure of general formula I-B. In yet other embodiments, compounds of the invention have the structure of general formula I-E. Or, compounds of the invention have the structure of general formula IC. Or, compounds of the invention have the structure of general formula IE.
  • R A and R B are each independently V-R v , or R A and R B , taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO 2 -, -NR'-, -S-, -SO,
  • R A and R B are optionally and independently substituted by q occurrences of U-R u , wherein q is 0-5, U is a bond or is an optionally substituted Ci-C 6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR 5 CO-, -S-, -SO, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, -NR 1 SO 2 NR 5 -, and each occurrence
  • R A and R B are each independently hydrogen, an optionally substituted d-Cgalkyl group, or V-R v , where V is as defined generally above, and R v is an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • R A and R B taken together with the nitrogen atom, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring.
  • R and R B are each independently hydrogen; an optionally substituted group selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or pentyl; an optionally substituted ring selected from:
  • R A and R B taken together are optionally substituted group selected from:
  • q is 0, 1, 2, or 3, and each occurrence of U-R u is independently hydrogen, R', -CH 2 R', halogen, CN, NO 2 , -N(R') 2 , -CH 2 N(R') 2 , -OR', -CH 2 OR', -SR', -CH 2 SR', -COOR', -NR'COR', -NR'COOR', -CON(R') 2 , -SO 2 N(R') 2 , - CONR'(CH 2 ) 2 N(R') 2 , -CONR(CH 2 ) 3 N(R') 2) -CONR'(CH 2 ) 4 N(R') 2 , -O(CH 2 ) 2 OR', O(CH 2 ) 3 OR', O(CH 2 ) 4 OR ⁇ -O(CH 2 ) 2 N(R') 2 , -O(CH 2 ) 2 OR', O(CH 2 )
  • q is 1, 2, or 3 and each occurrence of U-R u is independently F, Cl, Br, CN, -OH, -NH 2 , -CH 2 OH, -C r C 6 alkyl, -OtCi-Cealkyl), -CH 2 O(d-C 6 alkyl), -CO(C r C 6 alkyl), -COO(Ci-C 6 alkyl), -NHSO ⁇ CrQalkyl), -SO 2 NH 2 , -CONH 2 , -CON(CrC 6 alkyl), -SO 2 (C !
  • each of the foregoing phenyl, benzyl, and Cj-C 6 alkyl groups is independently and optionally substituted, and wherein each of the foregoing CrCealkyl groups is linear, branched, or cyclic.
  • R 1 is absent or is Y-R ⁇ ; wherein Y is a bond or is an optionally substituted C 1 -C 6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -O-, -NRCO-, -S-, -SO 2 -, -NR-, -SO 2 NR-, or -NRSO 2 -, and each occurrence of R ⁇ is independently R', OR', SR', N(R' ) 2 , halogen, NO 2 , or CN, provided that when R 1 is present, it is always bonded to the nitrogen atom through a carbon atom.
  • R 1 when R 1 is present, R 1 is Y-R ⁇ , wherein Y is an optionally substituted C 1 -C 4 alkylidene chain, wherein one or two non-adjacent methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO 2 -, - NR-, -SO 2 NR-, or -NRSO 2 -, and each occurrence of R ⁇ is independently R', OR', SR', N(R') 2 , halogen, NO 2 , or CN.
  • R 1 is optionally substituted d-C 4 alkyl.
  • R 1 is -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -(CH 2 ) 2 OR ⁇ - (CH 2 ) 3 OR ⁇ -(CH 2 ) 2 N(R') 2 , -(CH 2 ) 3 N(R') 2 , -(CH 2 ) 2 NRCOR' , or -(CH 2 ) 3 NRCOR' .
  • R 2 and R 3 are each independently -T-R z , or R 2 and R 3 , taken together, form an optionally substituted 5- or 6- membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R 2 and R 3 taken together is optionally substituted at one or more carbon atoms or one or more substituable nitrogen atoms with x independent occurrences of Q-R x , wherein x is 0-5.
  • R 2 and R 3 are each independently -T-R z .
  • R 2 and R 3 are each independently hydrogen, halogen, or an optionally substituted group selected from C 1-6 alkyl, aryl, aryl(C 1-6 )alkyl, -N(R') 2 , -CH 2 N(R') 2 , OR', -CH 2 OR', SR', - CH 2 SR', COOR', -NRCOR', -(CH 2 ) 2 N(R') 2 , -(CH 2 ) 2 OR ⁇ -(CH 2 ) 2 SR ⁇ -COR', -CON(R') 2 , SO 2 R', or -SO 2 N(R' ) 2 .
  • R 2 and R 3 are each independently H, Cl, Br, F, CF 3 , Me, Et, -COOH, NH 2 , -N(CH 3 ) 2 , -N(Et) 2 , -N(IPr) 2 , -O(CH 2 ) 2 OCH 3 , -CO(C r C 4 alkyl), - CONH 2 , -COOCH 3 , -OH, -CH 2 OH, -NHCOCH 3 , -SO 2 (C i-C 4 alkyl), -SO 2 NH 2 , -SO 2 N(CH 3 ) 2 , or an optionally substituted group selected from C 1-4 alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.
  • one or more hydrogen atoms on any substitutable nitrogen or carbon atom may optionally be substituted with one or more independent occurrences of Q-R x .
  • rings formed by R 2 and R 3 taken together are optionally substituted with x occurrences of Q-R x , wherein x is 0-5.
  • x is 0-4, and each occurrence of Q-R x , when present, is independently halogen, CN, NO 2 , or an optionally substituted group selected from Ci_ 4 alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, -N(R') 2 , -CH 2 N(R') 2> -OR', -CH 2 OR', -SR', -SO 2 R', -CH 2 SR', -COOR', -NRCOR', -C0N(R') 2 , or -S(O) 2 N(R') 2 .
  • each occurrence of Q-R x when present, is Cl, Br, F, CF 3 , methyl, ethyl, propyl, butyl, CN, -COOH, - N(CH 3 ) 2 , -N(Et) 2 , -N(JPr) 2 , -O(CH 2 ) 2 OCH 3 , -CONH 2 , -COOCH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , - OCH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CH 3 , -CH 2 OH, -NHCOCH 3 , -SO 2 NH 2 , or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl
  • G 2 and G 3 are each independently absent or an optionally substituted C 1 -C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with CO, CS, SO, SO 2 , NR', N(SO 2 R')-, N(COR')-, O, or S, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
  • G 2 is a Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -N(SO 2 R')-, N(COR')-, - O-, -S-, -CO-, -CS, or -SO 2 -, and wherein any hydrogen atom in the CrCsalkylidene chain is optionally and independently substituted with R'.
  • G 2 is -(C(R') 2 ) 1-3 -, - NR'-, -N(SO 2 R')-, N(COR')-, -C(R') 2 NR ⁇ or -NR'C(R') 2 -.
  • G 2 is - CHR', wherein R' is hydrogen, or optionally substituted Ci-C 4 alkyl.
  • G 2 is selected from CH 2 , CH(CH 3 ), CH(CH 2 -CH 3 ), CH(CH 2 CH 2 CH 3 ), or C(CH 3 ) 2 .
  • G 2 is CH(CH 3 ).
  • G 2 is absent.
  • G 2 is a C 3 -C 6 spirocycloalkylidene ring. In such a ring, one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO 2- , -NR'-, N(SO 2 R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
  • G 2 is spirocycloalkyl, spirocyclopentyl, or spirocyclohexyl.
  • G 2 is a C 3 -C 6 spirocycloalkylidene ring, wherein any hydrogen atom in the ring is optionally and independently substituted with R'.
  • G 2 is selected from spirocyclopropyl, spirocyclopentyl, or spirocyclohexyl. In yet other embodiments, G 2 is spirocyclopropyl.
  • G 3 is an optionally substituted Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -O-, - S-, -CO-, -CS-, or -SO 2 -, and wherein any hydrogen atom in the d-Csalkylidene chain is optionally and independently substituted with R'.
  • G 3 is -(C(R')2)i-3- > - NR'-, -CO-, -SO 2 -, or -CONR-.
  • G 3 is -CO-, -SO 2 -, -SO 2 -CH 2 -, or - CONH-.
  • B is an optionally substituted group selected from C 6-1 O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or is an optionally substituted C 1 -C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, -SO 2- , -NR'-, -N(SO 2 R'), - N(COR')-, -O, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
  • B is -NR'C(R') 2 NR'-, -NR'(C(R') 2 ) 2 NR'-, - NR'(C(R') 2 ) 3 NR'-, -NR'(C(R') 2 ) 4 NR'-, or is an optionally substituted 5-, 6- or 7-membered
  • at least one of X 1 , X 2 , X 3 , X 4 , X 5 or X 6 is a nitrogen atom.
  • at least one of X 2 or X 5 is a nitrogen atom.
  • At least one of X 2 or X 5 is a nitrogen atom, and each occurrence of X 1 , when present, and X 3 , X 4 , and X 6 are each independently C(R') 2 .
  • X 2 is nitrogen, X 5 is CR', and and each occurrence of X 1 , when present, and X 3 , X 4 , and X are each independently C(R') 2.
  • X 2 is CR', X 5 is N, and X 3 , X 4 , and X 6 are each independently C(R' ) 2 .
  • X 2 and X are each N, and X , X , and X are each independently C(R' ) 2.
  • R' is R
  • R 2 and R 3 taken together form an optionally substituted phenyl group and compounds have the formula II:
  • G 1 O, -R ⁇ , - OR A , SR A , or NR A R B , and compounds of formula H-A, II-B, H-C, H-D, and H-E are provided as depicted generally below.
  • rings formed by R 2 and R 3 taken together are optionally substituted with x occurrences of Q-R x , wherein x. is 0-5.
  • x is 0-4, and each occurrence of Q-R x , when present, is independently halogen, CN, NO 2 , or an optionally substituted group selected from C 1-4 alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, -N(R') 2 , -CH 2 N(R') 2 , -OR', -CH 2 OR', -SR', -SO 2 R', -CH 2 SR', -COOR', -NRCOR', -CON(R') 2 , or -S(O) 2 N(R') 2 .
  • each occurrence of Q-R x when present, is Cl, Br, F, CF 3 , methyl, ethyl, propyl, butyl, CN, -COOH, - N(CH 3 ) 2 , -N(Et) 2 , -N(iPr) 2 , -O(CH 2 ) 2 OCH 3 , -CONH 2 , -COOCH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , - OCH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CH 3 , -CH 2 OH, -NHCOCH 3 , -SO 2 NH 2 , or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl
  • G 2 and G 3 are each independently absent or an optionally substituted C 1 -C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with CO, CS, SO, SO 2 , NR', N(SO 2 R')-, N(COR')-, O, or S, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
  • G 2 is a Q-Caalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -N(SO 2 R')-, N(COR')-, - O-, -S-, -CO-, -CS, or -SO 2 -, and wherein any hydrogen atom in the Q-Csalkylidene chain is optionally and independently substituted with R'.
  • G 2 is -(C(R') 2 ) 1-3 -, - NR'-, -N(SO 2 R')-, N(COR')-, -C(R') 2 NR'-, or -NR'C(R') 2 -.
  • G 2 is - CHR', wherein R' is hydrogen, or optionally substituted C 1 -QaIkVl.
  • G 3 is an optionally substituted Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -O-, - S-, -CO-, -CS-, or -SO 2 -, and wherein any hydrogen atom in the d-Csalkylidene chain is optionally and independently substituted with R'.
  • G 3 is -(C(R') 2 ) 1-3 -, - NR'-, -CO-, -SO 2 -, or -CONR-.
  • B is absent or is an optionally substituted group selected from C 6-10 aryl, a hebroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or is an optionally substituted C 1 -C 6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, -SO 2- , -NR'-, -N(SO 2 R'), -N(COR')-, -O, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
  • B is -NR'C(R') 2 NR'-, -NR'(C(R') 2 ) 2 NR'-, -
  • at least one of X 1 , X 2 , X 3 , X 4 , X 5 or X 6 is a nitrogen atom.
  • at least one of X 2 or X 5 is a nitrogen atom.
  • At least one of X or X is a nitrogen atom, and each occurrence of X , when present, and X 3 , X 4 , and X 6 are each independently C(R' ) 2 .
  • X 2 is nitrogen, X 5 is CR', and and each occurrence of X 1 , when present, and X 3 , X 4 , and X 6 are each independently C(R') 2 .
  • X 2 is CR', X D is N, and X 3 , X 4 , and X 6 are each independently C(R') 2 .
  • X 2 and X 5 are each N, and X 3 , X 4 , and X 6 are each independently C(R' ) 2.
  • B is an optionally substituted 5-, 6- or 7-membered
  • At least one of X 1 , X 2 , X 3 , X 4 , X 5 or X 6 is a nitrogen atom. In yet other embodiments, at least one of X 2 or X 5 is a nitrogen atom. In still other embodiments, at least one of X 2 or X 5 is a nitrogen atom and each occurrence of X 1 , when present, and X 3 , X 4 , and X 6 are each independently C(R') 2 .
  • X 2 is nitrogen, X 5 is CR', and and each occurrence of X 1 , when present, and X 3 , X*, and X 6 are each independently C(R' ) 2 .
  • X 2 is CR', X 5 is N, and X 3 , X 4 , and X 6 are each independently C(R' ) 2 .
  • X 2 and X 5 are each N, and X 3 , X 4 , and X 6 are each independently C(R') 2.
  • G 1 O, -R ⁇ , -OR A , SR ⁇ , or NR A R B , and compounds having the following general structures III-A, III-B, IH-C, IH-D, and HI-E, are provided as depicted generally below.
  • G 1 0, -R A , -OR A , SR ⁇ , or NR A R B , and G 3 is bonded to X 5 and compounds having formulae IV-A, IV-B, IV-C, IV-D, and IV-E, are provided as depicted generally below.
  • R 2 and R 3 taken together form an optionally substituted phenyl group
  • G 1 O, -R A , SR A , or NR A R B
  • G 3 is bonded to X 5 and compounds having formulae V-A, V-B, V-C, V-D, and V-E, are provided as depicted generally below.
  • Ar 1 is absent or is a 3-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar 1 is optionally substituted with m independent occurrences of -W-R w , wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C 6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -O-, - NRCONR-, -OCONR-, -NRNR, -NRCOCO
  • Ar 1 is selected from:
  • Ar 1 is an optionally substituted group selected from a-i, a-ii, a-v, a-vi, a-vii, a-xx, a-xLii, a-xLiii, a-xLiv, a-xLv, or a-xLvi.
  • Ar 1 is an optionally substituted phenyl group (a-i).
  • W is a bond or is an optionally substituted C 1-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by O, NR, S, SO 2 , or COO, CO, and R w is R' or halogen.
  • each occurrence of WR W is independently -Ci -3 alkyl, -O(C 1-3 alkyl), -CF 3 , -OCF 3 , -SCF 3 , -F, -Cl, -Br, or -COOR', -COR', -O(CH 2 ) 2 N(R)(R'), -0(CH 2 )N(R)(R'), -CON(R)(R'), -(CH 2 ) 2 OR ⁇ - (CH 2 )OR', optionally substituted phenyl, -N(R)(R'), -(CHz) 2 N(R)(R'), or -(CH 2 )N(R)(R').
  • R A and R B are each independently hydrogen, an optionally substituted group selected from Ci-C 7 alkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocyclyl, or R A and R B , taken together, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring;
  • R 1 is -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -(CHa) 2 OR', -(CH 2 ) 3 OR ⁇ - (CH 2 ) 2 N(R') 2 , -(CH 2 ) 3 N(R') 2 , -(CH 2 ) 2 NRCOR ⁇ or -(CH 2 ) 3 NRCOR' .
  • x is 0, 1, or 2, and each occurrence of -Q-R x , when present, is Cl, Br, F, CF 3 , methyl, ethyl, propyl, butyl, CN, -COOH, -N(CH 3 ) 2 , -N(Et) 2 , -N(IPr) 2 , -O(CH 2 ) 2 OCH 3 , -CONH 2 , - COOCH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CH 3 , -CH 2 OH, - NHCOCH 3 , -S ⁇ 2 NH 2 , or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyrid
  • G 2 is -(C(R 1 Kh -3 -, -NR'-, -C(R') 2 NR ⁇ or -NR'C(R') 2 -;
  • Ar 1 is selected from one of rings a-i through a-xLVi; and each occurrence of WR W is independently -C 1-3 alkyl, -O(C 1-3 alkyl), -CF 3 , -OCF 3 , -SCF 3 , -F, -Cl, -Br, or -COOR', -COR', -O(CH 2 ) 2 N(R)(R'), -0(CH 2 )N(R)(R'), -C(O)N(R)(R'), - (CH 2 ) 2 OR ⁇ -(CH 2 )OR', optionally substituted phenyl, -N(R)(R'), -(CH 2 ) 2 N(R)(R'), or - (CH 2 )N(R)(R').
  • G 2 is CH(C 1- 3 alkyl) or spirocyclopropyl; G 3 is -CO-, -SO 2 -, or -CONR-; and Ar 1 is phenyl optionally substituted with -WR W .
  • the compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general scheme below, and the preparative examples that follow.
  • Scheme IA, Scheme IB, and Scheme IC below depict general conditions for the synthesis of compounds of formula I where G 2 is -CH(CH 3 )-, and B is piperizinyl.
  • Scheme HA depicts conditions for the synthesis of one exemplary embodiment for compounds of formula I where G 2 is -CH(CH 3 )-, R 1 is n-propyl, B is piperizinyl, G 3 is SO 2 , and Ar 1 is optionally substituted phenyl.
  • Scheme III depicts conditions for the synthesis of one exemplary embodiment for compounds of formula I where Q 2 is -CH(CH 3 )-, R 1 is methyl, B is a diamine linker (cyclic or linear and optionally substituted), and Q 3 is SO 2 .
  • Scheme VII depicts conditions for the conversion of bromine to cyano derivatives.
  • Scheme VIII depicts conditions for the conversion of cyano to amide and tetrazole derivatives.
  • Scheme X depicts conditions for converting a nitro derivative to the amino or NHC(O)CH 3 derivative.
  • Scheme XII depicts the conditions for synthesis of compounds of formula I, wherein G 1 is R A .
  • Scheme XIV depicts the conditions for the synthesis of an exemplary embodiment of formula I, wherein R and R together form a pyrazine ring, G is OR A , B is a piperazine ring, G 3 is SO 2 .
  • Scheme XV depicts the conditions for the synthesis of compounds of formula I, wherein G 1 is hydrogen, G 2 is CH(CH 3 ), B is piperazine, G 2 is SO 2 .
  • Scheme XVIA, Scheme XVIB, and Scheme XVIC below depict general conditions for the synthesis of compounds of formula I wherein R 2 and R 3 do not cyclize, and B is piperazinyl.
  • Scheme XVII depicts the conditions for the synthesis of one exemplary embodiment of formula I, wherein R A and R B together form piperidyl, G 2 is - CH(CH 3 )-, G 3 is SO 2 , and Ar 1 is 4-methoxyphenyl.
  • Scheme XVIII depicts the conditions for the synthesis of an exemplary embodiment of compound of formula I, wherein R A a r d R B together form piperidyl, G 2 is -CH(CH 3 )-, G 3 is SO 2 , and Ar 1 is 4-methoxyphenyl.
  • Scheme XIX depicts the conditions for the synthesis of compounds of formula I, wherein G 1 is alkoxy, and R 2 and R 3 do not cyclize to form a ring.
  • Scheme XX depicts the conditions for the synthesis of an exemplary compound of formula I, wherein G 1 is cyclopentyloxy, and R 2 and R 3 both are hydrogen.
  • Scheme XXI depicts the conditions for the general synthesis of compounds of formula I, wherein R 2 is carboethoxy, and G 1 is alkoxy.
  • Scheme XXII depicts the conditions for the synthesis of an exemplary embodiment of formula I, wherein R 2 is carboethoxy, G 1 is cyclopentyloxy, G 2 is - CH(CH 3 )-, G 3 is SO 2 , B is piperazyl, and Ar 1 is 4-methoxyphenyl.
  • Scheme XXIII depicts the conditions for the general synthesis of compounds of formula I, wherein R 2 and R 3 cyclize to form a phenyl ring, G 1 is an alkoxy and B is a piperidyl ring.
  • Scheme XXIV depicts an exemplary embodiment of compound of formula I, wherein R A is cyclopentyloxy, B is piperidinyl, G 1 is -CH(CH 3 )-, G 3 is SO 2 , and Ar 1 is 4-methoxyphenyl.
  • the present invention provides compounds that are useful as modulators of ABC transporters and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary
  • compositions comprising any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (Ci ⁇ aIkVl) 4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salt?
  • nontoxic ammonium include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
  • the present invention provides a method of treating a condition, disease, or disorder implicated by ABC transporter activity.
  • the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of ABC transporter activity, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
  • the present invention provides a method of treating Cystic fibrosis; Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hufler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type ⁇ ,
  • Polyendocrinopathy/Hyperinsulemia Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform
  • the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type ⁇ , Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Heredit
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CD
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adj
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • a compound of the present invention In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled deliyery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as modulators of ABC transporters.
  • the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of ABC transporters is implicated in the disease, condition, or disorder.
  • hyperactivity or inactivity of an ABC transporter is implicated in a particular disease, condition, or disorder
  • the disease, condition, or disorder may also be referred to as a "ABC transporter-mediated disease, condition or disorder”.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an ABC transporter is implicated in the disease state.
  • ABC transporter may be assayed according to methods described generally in the art and in the Examples herein.
  • the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as "appropriate for the disease, or condition, being treated”.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to modulating ABC transporter activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Modulation of ABC transporter activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of ABC transporters in biological and pathological phenomena; and the comparative evaluation of new modulators of ABC transporters.
  • a method of modulating activity of an anion channel in vitro or in vivo comprising the step of contacting said channel with a compound of formula (I).
  • the anion channel is a chloride channel or a bicarbonate channel. In other preferred embodiments, the anion channel is a chloride channel.
  • the present invention provides a method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (I).
  • the term "functional ABC transporter” as used herein means an ABC transporter that is capable of transport activity.
  • said functional ABC transporter is CFTR.
  • the activity of the ABC transporter is measured by measuring the transmembrane voltage potential.
  • Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
  • the optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC 2 (3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor.
  • FRET fluorescence resonant energy transfer
  • V m fluorescent phospholipid
  • the changes in fluorescence emission can be monitored using VIPRTM II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
  • the present invention provides a kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo comprising (i) a composition comprising a compound of formula (I); and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said ABC transporter or a fragment thereof.
  • the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said ABC transporter or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the ABC transporter in the presence of the additional compound with the density of the ABC transporter in the presence of a composition of formula (I).
  • the kit is used to measure the density of CFTR.
  • the substrate of 6-bromo-2-ethyl-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.189 mmol), KCN (23.1 mg, 0.37 mmol), Pd (PPh 3 ) 4 (10.0 mg, 0.0094 mmol), and CuI (3.6 mg, 0.019 mmol) was added to a flask, which was flushed with N 2 .
  • the solvent acetonitrile (2 ml) was added via syringe.
  • the resulting mixture was irradiated at 170 0 C for 2 hours in the SmithSynthesizer Microwave Reactor (Personal Chemistry) with vigorous agitation by a magnetic stirrer.
  • the substrate of 6-bromo-2-ethyl-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.189 mmol), sodium methanesulfinate (28.8 mg, 0.29 mmol) and copper (I) iodide (53.7 mg, 0.29 mmol) was placed in a flask, which was flushed with N 2 .
  • DMF (2 ml) was added via syringe.
  • the resulting mixture was irradiated at 180 0 C for 30 minutes in the SmithSynthesizer Microwave reactor (Personal Chemistry) with vigorous agitation by a magnetic stirrer.
  • the mixture was cooled to room temperature, diluted with ethyl acetate (5 ml), and then filtered.
  • Trifluoroacetic acid (2.5 mL) was added to a solution of [4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-acetic acid terr-butyl ester (1.48g, 4 mmol) in dichloromethane (10 mL). The reaction was stirred at room temperature for 3 days. The solvent was removed in vacuo and the residue was triturated with diethyl ether. Filtration yielded the product as a white solid (1.25 g, quant.).
  • Step 2 Preparation of 2-Ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one: A mixture of 2-amino-5- fluorobenzoic acid (23.3 g, 0.15 mol) and propionic acid anhydride (150 mL) was heated to reflux for 3 hr, then the propionic acid anhydride was removed in vacuo to afford 2-ethyl-6- fluoro-benzo[d][l,3]oxazin-4-one 2 as a gray solid, which was used directly in the next step.
  • Step 3 Preparation of 2-Ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one: A mixture of 2-ethyl-6- fluoro-benzo[d][l,3]oxazin-4-one (25 g) and ammonia (300 mL, 25-28%) was stirred overnight. The solid was filtered to give 2-ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one 3 as a white solid (23 g, 80%).
  • Step 4 Preparation of 2-(l-Bromo-ethyl)-6-fluoro-3H-quinazolin-4-one: To a solution of 2- ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one 3 (19.2 g, 0.1 mol) and sodium acetate (8.2 g, 0.1 mol) in acetic acid (500 mL) was added dropwise a solution of bromine (16.0 g, 0.1 mol) in acetic acid (40 mL) at 10 0 C. After stirred at r.t. for 2 days, the reaction mixture was gradually poured into cold water.
  • Step 5 Preparation of 6-Fluoro-2- ⁇ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl ⁇ -3H-quinazolin-4-one
  • 6-Fluoro-2- ⁇ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl ⁇ -3H-quinazolin-4-one was prepared by using the same method as described in Scheme I. (Yield 431.0 mg, 13.1 %). %).
  • 6-Fluoro-2- ⁇ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl ⁇ -4-piperidin-l-yl- quinazoline was prepared using the same method as described in Scheme V (Yield 20.5 mg, 23.5 %). MS m/z calc. 413.0 found (ESI); 514.4 (M + I) + . Retention time 2.82 minutes.
  • 6-Fluoro-2- ⁇ 1 -[4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl ⁇ -4-(4-methyl-piperidin- 1 - yl)-quinazoline was prepared by using the same method as described in Scheme V (Yield 50.2 mg, 57.3 %). MS m/z calc. 527.0 found (ESI); 528.0 (M + I) + . Retention time 2.96 minutes.
  • Step 3 3-Methyl-2-[l-(pi ⁇ eridin-4-ylamino)-ethyl]-3H-quinazolin-4-one (57.2 mg, 0.2 mmol) and triethylamine (167 ⁇ L, 0.4 mmol) were dissolved in dioxane (1 mL) and to this was added 4- methoxybenzenesulfonyl chloride (62 mg, 0.3 mmol). The reaction was shaken at room temperature overnight. Dichloromethane (2 mL) and water (2 mL) were added and the reaction tube was shaken. The top aqueous layer was aspirated off and the organic layer was concentrated in vacuo.
  • Step 1 N-(2-Formyl-phenyl)-propionamide
  • Ste2_4 2- ⁇ l-[4-(4-Bromo-benzenesuIfonyl)-piperazin-l-yl]-ethyl ⁇ - quinazoline
  • Methyl 2-bromo propionate (181 g, 1 mol) was preheated at 140°C and then the triethyl phosphite was added dropwise over a period of 2 hours. Ethyl bromide was removed from the system and the temperature was raised to 160°C. After the addition was complete, the temperature was raised to 190 0 C for 1 hr. The mixture was fractionated to give the product as a colorless liquid (185 g, 82.6%, Bp 16mmHg 142-146°C).
  • step 1 To the sample of step 1 dissolved in THF (5ml) was added piperidine (278 mg, 3.28 mmol) and the reaction was heated at 60 0 C for 0.5 hour. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was re- dissolvent in MeOH (2 ml) and purified by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Binders And Loading Units For Sheaves (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)

Abstract

The present invention relates to compounds of Formula (I) as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Description

PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C. §119 to U.S. Provisional Application numbers: 60/476,698 filed June 6, 2003, entitled "Modulators of ATP- Binding Cassette Transporters"; 60/500,132, filed September 4, 2003, entitled "Modulators of ATP-Binding Cassette Transporters"; and 60/520,181, filed November 14, 2003, entitled "Modulators of ATP-Binding Cassette Transporters", and the entire contents of each of these applications is hereby incorporated by reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to modulators of ATP-Binding Cassette
("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
BACKGROUND OF THE INVENTION
[0003] ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions. ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents. To date, 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
[0004] ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
[0005] One member of the ABC transporter family commonly associated with disease is the cAMP/ATP-mediated anion channel, CFTR. CFTR is expressed in a variety of cells types, including absorptive and secratory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
[0006] The gene encoding CFTR has been identified and sequenced (See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P. et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989) Science 245:1066-1073). A defect in this gene causes mutations in CFTR resulting in Cystic Fibrosis ("CF"), the most common fatal genetic disease in humans. Cystic Fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
[0007] In patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death. In addition, the majority of Males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the CF associated gene, individuals with a single copy of the CF associated gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea - perhaps explaining the relatively high frequency of the CF gene within the population. [0008] Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073-1080; Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, > 1000 disease causing mutations in the CF gene have been identified (http://www.genet.sickkids.on.ca/cftr/). The most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as ΔF508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease .
[0009] The deletion of residue 508 in ΔF508-CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to exit the ER, and traffic to the plasma membrane. As a result, the number of channels present in the membrane is far less than observed in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies have shown, however, that the reduced numbers of ΔF508-CFTR in the membrane are functional, albeit less than wild-type CFTR. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al., supra.; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to DF508- CFTR, other disease causing mutations in CFTR that result in defective trafficking, synthesis, and/or channel gating could be up- or down-regulated to alter anion secretion and modify disease progression and/or severity.
[0010] Although CFTR transports a variety of molecules in addition to anions, it is clear that this role (the transport of anions) represents one element in an important mechanism of transporting ions and water across the epithelium. The other elements include the epithelial Na+ channel, ENaC, Na+/2C17K+ co-transporter, Na+-K+-ATPaSe pump and the basolateral membrane K+ channels, that are responsible for the uptake of chloride into the cell.
[0011] These elements work together to achieve directional transport across the epithelium via their selective expression and localization within the cell. Chloride absorption takes place by the coordinated activity of ENaC and CFTR present on the apical membrane and the Na+-K+-ATPase pump and Cl- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via Cl" channels, resulting in a vectorial transport. Arrangement of Na+/2C17K+ co-transporter, Na+-K+-ATPase pump and the basolateral membrane K+ channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride.
[0012] In addition to Cystic Fibrosis, modulation of CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome. COPD is characterized by airflow limitation that is progressive and not fully reversible. The airflow limitation is due to mucus hypersecretion, emphysema, and bronchiolitis. Activators of mutant or wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD. Specifically, increasing anion secretion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mcuociliary clearance and a reduction in the symptoms associated with COPD. Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles. There are many causes of dry eye, some of which include age, Lasik eye surgery, arthritis, medications, chemical/thermal burns, allergies, and diseases, such as Cystic Fibrosis and Sjogrens's syndrome. Increasing anion secretion via CFTR would enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease. Sjogrens's syndrome is an autoimmune disease in which the immune system attacks moisture- producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
[0013] As discussed above, it is believed that the deletion of residue 508 in
ΔF508-CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane. As a result, insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced. Infact, this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery, has been shown to be the underlying basis not only for CF disease, but for a wide range of other isolated and inherited diseases. The two ways that the ER machinery can malfunction is either by loss of coupling to ER export of the proteins leading to degradation, or by the ER accumulation of these defective/misfolded proteins [Aridor M, et al, Nature Med., 5(7), pp 745- 751 (1999); Shastry, B.S., et al, Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J., et al, Swiss Med WkIy, 132, pp 211-222 (2002); Morello, JP et al, TIPS, 21, pp. 466- 469 (2000); Bross P., et al., Human Mut., 14, PP- 186-198 (1999)]. The diseases associated with the first class of ER malfunction are Cystic fibrosis (due to misfolded ΔF508-CFTR as discussed above), Hereditary emphysema (due to al- antitrypsin; non Piz variants), Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses (due to Lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β- Hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus (due to Insulin receptor), Laron dwarfism (due to Growth hormone receptor), Myleoperoxidase deficiency, Primary hypoparathyroidism (due to Preproparathyroid hormone), Melanoma (due to Tyrosinase). The diseases associated with the latter class of ER malfunction are Glycanosis, CDG type 1, Hereditary emphysema (due to αl-Antitrypsin (PiZ variant), Congenital hyperthyroidism, Osteogenesis imperfecta (due to Type I, II, IV procollagen), Hereditary hypofibrinogenemia (due to Fibrinogen), ACT deficiency (due to αl-Antichymotrypsin), Diabetes insipidus (DI), Neurophyseal DI (due to Vasopvessin hormone/V2-receptor), Neprogenic DI (due to Aquaporin II), Charcot-Marie Tooth syndrome (due to Peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease (due to Prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A) and Straussler-Scheinker syndrome (due to Prp processing defect).
[0014] In addition to up-regulation of CFTR activity, reducing anion secretion by CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport. The mechanism involves elevation of cAMP and stimulation of CFTR.
[0015] Although there are numerous causes of diarrhea, the major consequences of diarrheal diseases, resulting from excessive chloride transport are common to all, and include dehydration, acidosis, death and impaired growth.
[0016] Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
[0017] Secretory diarrheas are also a dangerous condition in patients of acquired immunodeficiency syndrome (AIDS) and chronic inflammatory bowel disease (IBD). 16 million travelers to developing countries from industrialized nations every year develop diarrhea, with the severity and number of cases of diarrhea varying depending on the country and area of travel.
[0018] Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
[0019] The most common diarrheal causing bacteria is enterotoxogenic E-coli (ETEC) having the K99 pilus antigen. Common viral causes of diarrhea include rotavirus and coronavirus. Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
[0020] Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease. [0021] Accordingly, there is a need for modulators of an ABC transporter activity, and compositions thereof, that can be used to modulate the activity of the ABC transporter in the cell membrane of a mammal.
[0022] There is a need for methods of treating ABC transporter mediated diseases using such modulators of ABC transporter activity.
[0023] There is a need for methods of modulating an ABC transporter activity in an ex vivo cell membrane of a mammal.
[0024] There is a need for modulators of CFTR activity that can be used to modulate the activity of CFTR in the cell membrane of a mammal.
[0025] There is a need for methods of treating CFTR-mediated diseases using such modulators of CFTR activity.
[0026] There is a need for methods of modulating CFTR activity in an ex vivo cell membrane of a mammal.
SUMMARY OF THE INVENTION
[0027] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ABC transporter activity. These compounds have the general formula I:
Figure imgf000008_0001
I or a pharmaceutically acceptable salt thereof, wherein G1, R1, R2, R3 and L are described generally and in classes and subclasses below.
[0028] These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease, Fabry disease, or Straussler-Scheinker syndrome.
DETAILED DESCRIPTION OF THE INVENTION
[0029] /. General Description of Compounds of the Invention:
[0030] The present invention relates to compounds of formula I useful as modulators of ABC transporter activity:
Figure imgf000009_0001
I or a pharmaceutically acceptable salt thereof, wherein:
G1 is =0, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR1NR', -NR'NR'CO-, -NR1CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR1SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RΛ and RB, or any ring formed by RA and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR7SO2-, -NR5SO2NR'-, and each occurrence of Ru is independently R', halogen, NO2, or CN,
R1 is absent or is Y-Rγ;
Y is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R5, OR', SR', N(R5 )2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is O- 5;
T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R', halogen, NO2, or CN;
Q is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Q are optionally and independnetly replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rx is independently R', halogen, NO2, or CN; L is G2-B-G3-Ar\ wherein G2 is absent, an optionally substituted Ci-C6 alkylidene chain, or a C3-C6 spirocycloalkylidene ring, wherein one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R';
G3 is absent or an optionally substituted Ci-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R';
B is absent or is an optionally substituted C6-Io aryl> a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a Ci-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rw is independently R', halogen, NO2, or CN; provided that G2, B, G3, and Ar1 are not simultaneously absent.
[0031] In certain other embodiments, for compounds of general formula I, none of G2, B, G3, or Ar1 is absent and thus compounds of formula I are provided:
Figure imgf000012_0001
I or a pharmaceutically acceptable salt thereof, wherein:
G1 is =0, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR1CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR5SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RΛ and RB, or any ring formed by RA and
R taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, -NR5SO2NR'-, and each occurrence of Ru is independently R5, halogen, NO2, or CN;
R1 is absent or is Y-Rγ; wherein Y is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR', SR', N(R')2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom thiough a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is 0- 5;
T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R', halogen, NO2, or CN;
Q is a bond or is an optionally substituted CpC6 alkylidene chain wherein up to two methylene units of Q are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rx is independently R', halogen, NO2, or CN;
Figure imgf000013_0001
wherein G2 is absent, an optionally substituted C1-C6 alkylidene chain, or a C3-C6 spirocycloalkylidene ring, wherein one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -O-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
G3 is absent or an optionally substituted Ci-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
B is absent or is an optionally substituted C6-1O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C1-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rwis independently R', halogen, SCF3,[κci] NO2, or CN; provided that: i) when B is piperazinyl, G1 is =O, G2 is CHMe, and G3 is -CONH-, then R1 is not benzyl or ethyl; ii) when R2 and R3, taken together form a fused thieno ring, then G1 is not NH2 or optionally substituted phenyl; iii) when G1 is hydrogen, R2 and R3, taken together form a fused benzene ring, and x is 3, then each occurrence of Q-Rx is not OMe; iv) G1, R2 and R3 are not each simultaneously hydrogen; v) if G1 is hydrogen, then G2 is not CO; and vi) 2H Indol-2-one, l,3-dihydro-3,3,7-trimethyl-4-[3-[4-(2-quinazolinylmethyl)- l-piperazinyl]propoxy] and 2(1H)-Quinoline, 3,4-dihydro-8-methyl-5-[3-4-(2- quinazolinyl methyl)- l-piperazinyl]propoxy are excluded.
[0032] 2. Compounds and Definitions:
[0033] Compounds of this invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated.
[0034] The term "ABC-transporter" as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro. The term "binding domain" as used herein means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et al., J. Gen. Physiol. (1998): 111(3), 477-90.
[0035] The term "CFTR" as used herein means cystic fibrosis transmembrane regulator or a mutation thereof capable of regulator activity, including, but not limited to, ΔF508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
[0036] The term "modulating" as used herein means increasing or decreasing by a measurable amount.
[0037] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0038] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." In general, the term "substituted", whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 4O0C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
[0039] The term "aliphatic" or "aliphatic group", as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" "cycloaliphatic" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. [0040] The term "heteroaliphatic", as used herein, means aliphatic groups wherein one or two carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon. Heteroaliphatic groups may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" groups.
[0041] The term "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom. In some embodiments, the "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
[0042] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)).
[0043] The term "unsaturated", as used herein, means that a moiety has one or more units of unsaturation.
[0044] The term "alkoxy", or "thioalkyl", as used herein, refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen ("alkoxy") or sulfur ("thioalkyl") atom.
[0045] The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br, or I.
[0046] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxy alkyl", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". The term "aryl" also refers to heteroaryl ring systems as defined hereinbelow. [0047] The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".
[0048] An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group are selected from halogen; -R°; -OR°; -SR°; 1,2-methylene-dioxy; 1,2-ethylenedioxy; phenyl (Ph) optionally substituted with R0; -0(Ph) optionally substituted with R0; -(CH2)1-2(Ph), optionally substituted with R0; -CH=CH(Ph), optionally substituted with R0; -NO2; -CN; -N(R°)2; -NR0C(O)R0; -NR°C(0)N(R°)2; -NR0CO2R0; -NR0NR0C(O)R0; -NR°NR°C(0)N(R°)2; -NR0NR0CO2R0; -C(O)C(O)R0; -C(O)CH2C(O)R0; -CO2R0; -C(O)R0; -C(O)N(R°)2; -OC(O)N(R°)2; -S(O)2R0; -SO2N(R°)2; -S(O)R0; -NR°SO2N(R°)2; -NR0SO2R0; -C(=S)N(R°)2; -C(=NH)-N(R°)2; or -(CH2)0-2NHC(O)R° wherein each independent occurrence of R° is selected from hydrogen, optionally substituted C1^ aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(Ph), or -CH2(Ph), or, notwithstanding the definition above, two independent occurrences of R°, on the same substituent or different substituents, taken together with the atom(s) to which each R° group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Optional substituents on the aliphatic group of R° are selected from NH2, NH(C1-4aliphatic), N(Ci.4aliphatic)2, halogen, Ci-4aliphatic, OH, O(Ci-4aliphatic), NO2, CN, CO2H, CO2(Ci-4aliphatic), 0^aIoC1-4 aliphatic), or haloC1-4aliphatic, wherein each of the foregoing C1-4aliphatic groups of R° is unsubstituted.
[0049] An aliphatic or heteroaliphatic group, or a non-aromatic heterocyclic ring may contain one or more substituents. Suitable substituents on the saturated carbon of an aliphatic or heteroaliphatic group, or of a non-aromatic heterocyclic ring are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group and additionally include the following: =O, =S, =NNHR*, =NN(R*)2, =NNHC(0)R*, =NNHCO2(alkyl), =NNHSO2(alkyl), or =NR*, where each R is independently selected from hydrogen or an optionally substituted C1-6 aliphatic. Optional substituents on the aliphatic group of R* are selected from NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, Ci-4 aliphatic, OH, 0(C1-4 aliphatic), NO2, CN, CO2H, CO2(Ci-4 aliphatic), O(halo C1-4 aliphatic), or halo(Ci.4 aliphatic), wherein each of the foregoing C1-4aliphatic groups of R* is unsubstituted.
[0050] Optional substituents on the nitrogen of a non-aromatic heterocyclic ring are selected from -R+, -N(R+)2, -C(O)R+, -CO2R+, -C(O)C(O)R+, -C(O)CH2C(O)R+, -SO2R+, -SO2N(R+)2, -C(=S)N(R+)2, -C(=NH)-N(R+)2, or -NR+SO2R+; wherein R+ is hydrogen, an optionally substituted Ci-6 aliphatic, optionally substituted phenyl, optionally substituted -0(Ph), optionally substituted -CH2(Ph), optionally substituted -(CH2)1-2(Ph); optionally substituted - CH=CH(Ph); or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring having one to four heteroatoms independently selected from oxygen, nitrogen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R+, on the same substituent or different substituents, taken together with the atom(s) to which each R+ group is bound, form a 3-8- membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Optional substituents on the aliphatic group or the phenyl ring of R+ are selected from NH2, NH(Ci-4 aliphatic), N(Ci-4 aliphatic)2, halogen, C1-4 aliphatic, OH, 0(Ci-4 aliphatic), NO2, CN, CO2H, CO2(Ci-4 aliphatic), O(halo Ci-4 aliphatic), or halo(C1-4 aliphatic), wherein each of the foregoing Ci-4aliphatic groups of R+ is unsubstituted.
[0051] The term "alkylidene chain" refers to a straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule. The term "spirocycloalkylidene" refers to a carbocyclic ring that may be fully saturated or have one or more units of unsaturation and has two points of attachment from the same ring carbon atom to the rest of the molecule.
[0052] As detailed above, in some embodiments, two independent occurrences of R0 (or R+, or any other variable similarly defined herein), are taken together together with the atom(s) to which each variable is bound to form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary rings that are formed when two independent occurrences of R0 (or R+, or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R0 (or R+, or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R°)2, where both occurrences of R0 are taken together with the nitrogen atom to form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R° (or R+, or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for example where a phenyl group is substituted with two occurrences of OR0
Figure imgf000020_0001
these two occurrences of R0 are taken together with the oxygen atoms to which
they are bound to form a fused 6-membered oxygen containing ring:
Figure imgf000020_0002
It will be appreciated that a variety of other rings can be formed when two independent occurrences of R° (or R+, or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound and that the examples detailed above are not intended to be limiting.
[0053] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each, asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
[0054] 3. Description of Exemplary Compounds: [0055] As described generally above, for compounds of the invention, G1 is =0, -RA, - ORΛ, SRA, or NRARB. As depicted for compounds of structural formula I, the bond between the nitrogen atom and C-G1 can be a single or double bond (as represented by the dotted line), depending upon the G1 substituent. For example, when G1 is =O, the bond between the nitrogen atom and the carbon atom of C-G1 is a single bond, and thus R1 will be present. Additionally, when G1 is -RA, -ORA, SRA, or NRARB, the bond between the nitrogen atom and the carbon atom of C-G1 is a double bond, and thus R1 will be absent. Accordingly, the present invention provides compounds having any one of the following general structures I- A, I-B, I-C, I-D and I- E, as depicted below.
Figure imgf000021_0001
Figure imgf000021_0002
I-D I-E
[0056] In some embodiments, compounds of the invention have the structure of general formula I-A. In other embodiments, compounds of the invention have the structure of general formula I-B. In yet other embodiments, compounds of the invention have the structure of general formula I-E. Or, compounds of the invention have the structure of general formula IC. Or, compounds of the invention have the structure of general formula IE.
[0057] As described generally above, RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR'SO2-, -NR5SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN. As also described above, RA and RB, or any ring formed by RA and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR5CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, -NR1SO2NR5-, and each occurrence of Ru is independently R5, halogen, NO2, or CN. [0058] In some embodiments RA and RB are each independently hydrogen, an optionally substituted d-Cgalkyl group, or V-Rv, where V is as defined generally above, and Rv is an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, RA and RB, taken together with the nitrogen atom, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring. In other embodiments, R and RB are each independently hydrogen; an optionally substituted group selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or pentyl; an optionally substituted ring selected from:
Figure imgf000022_0001
11 in IV
Figure imgf000022_0002
Vl VIl VlU
Figure imgf000022_0003
IX XI XIl
Figure imgf000023_0001
XlU XlV XV XVl
Figure imgf000023_0002
XVU XVlU XlX XX
Figure imgf000023_0003
XXl XXU XXUl XXlV
Figure imgf000023_0004
XXV XXVI XXVH XXVHl
Figure imgf000023_0005
XXlX XXX XXXl xxxii
Figure imgf000023_0006
XXXlU xxxiv XXXV
Figure imgf000024_0001
XXXVl XXXVW XXXVlU XXXlX
Figure imgf000024_0002
XL xLi xLii xLiii
Figure imgf000024_0003
xLiv XLV or xLvi
or RA and RB, taken together are optionally substituted group selected from:
Figure imgf000024_0004
a
Figure imgf000024_0005
g
Figure imgf000024_0006
m n or [0059] In some embodiments, q is 0, 1, 2, or 3, and each occurrence of U-Ru is independently hydrogen, R', -CH2R', halogen, CN, NO2, -N(R')2, -CH2N(R')2, -OR', -CH2OR', -SR', -CH2SR', -COOR', -NR'COR', -NR'COOR', -CON(R')2, -SO2N(R')2, - CONR'(CH2)2N(R')2, -CONR(CH2)3N(R')2) -CONR'(CH2)4N(R')2, -O(CH2)2OR', O(CH2)3OR', O(CH2)4OR\ -O(CH2)2N(R')2, -O(CH2)3N(R')2, -O(CH2)4N(R')2, -NR5CH(CH2OH)R', - NR1CH(CH2CH2OH)R', -NR'(CH2)R', -NR'(CH2)2R', -NR'(CH2)3R', -NR'(CH2)4R\ - NR'(CH2)N(R')2, -NR'(CH2)2N(R')2, -NR'(CH2)3N(R')2, -NR' (CHz)4N(R^2, -NR'(CH2)OR', - NR'(CH2)2OR', -NR'(CH2)3OR\ or -NR'(CH2)4OR'. In still other embodiments, q is 1, 2, or 3 and each occurrence of U-Ru is independently F, Cl, Br, CN, -OH, -NH2, -CH2OH, -CrC6alkyl, -OtCi-Cealkyl), -CH2O(d-C6alkyl), -CO(CrC6alkyl), -COO(Ci-C6alkyl), -NHSO^CrQalkyl), -SO2NH2, -CONH2, -CON(CrC6alkyl), -SO2(C !-C6alkyl), -SO2phenyl, phenyl, benzyl, -N(C1- Cβalkyl)2, or -S (C1-QaIkVl), wherein each of the foregoing phenyl, benzyl, and Cj-C6alkyl groups is independently and optionally substituted, and wherein each of the foregoing CrCealkyl groups is linear, branched, or cyclic.
As also described generally above, R1 is absent or is Y-Rγ; wherein Y is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -O-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR', SR', N(R' )2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom. In certain embodiments, when R1 is present, R1 is Y-Rγ, wherein Y is an optionally substituted C1-C4alkylidene chain, wherein one or two non-adjacent methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, - NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR', SR', N(R')2, halogen, NO2, or CN. In other embodiments, R1 is optionally substituted d-C4alkyl. In still other embodiments, R1 is -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -(CH2)2OR\ - (CH2)3OR\ -(CH2)2N(R')2, -(CH2)3N(R')2, -(CH2)2NRCOR' , or -(CH2)3NRCOR' .
[0060] As described generally for compounds of formula (I), R2 and R3 are each independently -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6- membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms or one or more substituable nitrogen atoms with x independent occurrences of Q-Rx, wherein x is 0-5.
[0061] In certain embodiments, R2 and R3 are each independently -T-Rz. In some embodiments, R2 and R3 are each independently hydrogen, halogen, or an optionally substituted group selected from C1-6alkyl, aryl, aryl(C1-6)alkyl, -N(R')2, -CH2N(R')2, OR', -CH2OR', SR', - CH2SR', COOR', -NRCOR', -(CH2)2N(R')2, -(CH2)2OR\ -(CH2)2SR\ -COR', -CON(R')2, SO2R', or -SO2N(R' )2. In other embodiments, R2 and R3 are each independently H, Cl, Br, F, CF3, Me, Et, -COOH, NH2, -N(CH3)2, -N(Et)2, -N(IPr)2, -O(CH2)2OCH3, -CO(CrC4alkyl), - CONH2, -COOCH3, -OH, -CH2OH, -NHCOCH3, -SO2(C i-C4alkyl), -SO2NH2, -SO2N(CH3)2, or an optionally substituted group selected from C1-4alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.
[0062] In still other embodiments R2 and R3 taken together form a ring selected from:
Figure imgf000026_0001
o
Figure imgf000026_0002
u
Figure imgf000026_0003
W X
Figure imgf000027_0001
aa bb CC dd
Figure imgf000027_0002
ee ff gg hh
Figure imgf000027_0003
ii JJ kk U
Figure imgf000027_0004
mm nn oo PP
Figure imgf000027_0005
qq rr ss tt
Figure imgf000027_0006
uu or vv
[0063] It will also be appreciated that one or more hydrogen atoms on any substitutable nitrogen or carbon atom may optionally be substituted with one or more independent occurrences of Q-Rx. [0064] As described generally above, rings formed by R2 and R3 taken together are optionally substituted with x occurrences of Q-Rx, wherein x is 0-5. In certain embodiments, x is 0-4, and each occurrence of Q-Rx, when present, is independently halogen, CN, NO2, or an optionally substituted group selected from Ci_4alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, -N(R')2, -CH2N(R')2> -OR', -CH2OR', -SR', -SO2R', -CH2SR', -COOR', -NRCOR', -C0N(R')2, or -S(O)2N(R')2. In other embodiments, each occurrence of Q-Rx, when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, - N(CH3)2, -N(Et)2, -N(JPr)2, -O(CH2)2OCH3, -CONH2, -COOCH3, -OH, -OCH3, -OCH2CH3, - OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, -NHCOCH3, -SO2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole. In other embodiments, x is 2. In still other embodiments, x is 1. In yet other embodiments, x is O.
[0065] As described generally above, G2 and G3 are each independently absent or an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with CO, CS, SO, SO2, NR', N(SO2R')-, N(COR')-, O, or S, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
[0066] In some embodiments, G2 is a Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -N(SO2R')-, N(COR')-, - O-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the CrCsalkylidene chain is optionally and independently substituted with R'. In other embodiments, G2 is -(C(R')2)1-3-, - NR'-, -N(SO2R')-, N(COR')-, -C(R')2NR\ or -NR'C(R')2-. In still other embodiments G2 is - CHR', wherein R' is hydrogen, or optionally substituted Ci-C4alkyl. In yet other embodiments, G2 is selected from CH2, CH(CH3), CH(CH2-CH3), CH(CH2CH2CH3), or C(CH3)2. In yet other embodiments, G2 is CH(CH3).
[0067] In some embodiments, G2 is absent. In yet other embodiments, G2 is a C3-C6 spirocycloalkylidene ring. In such a ring, one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'. In yet other embodiments, G2 is spirocycloalkyl, spirocyclopentyl, or spirocyclohexyl.
[0068] In some embodiments, G2 is a C3-C6spirocycloalkylidene ring, wherein any hydrogen atom in the ring is optionally and independently substituted with R'. In certain embodiment, G2 is selected from spirocyclopropyl, spirocyclopentyl, or spirocyclohexyl. In yet other embodiments, G2 is spirocyclopropyl.
[0069] In some embodiments, G3 is an optionally substituted Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -O-, - S-, -CO-, -CS-, or -SO2-, and wherein any hydrogen atom in the d-Csalkylidene chain is optionally and independently substituted with R'. In other embodiments, G3 is -(C(R')2)i-3-> - NR'-, -CO-, -SO2-, or -CONR-. In yet other embodiments, G3 is -CO-, -SO2-, -SO2-CH2-, or - CONH-.
[0070] In certain embodiments, B is an optionally substituted group selected from C6-1O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or is an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), - N(COR')-, -O, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
[0071] In some embodiments, B is -NR'C(R')2NR'-, -NR'(C(R')2)2NR'-, - NR'(C(R')2)3NR'-, -NR'(C(R')2)4NR'-, or is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure
Figure imgf000029_0001
, wherein n is 0, 1, or 2; X2 and Xs are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R')2, -O-, -NR-, S, C=O, or C=S. In still other embodiments, at least one of X1, X2, X3, X4, X5 or X6 is a nitrogen atom. In yet other embodiments, at least one of X2 or X5 is a nitrogen atom. In still other embodiments, at least one of X2 or X5 is a nitrogen atom, and each occurrence of X1, when present, and X3, X4, and X6 are each independently C(R')2. In yet other embodiments, X2 is nitrogen, X5 is CR', and and each occurrence of X1, when present, and X3, X4, and X are each independently C(R')2. In still other embodiments, X2 is CR', X5 is N, and X3, X4, and X6 are each independently C(R' )2. In yet other embodiments, X2 and X are each N, and X , X , and X are each independently C(R' )2.
[0072] In some embodiments, R' is R
[0073] In yet other embodiments, R2 and R3, taken together form an optionally substituted phenyl group and compounds have the formula II:
Figure imgf000030_0001
II
[0074] In yet other embodiments for compounds of general formula II, G1 is =O, -RΛ, - ORA, SRA, or NRARB, and compounds of formula H-A, II-B, H-C, H-D, and H-E are provided as depicted generally below.
Figure imgf000030_0002
H-A II-B ii-c
Figure imgf000030_0003
H-D II-E
[0075] As described generally above, rings formed by R2 and R3 taken together are optionally substituted with x occurrences of Q-Rx, wherein x. is 0-5. In certain embodiments, x is 0-4, and each occurrence of Q-Rx, when present, is independently halogen, CN, NO2, or an optionally substituted group selected from C1-4alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, -N(R')2, -CH2N(R')2, -OR', -CH2OR', -SR', -SO2R', -CH2SR', -COOR', -NRCOR', -CON(R')2, or -S(O)2N(R')2. In other embodiments, each occurrence of Q-Rx, when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, - N(CH3)2, -N(Et)2, -N(iPr)2, -O(CH2)2OCH3, -CONH2, -COOCH3, -OH, -OCH3, -OCH2CH3, - OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, -NHCOCH3, -SO2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole. In other embodiments, x is 2. In still other embodiments, x is 1. In yet other embodiments, x is O.
[0076] As described generally above, G2 and G3 are each independently absent or an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with CO, CS, SO, SO2, NR', N(SO2R')-, N(COR')-, O, or S, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'.
[0077] In some embodiments, G2 is a Q-Caalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -N(SO2R')-, N(COR')-, - O-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the Q-Csalkylidene chain is optionally and independently substituted with R'. In other embodiments, G2 is -(C(R')2)1-3-, - NR'-, -N(SO2R')-, N(COR')-, -C(R')2NR'-, or -NR'C(R')2-. In still other embodiments G2 is - CHR', wherein R' is hydrogen, or optionally substituted C1-QaIkVl.
[0078] In some embodiments, G3 is an optionally substituted Q-Csalkylidene chain wherein one or two methylene units are optionally and independently replaced by -NR'-, -O-, - S-, -CO-, -CS-, or -SO2-, and wherein any hydrogen atom in the d-Csalkylidene chain is optionally and independently substituted with R'. In other embodiments, G3 is -(C(R')2)1-3-, - NR'-, -CO-, -SO2-, or -CONR-.
[0079] As described generally above, B is absent or is an optionally substituted group selected from C6-10 aryl, a hebroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or is an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'. [0080] In some embodiments, B is -NR'C(R')2NR'-, -NR'(C(R')2)2NR'-, -
NR'(C(R')2)3NR'-, -NR'(C(R')2)4NR'-, or is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure
Figure imgf000032_0001
wherein n is 0, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R' )2, -O-, -NR-, S, C=O, or C=S. In still other embodiments, at least one of X1, X2, X3, X4, X5 or X6 is a nitrogen atom. In yet other embodiments, at least one of X2 or X5 is a nitrogen atom. In still other embodiments, at least one of X or X is a nitrogen atom, and each occurrence of X , when present, and X3, X4, and X6 are each independently C(R' )2. In yet other embodiments, X2 is nitrogen, X5 is CR', and and each occurrence of X1, when present, and X3, X4, and X6 are each independently C(R')2. In still other embodiments, X2 is CR', XD is N, and X3, X4, and X6 are each independently C(R')2. In yet other embodiments, X2 and X5 are each N, and X3, X4, and X6 are each independently C(R' )2.
[0081] In still other embodiments, B is an optionally substituted 5-, 6- or 7-membered
1 x4
/ xXV2 χnχχS6 % * saturated, partially unsaturated or fully unsaturated ring having the structure "%. * '" and compounds have the structure of formula III:
Figure imgf000032_0002
III wherein G1, R1, R2, R3, G2, G3, and Ar1 are as described generally above and in classes and subclasses herein; n is 0, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R' )2, -O-, -NR-, S, C=O, or C=S.
[0082] In some embodiments, for compounds of formula III, at least one of X1, X2, X3, X4, X5 or X6 is a nitrogen atom. In yet other embodiments, at least one of X2 or X5 is a nitrogen atom. In still other embodiments, at least one of X2 or X5 is a nitrogen atom and each occurrence of X1, when present, and X3, X4, and X6 are each independently C(R')2. In yet other embodiments, X2 is nitrogen, X5 is CR', and and each occurrence of X1, when present, and X3, X*, and X6 are each independently C(R' )2. In still other embodiments, X2 is CR', X5 is N, and X3, X4, and X6 are each independently C(R' )2. In yet other embodiments, X2 and X5 are each N, and X3, X4, and X6 are each independently C(R')2.
[0083] In other embodiments, for compounds of general formula III described directly above, G1 is =O, -RΛ, -ORA, SRΛ, or NRARB, and compounds having the following general structures III-A, III-B, IH-C, IH-D, and HI-E, are provided as depicted generally below.
Figure imgf000033_0001
III-A III-B
Figure imgf000033_0002
m-c πi-D
Figure imgf000033_0003
III-E
[0084] In still other embodiments, for compounds of general formula III described directly above, G1 is =0, -RA, -ORA, SRΛ, or NRARB, and G3 is bonded to X5 and compounds having formulae IV-A, IV-B, IV-C, IV-D, and IV-E, are provided as depicted generally below.
Figure imgf000034_0001
IV-A IV-B
Figure imgf000034_0002
IV-C IV-D
Figure imgf000034_0003
IV-E
[0085] In yet other embodiments, for compounds of general formula III described directly above, R2 and R3, taken together form an optionally substituted phenyl group, G1 is =O, -RA, SRA, or NRARB, and G3 is bonded to X5 and compounds having formulae V-A, V-B, V-C, V-D, and V-E, are provided as depicted generally below.
Figure imgf000034_0004
V-A V-B
Figure imgf000034_0005
V C V-D
Figure imgf000035_0001
V-E
[0086] In general, as described above, Ar1 is absent or is a 3-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of -W-Rw, wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, - NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, - NRSO2-, -NRSO2NR-, and each occurrence of Rw is independently R', halogen, NO2, or CN.
[0087] In some embodiments, Ar1 is selected from:
(WRw)n O~(WRW) Vw tt /n
Figure imgf000035_0002
a-i a-u a-ui a-iv
Figure imgf000035_0003
a-v a-vi a-vu
Figure imgf000035_0004
a-vin a-ix a-x a-xi
Figure imgf000036_0001
a-xu a-xiu a-xrv a-xv
Figure imgf000036_0002
a-xvi a-xvu a-xvm a-xix
Figure imgf000036_0003
a-xx a-xxi a-xxπ a-xxiH
(WRw)m
Figure imgf000036_0004
a-xxiv a-xxv a-xxvi a-xxvii
Figure imgf000036_0005
a-xxviii a-xxix a-xxx a-xxxi
Figure imgf000036_0006
a-xxxM a-xxxiii a-xxxiv a-xxxv £* -(WRw)m -(WRw)m 4 -(WRw)m
a-xxxvi a-xxxvu a-xxxvm
H
(WRw)m
VO(WRw)π V v(WRw)m ^r (WRw)m
a-xxxix a-xL a-xLi a-xLii
Figure imgf000037_0001
a-xLiϋ a-xLiv a-xLv a-xLvi wherein m is 0, 1, 2, 3, 4 or 5, and wherein any Ar1 is bonded to G3 through any substitutable nitrogen or carbon atom, and wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom is substituted with one or more independent occurrences of W-R . In some embodiments, Ar1 is an optionally substituted group selected from a-i, a-ii, a-v, a-vi, a-vii, a-xx, a-xLii, a-xLiii, a-xLiv, a-xLv, or a-xLvi. In other embodiments, Ar1 is an optionally substituted phenyl group (a-i).
[0088] In other embodiments, W is a bond or is an optionally substituted C1-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by O, NR, S, SO2, or COO, CO, and Rw is R' or halogen. In still other embodiments, each occurrence of WRW is independently -Ci-3alkyl, -O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -CON(R)(R'), -(CH2)2OR\ - (CH2)OR', optionally substituted phenyl, -N(R)(R'), -(CHz)2N(R)(R'), or -(CH2)N(R)(R').
[0089] In addition to these subsets already described herein, in certain embodiments, for compounds of formulae V described directly above:
RA and RB are each independently hydrogen, an optionally substituted group selected from Ci-C7alkyl, C3-C7 cycloalkyl, or C3-C7 heterocyclyl, or RA and RB, taken together, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring; R1 is -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -(CHa)2OR', -(CH2)3OR\ - (CH2)2N(R')2, -(CH2)3N(R')2, -(CH2)2NRCOR\ or -(CH2)3NRCOR' . x is 0, 1, or 2, and each occurrence of -Q-Rx, when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, -N(CH3)2, -N(Et)2, -N(IPr)2, -O(CH2)2OCH3, -CONH2, - COOCH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, - NHCOCH3, -Sθ2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole; n is 1 and X1, X3, X4, and X6 are each CHR;
G2 is -(C(R1Kh-3-, -NR'-, -C(R')2NR\ or -NR'C(R')2-;
G3 is -(C(R')2)1-3-, -NR'-, -CO-, -SO2-, or -(C=O)NR'-;
Ar1 is selected from one of rings a-i through a-xLVi; and each occurrence of WRW is independently -C1-3alkyl, -O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -C(O)N(R)(R'), - (CH2)2OR\ -(CH2)OR', optionally substituted phenyl, -N(R)(R'), -(CH2)2N(R)(R'), or - (CH2)N(R)(R').
[0090] In other embodiments for compounds described directly above, G2 is CH(C1- 3alkyl) or spirocyclopropyl; G3 is -CO-, -SO2-, or -CONR-; and Ar1 is phenyl optionally substituted with -WRW.
[0091] Representative compounds of formula I are set forth below in Table 1.
[0092] Table 1.
Figure imgf000038_0001
Impel No, Structure
Figure imgf000039_0001
CmpdNo, Structure
Figure imgf000040_0001
Figure imgf000040_0002
ϊmpd No. fStrμcture
Figure imgf000041_0001
Figure imgf000041_0002
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
'nipd No. Structure*
39
Figure imgf000057_0001
40
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Cøipd No. j Structure
53
O
r
54
O
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
!mpd No, Structure
190
Figure imgf000131_0001
191
Figure imgf000131_0002
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Cmpd No. Structure ,
334
Figure imgf000203_0001
335
Figure imgf000203_0002
!inpd No. Structure
336
Figure imgf000204_0001
337
Figure imgf000204_0002
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
CmpdNo. Structure
n^
386
Figure imgf000229_0001
«
387
Figure imgf000229_0002
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
[0093] 4. General Synthetic Methodology:
[0094] The compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general scheme below, and the preparative examples that follow.
[0095] Scheme IA, Scheme IB, and Scheme IC below depict general conditions for the synthesis of compounds of formula I where G2 is -CH(CH3)-, and B is piperizinyl.
[0096] Scheme IA;
Figure imgf000238_0001
Scheme IB:
Figure imgf000238_0002
Scheme IC;
Figure imgf000238_0003
[0097] Scheme HA below depicts conditions for the synthesis of one exemplary embodiment for compounds of formula I where G2 is -CH(CH3)-, R1 is n-propyl, B is piperizinyl, G3 is SO2, and Ar1 is optionally substituted phenyl.
[0098] Scheme HA;
Figure imgf000239_0001
[0099] Scheme IIB below depicts conditions for the synthesis of one exemplary embodiment for compounds of formula I wherein (a) G1 is =O, G2 is -CH(CH3)-, R1 is H, B is piperizinyl, G3 is SO2, and Ar1 is 4-methoxyphenyl; (b) G1 is N-piperidinyl, G2 is -CH(CH3)-, B is piperizinyl, G3 is SO2, and Ar1 is 4-methoxyphenyl; and (c) G1 is cyclopentyloxy, G2 is - CH(CHs)-, B is piperizinyl, G3 is SO2, and Ar1 is 4-methoxyphenyl.
[00100] Scheme IIB:
Figure imgf000240_0001
[00101] Scheme III below depicts conditions for the synthesis of one exemplary embodiment for compounds of formula I where Q2 is -CH(CH3)-, R1 is methyl, B is a diamine linker (cyclic or linear and optionally substituted), and Q3 is SO2.
[00102] Scheme III:
Figure imgf000240_0002
Figure imgf000240_0003
N-Boc diamine [00103] Schemes IV and V below depict conditions for the synthesis of one exemplary embodiment for compounds of formula I where G1 is -ORA, SRA, or NRARB and is synthesized from compounds where G1 is =0.
[00104] Scheme IV;
Figure imgf000241_0001
Figure imgf000241_0002
[00105] Scheme V:
Figure imgf000242_0001
[00106] Scheme VI below depicts conditions for the preparation of quinazolinone analogs.
[00107] Scheme VI:
Figure imgf000242_0002
Figure imgf000243_0001
Figure imgf000243_0002
[00108] Scheme VII below depicts conditions for the conversion of bromine to cyano derivatives. [00109] Scheme VII:
KCN, CuI, Pd(PPh3)4 CH3CN, microwave
Figure imgf000243_0003
Figure imgf000243_0004
[00110] Scheme VIII below depicts conditions for the conversion of cyano to amide and tetrazole derivatives.
[00111] Scheme VIII:
Figure imgf000244_0001
[00112] Scheme IX below depicts conditions for the conversion of bromo to methylsulfonamide derivatives.
[00113] Scheme IX:
Figure imgf000244_0002
[00114] Scheme X below depicts conditions for converting a nitro derivative to the amino or NHC(O)CH3 derivative. [00115] Scheme X:
Figure imgf000245_0001
[00117] Scheme XI below depicts conditions for the synthesis of one exemplary embodiment of compounds of formula I, wherein G1 is =O, R1 is Me, G2 is isopropyl, B is piperazinyl, G3 is SO2, and Ar1 is 4-methoxyphenyl.
[00118] Scheme XI:
Figure imgf000245_0002
[00119] Scheme XII below depicts the conditions for synthesis of compounds of formula I, wherein G1 is RA.
[00120] Scheme XII:
POCIq
Figure imgf000245_0003
Figure imgf000245_0004
Figure imgf000245_0005
[00121] Scheme XIII below depicts an exemplary synthesis based on Scheme
XII.
[00122] Scheme XIII:
Figure imgf000246_0001
[00123] Scheme XIV below depicts the conditions for the synthesis of an exemplary embodiment of formula I, wherein R and R together form a pyrazine ring, G is ORA, B is a piperazine ring, G3 is SO2.
[00124] Scheme XIV:
Figure imgf000246_0002
[00125] Scheme XV below depicts the conditions for the synthesis of compounds of formula I, wherein G1 is hydrogen, G2 is CH(CH3), B is piperazine, G2 is SO2.
[00126] Scheme XV:
Figure imgf000246_0003
[00127] Scheme XVIA, Scheme XVIB, and Scheme XVIC below depict general conditions for the synthesis of compounds of formula I wherein R2 and R3 do not cyclize, and B is piperazinyl.
[00128] Scheme XVIA;
Figure imgf000247_0001
[00129] Scheme XVIB:
Figure imgf000247_0002
[00130] Scheme XVIC: OEt
EtOH, HCI H, EtOH
CN ^C EtOH, NH3 NH2 KO
NH.HCI
NH -COOEt
NBS, CHCI3 Benzoylperoxide
Figure imgf000248_0001
Figure imgf000248_0002
HNRARB
Figure imgf000248_0003
Figure imgf000248_0004
[00131] Scheme XVII below depicts the conditions for the synthesis of one exemplary embodiment of formula I, wherein RA and RB together form piperidyl, G2 is - CH(CH3)-, G3 is SO2, and Ar1 is 4-methoxyphenyl.
[00132] Scheme XVII;
Figure imgf000248_0005
[00133] Scheme XVIII below depicts the conditions for the synthesis of an exemplary embodiment of compound of formula I, wherein RA ar d RB together form piperidyl, G2 is -CH(CH3)-, G3 is SO2, and Ar1 is 4-methoxyphenyl.
[00134] Scheme XVIII
Figure imgf000249_0001
[00135] Scheme XIX below depicts the conditions for the synthesis of compounds of formula I, wherein G1 is alkoxy, and R2 and R3 do not cyclize to form a ring.
Figure imgf000249_0002
[00136] Scheme XX below depicts the conditions for the synthesis of an exemplary compound of formula I, wherein G1 is cyclopentyloxy, and R2 and R3 both are hydrogen.
Figure imgf000250_0001
[00137] Scheme XXI below depicts the conditions for the general synthesis of compounds of formula I, wherein R2 is carboethoxy, and G1 is alkoxy.
Figure imgf000250_0002
[00138] Scheme XXII below depicts the conditions for the synthesis of an exemplary embodiment of formula I, wherein R2 is carboethoxy, G1 is cyclopentyloxy, G2 is - CH(CH3)-, G3 is SO2, B is piperazyl, and Ar1 is 4-methoxyphenyl.
Figure imgf000250_0003
[00139] Scheme XXIII below depicts the conditions for the general synthesis of compounds of formula I, wherein R2 and R3 cyclize to form a phenyl ring, G1 is an alkoxy and B is a piperidyl ring.
Figure imgf000251_0001
[00140] Scheme XXIV below depicts an exemplary embodiment of compound of formula I, wherein RA is cyclopentyloxy, B is piperidinyl, G1 is -CH(CH3)-, G3 is SO2, and Ar1 is 4-methoxyphenyl.
Figure imgf000251_0002
[00141] Although certain exemplary embodiments are depicted and described above and herein, it will be appreciated that compounds of the invention can be prepared according to the methods described generally above using appropriate starting materials by methods generally available to one of ordinary skill in the art. [00142] 5. Uses, Formulation and Administration
[00143] Pharmaceutically acceptable compositions
[00144] As discussed above, the present invention provides compounds that are useful as modulators of ABC transporters and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease (due to Prion protein processing defect), Fabry disease and Straussler-Scheinker syndrome.
[00145] Accordingly, in another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
[00146] It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
[00147] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A "pharmaceutically acceptable salt" means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel.
[00148] Pharmaceutically acceptable salts are well known in the art. For example,
S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci^aIkVl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salt? include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[00149] As described above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
[00150] Uses of Compounds and Pharmaceutically Acceptable Compositions [00151] In yet another aspect, the present invention provides a method of treating a condition, disease, or disorder implicated by ABC transporter activity. In certain embodiments, the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of ABC transporter activity, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
[00152] In certain preferred embodiments, the present invention provides a method of treating Cystic fibrosis; Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hufler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type π,
Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease (due to Prion protein processing defect), Fabry disease, Straussler-Scheinker disease, secretory diarrhea, and polycystic kidney disease, comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above. [00153] According to an alternative preferred embodiment, the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
[00154] According to the invention an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type π, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scheinker disease, secretory diarrhea, and polycystic kidney disease.
[00155] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scheinker disease, secretory diarrhea, and polycystic kidney disease. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00156] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00157] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[00158] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[00159] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00160] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00161] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00162] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monoόtearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00163] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[00164] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00165] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled deliyery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[00166] As described generally above, the compounds of the invention are useful as modulators of ABC transporters. Thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of ABC transporters is implicated in the disease, condition, or disorder. When hyperactivity or inactivity of an ABC transporter is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "ABC transporter-mediated disease, condition or disorder". Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an ABC transporter is implicated in the disease state.
[00167] The activity of a compound utilized in this invention as a modulator of an
ABC transporter may be assayed according to methods described generally in the art and in the Examples herein.
[00168] It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated".
[00169] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[00170] The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
[00171] Another aspect of the invention relates to modulating ABC transporter activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00172] Modulation of ABC transporter activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of ABC transporters in biological and pathological phenomena; and the comparative evaluation of new modulators of ABC transporters.
[00173] In yet another embodiment, a method of modulating activity of an anion channel in vitro or in vivo, is provided comprising the step of contacting said channel with a compound of formula (I). In preferred embodiments, the anion channel is a chloride channel or a bicarbonate channel. In other preferred embodiments, the anion channel is a chloride channel.
[00174] According to an alternative embodiment, the present invention provides a method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (I). The term "functional ABC transporter" as used herein means an ABC transporter that is capable of transport activity. In preferred embodiments, said functional ABC transporter is CFTR.
[00175] According to another preferred embodiment, the activity of the ABC transporter is measured by measuring the transmembrane voltage potential. Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
[00176] The optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00177] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission can be monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
[00178] In another aspect the present invention provides a kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo comprising (i) a composition comprising a compound of formula (I); and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said ABC transporter or a fragment thereof. In one embodiment, the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said ABC transporter or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the ABC transporter in the presence of the additional compound with the density of the ABC transporter in the presence of a composition of formula (I). In preferred embodiments, the kit is used to measure the density of CFTR.
[00179] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLES
[00180] 2-Propionylamino-benzoic acid
Figure imgf000264_0001
To a solution of anthranilic acid (2.96 g, 21.6 mmol) in DMF (10 mL) cooled in an ice-water bath was added propionyl chloride. The reaction was stirred for 2 hours while warming to room temperature. Water (20 mL) was added and the mixture was stirred vigorously for 1 hour. The precipitate was then collected by vacuum filtration to give the product as a white solid (3.11 g , 75%). 1HNMR (CDCl3) δ 1.32 (t, 3H, J = 7.6 Hz), 2.53 (q, 2H, / = 7.6 Hz), 7.14 (t, IH, J = 8.2 Hz), 7.62 (t, IH, /= 8.7 Hz), 8.15 (dd, IH, J = 1.5, 8.1 Hz), 8.79 (dd, IH, 7 = 0.9, 8.5 Hz), 10.97 (s, IH).
[00181] 2-EthyI-benzo[d][l,3]oxazin-4-one
Figure imgf000264_0002
A mixture of 2-Propionylamino-benzoic acid (1.0 g, 5 mmol) and acetic anhydride (10 mL) were heated to reflux for 3 hours until TLC indicated that no more starting material remained. The remaining acetic anhydride was removed in vacuo. Toluene (2 mL) was added and then removed in vacuo. This was repeated 2 more times to try and remove final traces of acetic anhydride. The product was obtained as a pale yellow solid (820 mg, 90%). 1H NMR (CDCl3) δ 1.37 (t, 3H, J = 7.6 Hz), 2.73 (q, 2H, / = 7.6 Hz), 7.50 (t, IH, J = 7.6 Hz), 7.57 (d, IH, J = 8.0 Hz), 7.79 (t, IH, J = 7.7 Hz), 8.19 (d, IH, 7 = 8.1 Hz).
[001S2] 2-Ethyl-3-propyI-3H-quinazolin-4-one
Figure imgf000265_0001
A mixture of 2-ethyl-benzo[d][l,3]oxazin-4-one (541 mg, 3.1 mmol) and propylamine (254 μL, 3.1 mmol) were heated to 110° C for 1 hour. The crude product was purified by column chromatography (10 - 40% ethyl acetate - hexanes) to yield the product as a white solid (195 mg, 29%). 1H NMR (CDCl3) δ 1.03 (t, 3H, J = 7.4 Hz), 1.41 (t, 3H, J = 7.3 Hz), 1.76 (sex, 2H, J = 7.7 Hz), 2.86 (q, 2H, J = 7.4 Hz), 4.05 (t, 2H, J = 7.9 Hz), 7.42 (t, IH, J = 8.1 Hz), 7.63 (d, IH, / = 7.7 Hz), 7.70 (t, IH, / = 7.7 Hz), 8.24 (d, IH, J = 8.1 Hz).
[00183] 2-(l-Bromo-ethyl)-3-propyl-3H-quinazolin-4-one
Figure imgf000265_0002
To a solution of 2-ethyl-3-propyl-3H-quinazolin-4-one (125 mg, 0.58 mmol) and sodium acetate (48 mg, 0.58 mmol) in glacial acetic acid (1 mL) cooled in an ice bath was added dropwise a solution of bromine (29.8 μL, 0.58 mmol) in glacial acetic acid (0.5 mL). After addition was complete the reaction was heated to reflux for 2 hours. Water was then added to the solution and the mixture extracted with dichloromethane. The organic layer was then washed with 10% sodium bisulfite solution, water and then dried over magnesium sulfate, filtered and concentrated to yield the product as a brown oil (158 mg, 92%). 1H NMR (CDCl3) 5 1.05 (t, 3H, J = 7.3 Hz), 1.66 (m, IH), 1.91 (m, IH), 2.19 (d, 3H, J = 6.3 Hz), 3.89 (m, IH,), 4.53 (m, IH,), 5.04 (q, IH, J = 6.6 Hz), 7.49 (t, IH, J = 7.3 Hz), 7.73 (m, 2H), 8.27 (d, IH, J = 8.4 Hz).
[00184] 4-(4-Bromo-benzenesulfonyl)-piperazine-l- carboxylic acid tert-butyl ester
Figure imgf000266_0001
To a solution of tørt-butyl 1-piperazine-caxboxylate (932 mg, 5 mmol) and triethyl amine (836 μL, 6 mmol) in dioxane (10 mL) was added 4-bromo-benzenesulfonyl chloride (1.28 g, 5 mmol). A white precipitate begins to form almost immediately. The reaction mixture was stirred for 1 hour at room temperature and the filtered. The filtrate was concentrated in vacuo to yield the product as a shiny white solid (1.85 g, 91%). 1H NMR (CDCl3) δ 1.44 (s, 9H), 3.01 (t, 4H, J = 5.1 Hz), 3.53 (t, 4H, J = 5.1 Hz), 7.64 (dt, 2H, J = 2.1, 8.7 Hz), 7.70 (dt, 2H, 7 = 2.1, 8.7). [00185] l-(4-Bromo-benzenesulfbnyl)-piperazine
Figure imgf000266_0002
4-(4-Bromo-benzenesulfonyl)-piperazine-l-carboxylic acid tert-butyl ester (500 mg, 1.23 mmol) was dissolved in a mixture of dichloromethane (5 mL) and trifluoroacetic acid (5 mL) and stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo and then dissolved in dichloromethane and washed with saturated sodium bicarbonate solution and then water. The organic layer was then dried over magnesium sulfate and concentrated in vacuo to yield the product as a white solid (329, mg, 88%). 1H NMR (CDCl3) 5 1.77 (s, IH), 2.96 (m, 4H)5 3.01 (m, 4H), 7.64 (dt, 2H, J= 2.1,8.7 Hz), 7.69 (dt, 2H, J = 2.1, 8.7 Hz).
[00186] 2-{l-[4-(4-Bromo-benzenesulfonyI)-piperazin-l-yI]-ethyI}-3-propyl-
3H-quinazolin-4-one:
Figure imgf000266_0003
A mixture of 2-(l-bromo-ethyl)-3-propyl-3H-quinazolin-4-one (30 mg, 0.1 mmol) and l-(4- bromo-benzenesulfonyl)-piperazine (47 mg, 0.15 mmol) in ethanol (1 mL) was refluxed overnight. The reaction mixture was then concentrated in vacuo and purified by reverse phase HPLC to yield the product as a white powder (7 mg, 9%). 1H NMR (CDCl3) δ 1.03 (t, 3H, J = 5.8 Hz), 1.72 (sex, 2H, J= 6.0), 1.80 (d, 3H, /= 5.2), 3.48 (m, 6H), 3.90 (m, 3H), 4.23 (m, IH), 4.77 (q, IH1 J = 5.2 Hz), 7.58 (m, 3H), 7.68 (d, IH, J = 6.5 Hz), 7.72 (d, 2H, J = 1.1 Hz), 7.81 (t, IH, J = 6.2 Hz), 8.28 (d, IH, J = 6.5 Hz).
[00187] 2-EthyI-3-methyI-3H-quinazoIin-4-one
Figure imgf000267_0001
A mixture of anthranilic acid (13.7 g, 100 mmol), methylamine (2M solution in methanol, 100 mL, 200 mmol), triethylorthopropionate (40 mL, 200mmol), pΥSA (catalytic amount) was heated at 70°C with stirring for 3 days. The reaction mixture was cooled to room temperature, IN NaOH solution (160 mL) was added and the mixture stirred vigourously. The resulting precipitate was filtered, washed with water and dried under high vacuum to yield the product as a fluffy white solid (13.67g, 73%). 1H NMR (400 MHz, CDCl3) δ 1.41 (t, 3H, J = 7.4 Hz), 2.87 (q, 2H, J = 7.4 Hz), 3.64 (s, 3H), 7.44 (t, IH, 7 = 8.1 Hz), 7.65 (dd, IH, J = 8.8, 0.7 Hz), 7.72 (t, IH, J = 8.4 Hz), 8.27 (dd, IH, J = 9.2, 1.8 Hz); ESI-MS m/z 189.0 (M+l)+.
[00188] 2-(l-Bromo-ethyl)-3-methyl-3H-quinazolin-4-one
Figure imgf000267_0002
To a solution of 2-ethyl-3-methyl-3H-quinazolin-4-one (11.28 g, 60 mmol) and sodium acetate (4.92 g, 60 mmol) in glacial acetic acid (130 mL) heated to 50°C was added dropwise a solution of bromine (3.70 mL, 72 mmol) in glacial acetic acid (50 mL). After addition was complete the reaction was heated to refjux for 2 hours. The reaction was then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with 10% sodium bisulfite solution, water and dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified by column chromatography (0 - 25% ethyl acetate - hexanes) to yield the product as a white solid (12.68g, 79%). 1H NMR (400 MHz ,CDCl3) δ 2.19 (d, 3H, J = 6.6 Hz), 3.77 (s, 3H), 5.08 (q, IH, J = 6.6 Hz), 7.50 (t, IH, J = 8.1 Hz), 7.74 (m, 2H), 8.29 (d, IH, /= 8.9 Hz); ESI-MS m/z 267.0 (M+l)+.
[00189] 6-Bromo-2-ethyl-3-methyl-3H-quinazoIin-4-one
Figure imgf000268_0001
To a stirred solution of 2-amino-5-bromo-benzoic acid (10.00 g, 46.38 mmol) in methanol (25 mL) was added methylamine (100 ml of 2 M solution in methanol), p-toluenesulfonic acid monohydrate (8.82 g, 46.38 mmol), and triethyl orthopropionate (40.87g, 231.9 mmol). The reaction was refluxed for 18 hours, at which time it was allowed to cool to room temperature. The solution was concentrated under reduced pressure. The residue was partitioned between sodium carbonate aqueous (50 ml) and dichloromethane (50 ml). The organic layer was then washed with saturated brine (2 x 30 ml). The combined organic phase was dried over magnesium sulfate and filtered. The solvent was removed under vacuum. The resulting residue was purified by silica gel chromatography with 100% dichloromethane. The product was collected and was dried under reduced pressure to give 6-Bromo-2-ethyl-3-methyl-31ϊ-quinazolin-4-one (Yield 4.92 g, 39.9%). 1H NMR (400 MHz, CDCl3): D 1.42 (t, 3 H, J = 7.33 Hz), 2.86 (dd, 2 H, J = 14.65, 7.58 Hz), 7.45 (d, 1 H, J = 8.5 Hz), 7.80 (dd, 1 H, J = 8.50, 2.02 Hz), 8.40 (d, I H1 J = 2.05 Hz). MS m/z calc. 266.01, found (ESI); 267.0(M + I)+. Retention time 2.44 minutes. [00190] 6-Bromo-2- (l-bromo-ethyl)-3-methyl-3H-quinazolin-4-one
Figure imgf000268_0002
To a solution of 6-bromo-2-ethyl-3-rnethyl-3H-quinazolin-4-one (2.6 g, 9.73 mmol) in glacial acetic acid (2 ml) cooled in an ice bath was added dropwise a solution of bromine (3.1 g, 19.46 mmol) in glacial acetic acid (5 ml). After addition was complete, the reaction was heated to reflux for 18 hours. At which time it was allowed to cool to room temperature. Water was then added to the solution and the mixture was extracted with dichloromethane. The organic layer was then washed with 10% sodium bisulfite solution, and then washed with saturated brine (2 x 30 ml). The combined organic phase was collected and dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a brown crude product. The resulting residue was purified by silica gel chromatography with 50% dichloromethane in hexane. The product was collected and was dried under reduced pressure to give 6-Bromo-2- (l-bromo-ethyl)-3-methyl- 3#-quinazolin-4-one (Yield 2.78 g, 82.5%). 1H NMR (400 MHz, CDCl3): δ 2.23 (d, 3 H, J = 6.82 Hz), 3.80 (s, 3 H), 5.11 (q, I H, J = 13.14, 6.82 Hz), 7.64 (d, 1 H, J = 8.84 Hz), 7.87(dd, 1 H, J = 8.59, 2.26 Hz), 8.46 (d, I H, J = 2.26 Hz). MS m/z calc. 345.9, found (ESI); 347.0(M + I)+. Retention time 3.43 minutes.
[00191] 6-Bromo-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-
3-methyl-3ϋf-quinazolin-4-one
Figure imgf000269_0001
In a test tube containing of 6-bromo-2- (l-bromo-ethyl)-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.14 mmol) in acetonitrile (2 ml) was added KI (34.0 mg, 0.21 mmol), and 4-methoxy-l- benzenesulfonyl-piperazine (40.0 mg, 0.17 mmol). The reaction was heated for 18 hours. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was purified by ΗPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 6-Bromo-2- {l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-3H-quinazolin-4-one (Yield 30.1 mg, 39.9 %). 1H NMR (400 MHz, CDCl3): δ 1.86 (d, 3 H, 7 = 6.82 Hz), 3.63-3.39 (m, 6 H), 3.79-3.68 (m, 2 H), 3.80 (s, 3 H), 4.03 (s, 3 H), 4.82-4.74 (m, 1 H), 7.18-7.12 (m, 2 H), 7.70 (d, 1 H, J = 8.55 Hz), 7.84-7.79 (m, 2 H), 8.01 (dd, 2 H, J = 8.84, 2.27 Hz), 8.58 (d, 1 H, J = 2.5 Hz). MS m/z calc. 521.4, found (ESI); 523.2(M + I)+. Retention time 2.80 minutes.
[00192] 2-[l-(4-Benzenesulfonyl-piperazin-l-yl)-ethyl]-6-bromo-3-methyl-3flr- quinazolin-4-one
Figure imgf000269_0002
2-[l-(4-Benzenesulfonyl-piperazin-l-yl)-ethyl]-6-bromo-3-methyl-3H-quinazolin-4-one compound was synthesized by using the same method as described as Scheme IA or Scheme IB above. (Yield 27.35 mg, 38.4 %). 1H NMR (400 MHz, CDCl3): δ 1.86 (d, 3 H, J = 7.07 Hz), 3.30-3.17 (m, 4 H), 3.49-3.33 (m, 4 H), 3.61 (s, 3 H), 4.61-4.51 (m, 1 H), 7.54-7.42 (m, 3 H), 7.62-7.57 (m, 1 H), 7.72-7.67 (m, 2 H), 7.82 (dd, 1 H, J = 8.50, 2.51 Hz), 8.36 (d, 1 H, J = 2.5 Hz). MS m/z calc. 490.1, found (ESI); 491.2(M + I)+. Retention time 2.64 minutes.
[00193] 6-Bromo-3-methyl-2-{l-[4-(toIuene-4-suIfonyl)-piperazin-l-yl]-ethyl}-
3H-quinazoIin-4-one
Figure imgf000270_0001
6-Bromo-3-methyl-2-{ l-[4-(toluene-4-sulfonyl)-piperazin-l-yl]-ethyl}-3H-quinazolin-4-one compound was synthesized by using the same method as described as Scheme IA or Scheme IB. (Yield 8.17 mg, 11.16 %). 1H NMR (400 MHz, CDCl3): δ 1.79 (d, 3 H, J= 6.32 Hz), 2.47 (s, 3 H), 3.61-3.41 (m, 6 H), 3.68 (s, 1 H), 3.93-3.81 (m, 2 H), 4.86-4.77 (m, 1 H), 7.37 (d, 2 H, J = 7.83), 7.58 (d, 1 H, J = 8.5 Hz), 7.64 (d, 2 H, J = 8.5 Hz), 7.89 (dd, 1 H, J = 8.5, 2.5 Hz), 8.43 (d, 1 H, J = 2.5 Hz). MS m/z calc. 505.4, found (ESI); 507.2 (M + I)+. Retention time 2.80 minutes. [00194] 6-Bromo-2-{l-[4-(4-chIoro-benzenesuIfonyl)-piperazin-l-yI]-ethyl}-3- methyl-3H-quinazolin-4-one
Figure imgf000270_0002
6-Bromo-2-{ l-[4-(4-chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-3H-quinazolin-4- one compound was synthesized by using the same method described in Scheme IA or Scheme IB. (Yield 30.1 mg, 23.1 %). 1H NMR (400 MHz, CDCl3): δ 1.79 (d, 3 H, J = 6.82 Hz), 3.47- 3.38 (m, 2 H), 3.62-3.48 (m, 4 H), 3.68 (s, 3 H), 3.85-3.76 (m, 2 H), 4.79 (q, 1 H, J = 13.80, 7.07 Hz), 7.60-7.54(m, 3 H), 7.73-7.68(m, 2 H), 7.90 (dd, 1 H, J = 8.59, 2.27 Hz), 8.44 (d, I H, J = 2.5 Hz). MS m/z calc. 525.8, found (ESI); 527.2 (M + I)+. Retention time 2.94 minutes.
[00195] 6-Bromo-2-{l-[4-(4-bromo-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-3- methyl-3H-quinazolin-4-one
Figure imgf000271_0001
6-Bromo-2-{ l-[4-(4-bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-3H-quinazolin-4- one compound was synthesized by using the same method as described in Scheme IA or Scheme IB. (Yield 13.5 mg, 16.3 %). 1H NMR (400 MHz, CDCl3): δ 1.89 (d, 3 H, J = 7.07 Hz), 3.47-3.38 (m, 2 H), 3.64-3.49 (m, 4 H), 3.69 (s, 3 H), 3.83-3.74 (m, 2 H), 4.71 (q, I R, J = 13.64, 6.57, Hz), 7.65-7.59 (m, 3 H), 7.75-7.70 (m, 2 H), 7.90 (dd, 1 H, J= 8.59, 2.27 Hz), 8.44 (d, 1 H, J = 2.27 Hz). MS m/z calc. 570.3, found (ESI); 571.0 (M + I)+. Retention time 2.98 minutes.
[00196] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-5-chloro-3- methyl-31ϊ-qumazolin-4-one
Figure imgf000271_0002
2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-5-chloro-3-methyl-3H-quinazolin-4- one compound was synthesized by using the same method as described in Scheme IA or Scheme IB (Yield 25.39 mg, 32.2 %). MS m/z calc. 525.8, found (ESI); 527.1(M + I)+. Retention time 2.69 minutes.
[00197] 2-EthyI-3-methyI-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile
Figure imgf000271_0003
The substrate of 6-bromo-2-ethyl-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.189 mmol), KCN (23.1 mg, 0.37 mmol), Pd (PPh3)4 (10.0 mg, 0.0094 mmol), and CuI (3.6 mg, 0.019 mmol) was added to a flask, which was flushed with N2. The solvent acetonitrile (2 ml) was added via syringe. The resulting mixture was irradiated at 170 0C for 2 hours in the SmithSynthesizer Microwave Reactor (Personal Chemistry) with vigorous agitation by a magnetic stirrer. The mixture was cooled to room temperature, diluted with ethyl acetate (5 ml), and then filtered through Celite. The filtrate was washed with water and brine, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 2-Ethyl-3-methyl-4-oxo-3,4-dihydro-quinazoline-6- carbonitrile (Yield 16.8 mg, 46.2%). 1H NMR (400 MHz, CDCl3): δ^l.35 (t, 3 H, J = 7.30 Hz), 2. 85 (q, 2 H, 7= 14.62, 7.30 Hz), 3.54 (s, 3 H), 7.68 (d, 1 H, J = 8.58 Hz), 7.83 (dd, 1 H, J= 8.58, 2.02 Hz), 8.51 (d, I H, / = 2.02 Hz). MS IWL calc. 213.2, Found (ESI); 214.0 (MH-I)+. Retention time 2.13 minutes.
[00198] 2-(l-Bromo-ethyl)-3-methyl-4-oxo-3,4-dihydro-quinazoIine-6- carbonitrile
Figure imgf000272_0001
To a solution 2-isopropyl-3-methyl-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile (0.35 g, 1.64 mmol) in glacial acetic acid (10 ml) cooled in an ice bath was added dropwise a solution of bromine (0.52 g, 3.28 mmol) in glacial acetic acid (5 ml). After addition was complete, the reaction was heated to reflux for 18 hours. At which time it was allowed to cool to room temperature. Water was then added to the solution and the mixture was extracted with dichloromethane. The organic layer was then washed with 10% sodium bisulfite solution, and then washed with saturated brine (2 x 10 ml). The combined organic phase was collected and dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a brown crude product. The resulting residue was purified by silica gel chromatography with 50% dichloromethane in hexane. The product was collected and was dried under reduced pressure to give 2-(l-Bromo-ethyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile (Yield 0.35 g, 73.1 %). 1H NMR (400 MHz, CDCl3): δ 2.20 (d, 3 H, J = 6.54 Hz), 3.78 (s, 3 H), 5.17 (q, 1 H, J = 12.88, 6.54 Hz), 7.81 (d, 1 H, J = 8.84 Hz), 7.94 (dd, 1 H, 7 = 8.34, 2.02 Hz), 8.61 (d, 1 H, J = 2.02 Hz). MS m/z calc. 291.0, found (ESI); 292.0(M + I)+. Retention time 2.95 minutes.
[00199] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyI}-3-methyl-
4-oxo-3,4-dihydro-quinazoline-6-carbonitriIe
Figure imgf000273_0001
In a test tube containing of 2-(l-bromo-ethyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-6- carbonitrile (40.0 mg, 0.14 mmol) in acetonitrile (2 ml) was added KI (34.0 mg, 0.21 mmol), and (l-(4-Methoxy-benzenesulfonyl)-piperazine (46.4 mg, 0.21 mmol). The reaction was heated for 18 hours. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was dissolvent in DMSO (2 ml) and purified by HPLC (Gilson- 215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give the 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-3-methyl-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile compound (Yield 5.52mg, 8.2 %). 1H NMR (400 MHz, CDCl3): δ 1.64 (d, 3 H, J= 6.57 Hz), 3.29-3.10 (m, 6 H), 3.48-3.37 (m, 2 H), 3.68 (s, 3 H), 3.90 (s, 3 H), 4.53 (q, 1 H, 7 = 13.14, 5.81 Hz), 6.97 (d, 2 H, J = 2.02 Hz), 7.66 (d, 2 H, J = 8.84, Hz), 7.76 (d, I H, J = 8.59 Hz), 7.94 (dd, I H J = 8.59, 2.02 Hz), 8.57 (d, I U, J= 2.02 Hz). MS rn/z calc. 467.16, found (ESI); 468.4 (M + I)+. Retention time 2.75 minutes.
[00200] 3-Methyl-4-oxo-2-{l-[4-(toluene-4-sulfonyl)-piperazin-l-yl]-ethyl}-3,4- dihydro-quinazoline-6-carbonitriIe
Figure imgf000273_0002
3-Methyl-4-oxo-2-{ l-[4-(toluene-4-sulfonyl)-piperazin-l-yl]-ethyl}-3,4-dihydro-quinazόline-6- carbonitrile was synthesized by using the same method as described in Scheme IA or Scheme IB. (Yield 31.03 mg, 50.4 %). 1H NMR (400 MHz, CDCl3): δ 1.67 (d, 3 H, /= 6.28 Hz), 2.46 (s, 3 H)1 3.34-3.17 (m, 6 H), 3.56-3.47 (m, 2 H), 3.67 (s, 3 H), 4.60 (q, I H, J = 13.99, 6.57 Hz), 7.36 (d, 2 H, J = 8.08 Hz), 7.60 (d, 2 H, / = 8.08, Hz), 7.76 (d, 1 H, J = 8.59 Hz), 7.94 (dd, 1 H J = 8.59, 1.77 Hz), 8.56 (d, 1 H, J = 1.77 Hz). MS m/z calc. 451.17, found (ESI); 452.2 (M + I)+. Retention time 2.52 minutes. [00201] 2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyI}-3-methyl-4- oxo-3,4-dihydro-quinazoline-6-carbonitrile
Figure imgf000274_0001
2- { 1 - [4-(4-Chloro-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -3-methyl-4-oxo-3 ,4-dihydro- quinazoline-6-carbonitrile was synthesized by using the same method as described in Scheme IA or Scheme IB. (Yield 28.30 mg, 44.0 %). 1H NMR (400 MHz, CDCl3): δ 1.54 (d, 3 H, J = 6.82 Hz), 3.23-2.96 (m, 6 H), 3.35-3.25 (m, 2 H), 3.59 (s, 3 H), 4.41 (q, 1 H, J = 13.89, 6.82 Hz), 7.47-7.43 (m, 2 H), 7.61-7.56 (m, 2 H), 7.77-7.65 (m, 1 H), 7.85(dd, I H J = 8.59, 1.77 Hz), 8.47 (d, I U, J= 1.77 Hz). MS m/z calc. 471.1, found (ESI); 472.2 (M + I)+. Retention time 2.65 minutes.
[00202] 2-Ethyl-6-methanesulfonyl-3-methyl-3H-quinazolin-4-one
Figure imgf000274_0002
The substrate of 6-bromo-2-ethyl-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.189 mmol), sodium methanesulfinate (28.8 mg, 0.29 mmol) and copper (I) iodide (53.7 mg, 0.29 mmol) was placed in a flask, which was flushed with N2. DMF (2 ml) was added via syringe. The resulting mixture was irradiated at 1800C for 30 minutes in the SmithSynthesizer Microwave reactor (Personal Chemistry) with vigorous agitation by a magnetic stirrer. The mixture was cooled to room temperature, diluted with ethyl acetate (5 ml), and then filtered. The filtrate was washed with water and brine, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by ΗPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 2- Ethyl-6-methanesulfonyl-3-methyl-3H-quinazolin-4-one (Yield 12.5 mg, 25.1%). 1H NMR (400 MHz, CDCl3): δ 1.35 (t, 3 H, / = 7.58 Hz), 2.83 (dd, 2 H, J= 14.65, 7.58 Hz), 3.02 (s, 3 H), 3.58 (s, 3 H), 7.73 (d, 1 H, / = 8.84 Hz), 8.12 (dd, I H, J = 8.84 Hz), 8.77 (d, I H1 J = 2.02 Hz). MS m/z calc. 265.1, found (ESI); 266.0 (M + I)+. Retention time 2.41 minutes. [00203] 2-(l-Bromo-ethyl)-6-methanesuIfonyl-3-methyl-3H-quinazolin-4-one
Figure imgf000275_0001
To a solution 2-ethyl-6-methanesulfonyl-3-methyl-3H-quinazolin-4-one (300.0 mg, 1.13 mmol) in glacial acetic acid (10 ml) cooled in an ice bath was added dropwise a solution of bromine (0.39 g, 2.26 mmol) in glacial acetic acid (5 ml). After addition was complete, the reaction was heated to reflux for 18 hours. Evaporated acetic acid and then water was added to the solution and the mixture was extracted with dichloromethane. The organic layer was washed with 10% sodium bisulfite solution, and then washed with saturated brine (2 x 10 ml). The combined organic phase was collected and dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a brown crude product. The resulting residue was purified by silica gel chromatography with 50% ethyl acetate in hexane. The product was collected and was dried under reduced pressure to give 2-(l-Bromo-ethyl)-6-methanesulfonyl-3-methyl-3H-quinazolin- 4-one (Yield 339 mg, 87.2 %). 1H NMR (400 MHz, CDCl3): δ 2.13 (d, 3 H, J = 5.31 Hz), 3.04 (s, 3 H), 3.71 (s, 3 H), 5.05 (m, 1 H), 7.81 (d, 1 H, J = 7.58 Hz), 8.16 (d, 1 H, J = 7.58, Hz), 8.80 (s, 1 H). MS m/z calc. 343.98, found (ESI); 344.8 (M + I)+. Retention time 3.06 minutes.
[00204] 6-MethanesulfonyI-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyI}-3-methyl-3#-quinazolin-4-one
Figure imgf000275_0002
In a test tube containing of 2-(l-Bromo-ethyl)-6-methanesulfonyl-3-methyl-3H-quinazolin-4-one (40.0 mg, 0.12 mmol) in acetonitrile (2 ml) was added KI (28.0 mg, 0.18 mmol), and (l-(4- Methoxy-benzenesulfonyl)-piperazine (39.6 mg, 0.18 mmol). The reaction was heated at 800C for 18 hours. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was dissolvent in DMSO (2 ml) and purified by HPLC (Gilson- 215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 6-Methanesulfonyl-2-{ l-[4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-3H-quinazolin-4-one (Yield 32.4 mg, 55.2 %). 1H NMR (400 MHz, CDCl3): δ 1.82 (d, 3 H, J = 7.07 Hz), 3.12 (s, 3H), 3.64-3.40 (m, 4 H), 3.70 (s, 3 H), 4.00-3.86 (m, 7 H), 4.89 (q, 1 H, J = 14.40, 6.03 Hz), 7.05 (d, 2 H, J = 9.09 Hz), 7.68 (d, 2 H, J = 9.09, Hz), 7.84 (d, I B, J= 8.84 Hz), 8.25 (dd, I HJ= 8.84, 2.02 Hz), 8.82 (d, I U, J = 2.02 Hz). MS m/z calc. 490.1, found (ESI); 491.2 (M + I)+. Retention time 2.17 minutes.
[00205] 6-Methanesulfonyl-3-methyl-2-{l-[4-(toIuene-4-sulfonyl)-piperazin-l- yl]-ethyl}-3H-quinazolin-4-one
Figure imgf000276_0001
6-Methanesulfonyl-3-methyl-2-{ l-[4-(toluene-4-sulfonyl)-piperazin-l-yl]-ethyl}-3H-quinazolin- 4-one compound was synthesized by using the same method as described in Scheme IA or Scheme IB. (Yield 34.2 mg, 56.5 %). 1H NMR (400 MHz, CDCl3): δ 1.85 (d, 3 H, J= 6.32 Hz), 2.47 (s, 3 H), 3.13 (s, 3 H), 3.66-3.45 (m, 4 H), 3.71 (s, 3 H), 4.05-3.92 (m, 4 H), 4.89 (q, 1 H, J= 14.15, 6.32 Hz), 7.38 (d, 2 H, J= 8.08 Hz), 7.64 (d, 2 H, J = 8.34, Hz), 7.86 (d, I H1 J = 8.59 Hz), 8.27 (dd, 2 H J = 8.84, 2.27 Hz), 8.84 (d, 1 H, J= 2.27 Hz). MS m/z calc. 520.2, found (ESI); 521.4 (M + I)+. Retention time 2.23 minutes.
[00206] 2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6- methanesulfonyl-3-methyl-3#-quinazolin4-one
Figure imgf000276_0002
2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6-methanesulfonyl-3-methyl-3H- quinazolin-4-one compound was synthesized by using the same method as described in Scheme IA or Scheme IB (Yield 16.8 mg, 27.6 %). 1B. NMR (400 MHz, CDCl3): δ 1.85 (d, 3 H, J = 7.07 Hz), 3.13 (s, 3 H), 3.65-3.47 (m, 4 H), 3.70 (s, 3 H), 4.03-3.90 (m, 4 H), 4.88 (q, 1 H, J = 14.89, 6.57 Hz), 7.58 (d, 2 H, J = 9.09 Hz), 7.71 (d, 2 H, J = 9.09, Hz), 7.84 (d, I B, J = 8.84 Hz), 8.26 (dd, I H J = 8.84, 2.27 Hz), 8.83 (d, 1 H, J = 2.27 Hz). MS m/z calc. 524,1 found (ESI); 525.2 (M + I)+. Retention time 2.46 minutes.
[00207] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6- methanesulfonyI-3-methyl-3H-quinazolin-4-one
Figure imgf000277_0001
2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6-methanesulfonyl-3-methyl-3H- quinazolin-4-one compound was synthesized by using the same method as described ain Scheme IA or Scheme IB (Yield 35.8 mg, 54.3 %). 1H NMR (400 MHz, CDCl3): δ 1.86 (d, 3 H, J = 6.84 Hz), 3.13 (s, 3 H), 3.65-3.43 (m, 4 H), 3.71 (s, 3 H), 4.05-3.93 (m, 4 H), 4.85 (q, 1 H, J= 13.64, 6.57 Hz), 7.63 (d, 2 H, J = 8.84 Hz), 7.74 (d, 2 H, J = 8.84, Hz), 7.87 (d, 1 H, J = 8.34 Hz), 8.28 (dd, I H J= 8.34, 2.27 Hz), 8.86 (d, 1 H, J = 2.27 Hz). MS m/z calc. 568.0 found (ESI); 571.2 (M + I)+. Retention time 2.51 minutes.
[00208] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-
6-(lH-tetrazol-5-yl)-3i/-quinazolin-4-one
Figure imgf000277_0002
To the 1 ml DMF solution of 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3- methyl-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile (10.0 mg, 0.02 mmol) was added sodium azide (16.7 mg, 0.24 mmol) and ammonium chloride (12.8 mg, 0.24 mmol). The reaction test tube was flushed with N2 and was irradiated at 200 0C for 40 minutes in the SmithSynthesizer Microwave Reactor with vigorous agitation by a magnetic stirrer. The mixture was cooled to room temperature, the solvent was removed by reduce pressure and extracted with water and ethyl acetate, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 2-{ l-[4-(4- Methoxy-benzenesulfony^-piperazin-l-ylj-ethylJ-S-methyl-β-ClH-tetrazol-S-yO-SH-quinazolin- 4-one (Yield 3.09 mg, 9.8 %). 1H NMR (400 MHz, MeOD-d4): δ 1.79 (d, 3 H, J = 6.57 Hz), 3.29- 3.12 (m, 8 H), 3.70 (s, 3 H), 3.92 (s, 3 H), 4.70 (s, br, 1 H), 7.17 (d, 2 H, J = 9.09 Hz), 7.76 (d, 2 H, /= 9.09 Hz), 7.87 (d, 1 H, /= 8.59 Hz), 8.47 (dd, 1 H, J = 8.59, 1.77 Hz), 8.89 (d, 1 H, / = 1.77 Hz). MS m/z calc. 510.18 found (ESI); 511.4 (M + I)+. Retention time 2.2 minutes.
[00209] 2-{l-[4-(4-Chloro-benzenesulfonyI)-piperazin-l-yl]-ethyl}-3-methyl-6-
(lH-tetrazol-5-yl)-3ff-quinazolin-4-one
Figure imgf000278_0001
2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-6-(lH-tetrazol-5-yl)-3H- quinazolin-4-one compound was synthesized by using the same method as described as above (Yield 40.0 mg, 38.9 %). 1H NMR (400 MHz, MeOD.d4): δ 1.64 (d, 3 H, J = 6.06 Hz), 3.12-3.04 (m, 4 H), 3.16-3.54 (m, 4 H), 3.70 (s, 3 H), 4.64 (s, br, 3 H), 7.71-7.63 (m, 2 H), 7.83-7.76(m, 2 H), 7.87 (d, 1 H, J = 8.84 Hz), 7.98 (s, 1 H), 8.46 (dd, 1 H, J = 8.59, 2.02 Hz), 8.88 (d, 1 H J = 2.02 Hz). MS m/z calc. 514.1 found (ESI); 515.1 (M + I)+. Retention time 2.71 minutes.
[00210] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-
4-oxo-3,4-dihydro-quinazoHne-6-carboxylic acid amide
Figure imgf000278_0002
To the 2 ml 6 N HCl solution of 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3- methyl-4-oxo-3,4-dihydro-quinazoline-6-carbonitrile (40.0 mg, 0.085 mmol) was heated at 90 0C for 18 hours. The mixture was cooled to room temperature, the solvent was removed by reduce pressure and extracted with water and ethyl acetate, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give the 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piρerazin-l-yl]- ethyl}-3-methyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid amide compound (Yield 20.9 mg, 50.69 %). 1H NMR (400 MHz, MeOD-d4): δ 1.64 (d, 3 H, J = 6.57 Hz), 3.35-3.29 (m, 8 H), 3.67 (s, 3 H), 3.92 (s, 3 H), 4.70 (s, br, 1 H), 7.17 (d, 2 H, /= 8.84 Hz), 7.78-7.76 (m, 3 H), 8.38 (dd, 1 H, J = 8.59, 2.02 Hz), 8.88 (d, 1 H J = 2.02 Hz). MS m/z calc. 485.17 found (ESI); 487.2 (M + I)+. Retention time 2.18 minutes.
[00211] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-4- oxo-3,4-dihydro-quinazoline-6-carboxylic acid amide
Figure imgf000279_0001
2- { 1 -[4-(4-Bromo-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -3-methyl-4-oxo-3 ,4-dihydro- quinazoline-6-carboxylic acid amide compound was synthesized by using the same method as described as above (Yield 13.9 mg, 45.0 %). 1H NMR (400 MHz, MeOD^4): δ 1.64 (d, 3 H, / = 6.57 Hz), 3.39-3.20 (s, br, 8 H), 3.68 (s, 3 H), 4.67 (s, br, 1 H), 7.77-7.72 (m, 3 H), 7.88-7.84 (m, 2 H), 8.38 (dd, 1 H, J = 8.34, 2.02 Hz), 7.87 (d, 1 H, J = 2.02 Hz). MS m/z calc. 533.06 found (ESI); 537.2 (M + I)+. Retention time 2.74 minutes.
[00212] 2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-4- oxo-3,4-dihydro-quinazoline-6-carboxylic acid amide
Figure imgf000279_0002
2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3-methyl-4-oxo-3,4-dihydro- quinazoline-6-carboxylic acid amide compound was synthesized by using the same method as described as above (Yield 12.7 mg, 40.8 %). 1H NMR (400 MHz, MeOD-d4): δ 1.65 (d, 3 H, J = 7.07 Hz), 3.34-3.33 (s, br, 8 H), 3.67 (s, 3 H), 4.67 (s, br, 1 H), 7.70 (d, 2 H, J = 8.59 Hz), 7.75
- 27S - (d, 1 H, J = 8.59 Hz), 7.82 (d, 2 H, / = 8.59 Hz), 8.38 (dd, 1 H, J = 8.59, 1.77 Hz), 8.89 (d, 7 1.77 Hz). MS in/z calc. 489.11 found (ESI); 491.0 (M + I)+. Retention time 2.69 minutes.
[00213] 6-Amino-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yI]-ethyl}-
3-methyl-3H-quinazolin-4-one
Figure imgf000280_0001
To the 15 ml ethanol solution of 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3- methyl-6-nitro-3H-quinazolin-4-one (560.0 mg, 1.14 mmol) was added ZnCl2 (1.08 g, 5.7 mmol). The reaction was refluxed for 2 hours with vigorous agitation by a magnetic stirrer. The mixture was cooled to room temperature, the solvent was removed by reduce pressure and extracted with Na2CO3 aqueous and ethyl acetate, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by ΗPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 6-Amino-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin- l-yl]-ethyl}-3-methyl-3H-quinazolin-4-one (Yield 427.3 mg, 81.9 %). 1H NMR (400 MHz, DMSO-d6): δ 1.72 (d, 3 H, J = 6.57 Hz), 3.44-3.29 (m, 4 H), 3.62-3.50 (m, 4 H), 3.65 (s, 3 H), 3.93 (s, 3 H), 4.70 (q, 1 H, J = 12.88, 6.82 Hz), 7.19 (d, 2 H, /= 8.84 Hz), 7.49 (dd, 1 H, J = 8.84, 2.53 Hz), 7.65 (d, 1 H, J = 8.59 Hz), 7.81-7.77 (m, 3 H). MS m/z calc. 457.2 found (ESI); 458.2 (M + I)+. Retention time 2.28 minutes.
[00214] 6-Amino-2-{l-[4-(4-bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3- methyI-3H-quinazolin-4-one
Figure imgf000280_0002
6-Amino-2-{ l-[4-(4-bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl } -3-methyl-3H-quinazolin-4- one compound was synthesized by using the same method as described as above (Yield 448.3 mg, 85.0 %). 1H NMR (400 MHz, MeOD-d4): δ 1.55-1.32 (m, 3 H), 3.35-2.85 (m, 8 H), 3.52 (s, 3 H), 4.53 (s, br, 1 H), 7.10 (dd, 1 H, J= 8.59, 2.53 Hz), 7.23 (d, 1 H, /= 2.53 Hz), 7.39 (d, 1 H, J = 8.84 Hz), 7.58 (d, 2 H, J = 8.08 Hz). 7.9 l(d, 2 H, J = 7.83 Hz), MS m/z calc. 507.2 found (ESI); 508.0 (M + I)+. Retention time 2.52 minutes.
[00215] N-(2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3- methyl-4-oxo-3,4-dihydro-quinazolin-6-yI)-acetamide
Figure imgf000281_0001
To the 1 ml DMF solution of 6-Amino-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-3-methyl-3H-quinazolin-4-one (50.0 mg, 0.11 mmol) was added acetyl chloride (9.44 mg, 0.12 mmol). The reaction was stirred for 2 hours. The solvent was removed by reduce pressure and extracted with Na2CO3 aqueous and ethyl acetate, dried over anhydrous MgSO4, and concentrated by rotary evaporation. Purification was accomplished by ΗPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give the N-(2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-3-methyl-4-oxo-3,4-dihydro-quinazolin-6-yl)-acetamide (Yield 8.29 mg, 14.9 %). 1H NMR (400 MHz, MeOD.d4): δ 1.70 (d, 3 H, J = 6.57 Hz), 2.18 (s, 3 H), 3.57-3.43 (m, 8 H), 3.64 (s, 3 H), 3.93 (s, 3 H), 4.84 (q, 1 H, J = 6.57, 6.06 Hz), 7.19 (d, 2 H, J = 9.09 Hz), 7.64 (d, 1 H, J = 8.34 Hz), 7.79(d, 2 H, J = 9.09 Hz), 7.98 (dd, 1 H, J = 8.59, 2.78 Hz), 8.46 (d, J - 2.27 Hz). MS m/z calc. 499.2 found (ESI); 500.2 (M + I)+. Retention time 2.42 minutes.
[00216] 3-Isobutyl-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-3H-quinazolin-4-one
Figure imgf000281_0002
In a flask containing of 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H- quinazolin-4-one (50.0 mg, 0.12 mmol) in DMF was added I-Iodo-2-methylpropane (42.0 mg, 0.24 mmol), K2CO3 (80.0 mg, 0.6 mmol). The mixture was heated at 90 0C for 2 hours with stirring. After cooling down to room temperature, the excess K2CO3 was filtrated; the solution was treated with TFA (0.5 ml) and water (0.1 ml) with stirring at 900C for 2 hrs. Purification by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase) yielded 3- Isobutyl-2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -3H-quinazolin-4-one (Yield 21.0 mg, 37.0 %) that was dried under reduced pressure. 1H NMR (400 MHz, DMSO-6): δ 0.98(d, 3 H, J = 6.82 Hz), 1.01(d, 3 H, J = 6.82 Hz), 1.76(d, 3 H, J = 6.82 Hz), 2.08-1.99(m, 1 H), 3.51-3.19 (m, 6 H), 3.86-3.75(m, 2 H), 3.93 (s. 3 H), 4.16-3.93(m, 2 H), 4.84 (q, 1 H, / = 12.88, 7.07 Hz), 7.03(dd, 2 H, J = 6.82, 2.27 Hz), 7.57(dt, 1 H, J = 8.08, 1.01 Hz), 7.67(dd, 2 H, J = 6.82, 2.27 Hz), 7.71(d, 1 H, J = 8.08, Hz), 7.82(dt, 1 H, 8.59, 1.52 Hz), 8.39 (dd, 1 H, J = 8.08, 1.52 Hz). MS m/z calc. 484.21, found (ESI); 485.3 (M + I)+. Retention time 2.83 minutes.
[00217] 5-Chloro-2-isobutyrylamino-benzoic acid
Figure imgf000282_0001
To a solution of 2-amino-5-chloro-benzoic acid (3.43g, 20 mmol) in DMF (10 mL) cooled in an ice-water bath was added isobutyryl chloride (2.11 mL, 20 mmol). The reaction was stirred for 2 hours while warming to room temperature. Water (20 mL) was added and the mixture was stirred vigorously for 1 hour. The precipitate was then collected by vacuum filtration to give the product as a pale yellow solid (3.20 g, 66%). 1H NMR (400 MHz, DMSO-d6) δ 11.13 (s, IH), 8.52 (d, J = 9.0 Hz, IH), 7.92 (d, J = 2.6 Hz, IH), 7.66 (dd, J = 9.0, 2.7 Hz, IH), 2.58 (septet, J = 6.9 Hz, IH), 1.16 (d, J = 6.9 Hz, 6H).
[00218] 6-Chloro-2-isopropyl-benzo[d] [l,3]oxazin-4-one
Figure imgf000282_0002
A mixture of 2-amino~5-chloro-benzoic acid (3.02g, 12.5 mmol) and acetic anhydride (25 mL) were heated to reflux for 2 hours until TLC indicated that no more starting material remained. The remaining acetic anhydride was removed in vacuo. Toluene (2 mL) was added and then removed in vacuo. This was repeated 2 more times to try and remove final traces of acetic anhydride. The product was obtained as an orange solid (2.75g, 98%). 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, J = 2.5 Hz, IH), 7.94 (dd, J = 8.6, 2.5 Hz, IH), 7.63 (d, J = 8.6 Hz, IH), 2.92 (septet, J = 6.9 Hz, IH), 1.28 (d, J = 6.9 Hz, 6H).
[00219] 6-Chloro-2-isopropyl-3-methyl-3H-quinazolin-4-one
Figure imgf000283_0001
A mixture of 6-chloro-2-isopropyl-benzo[d][l,3]oxazin-4-one (2.75g, 12.3 mmol) and methylamine (7.4 mL, 14.8 mmol, 2M solution in MeOH) were heated to 90°C for 24 hours. The solvent was removed in vacuo and the residue was heated under reduced pressure to 160°C for 2 hours. The reaction mixture was purified by column chromatography (0 - 30% ethyl acetate - hexanes) to yield the product (960mg, 33%). 1H NMR H NMR (400 MHz, CDC13) δ 8.23 (d, J = 2.4 Hz, IH), 7.65 (dd, J = 8.7, 2.4 Hz, IH), 7.61 (d, J = 8.8 Hz, IH), 3.69 (s, 3H), 3.22 (septet, J = 6.7 Hz, IH), 1.39 (d, J = 6.7 Hz, 6H).
[00220] 2-(l-Bromo-l-methyI-ethyl)-6-chloro-3-methyl-3H-quinazolin-4-one
Figure imgf000283_0002
A solution of 6-chloro-2-isopropyl-3-methyl-3H-quinazolin-4-one (880mg, 3.7 mmol), N- bromosuccinimide (662mg, 3.7 mmol) and benzoyl peroxide (catalytic amount) in chloroform (20 mL) was heated to reflux for 2 hours. The reaction solution was concentrated in vacuo and purified by column chromatography (0 - 25% ethyl acetate - hexanes) to yield the product as a white solid (880mg, 76%). 1H NMR (400 MHz, CDC13) δ 8.26 (dd, J = 2.3, 0.3 Hz, IH), 7.69 (dd, J = 8.7, 2.4 Hz, IH), 7.64 (dd, J = 8.6, 0.3 Hz, IH), 3.98 (s, 3H), 2.30 (s, 3H); HPLC ret. time 3.75 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 317.0 (M+l)+.
[00221] 6-ChIoro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-l- methyl-ethyl}-3-methyI-3H-quinazolin-4-one
Figure imgf000284_0001
To a solution of l-(4-methoxy-benzenesulfonyl)-piperazine (51mg, 0.2 mmol) in THF (0.5 mL) cooled to -780C was added butyl lithium (125 μL, 0.2mmol, 1.6M solution in hexanes). This solution was allowed to stir for 10 minutes and then was transferred by syringe to a reaction tube containing a solution of 2-(l-Bromo-l-methyl-ethyl)-6-chloro-3-methyl-3H-quinazolin-4-one (32mg, 0.1 mmol) in THF (0.5 mL) also cooled to -780C. The reaction was allowed to slowly warm to room temperature while stirring overnight. The solution was then filtered and concentrated in vacuo. The residue was dissolved in DMSO and purified by LC-MS to yield the product (14mg, 29%). 1H NMR (400 MHz, CDC13) δ 8.21 (d, J = 2.3 Hz, IH), 7.69 (m, 3H), 7.62 (d, J = 8.7 Hz, IH), 7.04 (d, J = 8.9 Hz, 2H), 3.92 (s, 3H), 3.89 (s, 3H), 2.86 (m, 8H), 1.62 (s, 6H); HPLC ret. time 3.61 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 491.2 (M+l)+.
[00222] 2-(l-Bromo-ethyl)-3H-quinazolin-4-one
Figure imgf000284_0002
To a solution of 2-ethyl-3H-quinazolin-4-one (3.0 g, 17.22 mmol) in glacial acetic acid (50 ml) cooled in an ice bath was added dropwise a solution of bromine (2.75 g, 17.22 mmol) in glacial acetic acid (5 ml). After addition was complete, the reaction was heated to reflux for 18 hours. At which time it was allowed to cool to room temperature. Water was then added to the solution and the mixture was extracted with dichloromethane. The organic layer was then washed with 10% sodium bisulfite solution, and then washed with saturated brine (2 x 30 ml). The combined US2004/017673
organic phase was collected and dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a brown crude product. The resulting residue was purified by silica gel chromatography with 50% dichloromethane in hexane. The product was collected and was dried under reduced pressure to give 2-(l-Bromo-ethyl)-3H-quinazolin-4-one (Yield 3.02 g, 69.74%). 1H NMR (400 MHz, DMSO-6): δ 2.22 (d, 3 H, J = 6.57 Hz), 5.09 (q, 1 H, J = 14.40, 6.57 Hz), 7.57 (m, 1 H), 7.69(d, 1 H, J = 8.08 Hz), 7.87-7.80(m, 1 H), 8.12(d, 1 H, J = 6.82 Hz), 12.42(s, 1 H). MS m/z calc. 251.99, found (ESI); 253.0(M +I)+. Retention time 2.60 minutes.
[00223] Benzenesulfonic acid, 4-methoxy-, [[(4-methoxyphenyl)sulfonyl] imino]di-2,l-ethanediyl ester
Figure imgf000285_0001
To a solution of 2-(2-hydroxy-ethylamino)-ethanol (7g, 67 mmol) and 4- methoxybenzenesulfonyl chloride (4Og, 194 mmol) in THF (400 mL) KOH (100 mL, 40%) was added dropwise at 0°C, after stirring over 3 hr the mixture was filtrated and THF was evaporated in vacuo, then extracted with EtOAc (500 mL). The organic layer was washed with brine and dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column to afford Benzenesulfonic acid, 4-methoxy-, [[(4- methoxyphenyl)sulfonyl]imino]di-2,l-ethanediyl ester as a colorless gum (2Og, 49%). 1H NMR (DMSO - d6) δ 7.81 (d, J = 4.8 Hz, 4 H), 7.79 (d, J = 5.2 Hz, 2 H), 7.01 (d, / = 4.8 Hz, 4 H), 6.93 (d, J = 5.2 Hz, 2 H), 4.08 (t, J = 6 Hz, 4 H), 3.88 (s, 6 H), 3.86 (s, 3 H), 3.35 (t, J = 6 Hz, 4 H). MS (ESI) m/z (M+l) +: 615.7.
[00224] [4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-acetic acid tert-butyl ester
Figure imgf000285_0002
73
A mixture of glycine tert-buty\ ester hydrochloride (840mg, 5 mmol) and benzenesulfonic acid, 4-methoxy-, [[(4-methoxyphenyl)sulfonyl]imino]di-2,l-ethanediyl ester (3.07g, 5 mmol), potassium iodide (1.66g, 10 mmol) and potassium carbonate (6.9g, 50 mmol) in acetonitrile (50 mL) was heated at 65°C for 3 days. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (25 - 50% ethyl acetate - hexanes) to yield the product as a clear oil (1.56g, 84%). 1H NMR (400 MHz, CDC13) δ 7.69 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 3.88 (s, 3H), 3.10 (s, 2H), 3.06 (m, 4H), 2.65 (m, 4H), 1.45 (s, 9H).
[00225] [4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yI]-acetic acid
Figure imgf000286_0001
Trifluoroacetic acid (2.5 mL) was added to a solution of [4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-acetic acid terr-butyl ester (1.48g, 4 mmol) in dichloromethane (10 mL). The reaction was stirred at room temperature for 3 days. The solvent was removed in vacuo and the residue was triturated with diethyl ether. Filtration yielded the product as a white solid (1.25 g, quant.). 1H NMR (400 MHz, DMSO-d6) δ 7.70 (dt, J = 9.6, 2 A Hz, 2H), 7.21 (dt, J = 9.6, 2.4 Hz, 2H), 3.86 (m, 5H), 3.09 (m, 8H).
[00226] 2-{2-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-acetylamino}- benzamide
Figure imgf000286_0002
To a mixture of [4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-acetic acid (l.lOg, 3.5 mmol), HATU (1.33g, 3.5 mmol) and DIEA (1.22 mL, 7 mmol) in dichloromethane (40 mL) was added anthranilamide (714mg, 5.25 mmol). The reaction was stirred at room temperature for 1 hour and then the reaction mixture was concentrated in vacuo. The residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (50 - 100% ethyl acetate - hexanes) to yield the pure product. (1.18g, 78%). 1H NMR (400 MHz, CDC13) δ 11.82 (s, IH), 8.66 (d, J= 8.0 Hz, IH), 7.77 (d, J = 7.0 Hz, 2H), 7.51 (m, 2H), 7.11 (t, J = 7.6 Hz, IH), 7.05 (d, J = 7.1 Hz, 2H), 6.10 (br s, IH), 5.51 (br s, IH), 3.92 (s, 3H), 3.24 (m, 6H), 2.76 (t, J = 4.7 Hz, 4H); HPLC ret. time 2.46 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 433.1 (MH-I) +.
[00227] 2-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yImethyl]-3H- quinazolin-4-one
Figure imgf000287_0001
A mixture of 2~{2-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-acetylamino}- benzamide (432mg, 1 mmol), IN sodium hydroxide solution (5 mL) and 1,4-dioxane (5 mL) was stirred a room temperature for 1 day. The reaction mixture was concentrated to approximately half the volume and then neutralized with IN HCl solution. The product precipitated and was collected by filtration as a white solid (306mg, 74%). 1H NMR (400 MHz, CDC13) δ 8.26 (dd, J = 8.0, 1.3 Hz, IH), 7.79 (t, J = 8.4 Hz, IH), 7.73 (dt, J = 9.5, 2.5 Hz, 2H), 7.68 (d, J = 7.7 Hz, IH), 7.51 (t, J = 8.1 Hz, IH), 7.08 (dt, J = 9.5, 2.4 Hz, 2H), 3.94 (s, 3H), 3.65 (s, 2H), 3.11 (m, 4H), 2.75 (t, J = 4.9 Hz, 4H); HPLC ret. time 2.59 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 415.3 (M+l)+.
[00228] 2-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-ylmethyl]-4-piperidin-
1 -yl-quinazoline
Figure imgf000287_0002
2-[4-(4-Methoxy-benzenesulfonyl)-piρerazin-l-ylmethyl]-3H-quinazolin-4-one (83mg, 0.2 mmol) in POCl3 (1 mL) was heated to 90°C for 2 hours. Then the excess POCl3 was removed in vacuo. The residue was dissolved in toluene (5 mL) and then the solvent was removed in vacuo. This step was repeated twice more. The residue was then dissolved in THF (1 mL) and piperidine (197μL, 2 mmol) was added. The reaction was stirred at room temperature for 1 day. The reaction mixture was partitioned between dichloromethane and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by HPLC. 1H NMR (400 MHz, CDC13) δ 7.92 (m, 3H), 7.67 (m, 3H), 7.03 (d, J = 8.8 Hz, 2H), 4.70 (s, 2H), 4.12 (s, 4H), 3.90 (s, 3H), 3.45 (m, 8H), 1.88 (m, 6H); HPLC ret. time 2.61 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 482.0 (M+l)+.
[00229] 4-Cyclohexyloxy-2-[4-(4-methoxy-benzenesuIfonyl)7piperazin-l- ylmethyl]-quinazoline
Figure imgf000288_0001
2-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-ylmethyl]-3H-quinazolin-4-one (83mg, 0.2 mmol) in POCl3 (1 mL) was heated to 90°C for 2 hours. Then the excess POCl3 was removed in vacuo. The residue was dissolved in toluene (5 mL) and then the solvent was removed in vacuo. This step was repeated twice more. The residue was then dissolved in THF (1 mL) and cyclohexanol (211μL, 2 mmol) was added. The reaction was stirred at room temperature for 1 day. The reaction mixture was partitioned between dichloromethane and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by HPLC (in the absence of TFA). 1H NMR (400 MHz, CDC13) δ 8.16 (d, J = 7.5 Hz, IH), 7.89 (d, J = 8.3 Hz, IH), 7.79 (t, J = 7.3 Hz, IH), 7.72 (dt, J = 9.5, 2.4 Hz, 2H), 7.52 (t, / = 7.4 Hz, IH), 7.01 (dt, J = 9.5, 2.4 Hz, 2H), 5.39 (quintet, J = 4.2 Hz, IH), 3.90 (m, 5H), 3.16 (m, 4H), 2.90 (m, 4H), 1.66 (m, 10H); HPLC ret. time 2.93 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 497.3 (M+l)+. [00230] 4-CyclopentyIoxy-2-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- ylmethyl]-quinazoline
Figure imgf000289_0001
A mixture of 2-[4-(4-Methoxy-benzenesulfonyl)-piperazm-l-ylmethyl]-3H-quinazolin-4- one (83mg, 0.2 mmol), cyclopentyl iodide (46 μL, 0.4 mmol), and potassium carbonate (138 mg, 1 mmol) in DMF (1 mL) was heated to 90°C for 1 day. The reaction mixture was partitioned between dichloromethane and water. The organic layer was concentrated in vacuo and the residue was purified by HPLC (in the absence of TFA) to yield the product. 1H NMR (400 MHz, CDC13) δ 8.11 (d, J = 8.1 Hz, IH), 7.88 (d, J = 8.4 Hz, IH), 7.78 (t, J= 7.6 Hz, IH), 7.71 (d, J = 8.8 Hz, 2H), 7.51 (t, J = 7.5 Hz, IH), 7.00 (d, J = 8.8 Hz, 2H), 5.73 (quintet, J = 3.0 Hz, IH), 3.88 (m, 5H), 3.12 (m, 4H), 2.84 (m, 4H), 1.90 (m, 8H); HPLC ret. time 2.85 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 483.5 (M+l)+.
[00231] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3jHr- quinazolin-4-one
Figure imgf000289_0002
In a flask containing of 2-(l-bromo-ethyl)-3H-quinazolin-4-one (500.0 mg, 0.20 mmol) in acetonitrile (20 ml) was added KI (496.0 mg, 0.30 mmol), and l-(4-methoxy-benzenesulfonyl)- piperazine (509.6 mg, 0.20 mmol). The reaction was heated for 18 hours. The solution was concentrated under reduced pressure. The residue was partitioned between water (20 ml) and dichloromethane (20 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was purified by silica gel chromatography with 50% dichloromethane in hexane. The product was collected and dried under reduced pressure to give 2-{ l-[4-(4-Methoxy- benzenesulfonyl)-piperazm-l-yl]-ethyl}-3H-quinazolin-4-one (Yield 385.0 mg, 45.18 %). 1H NMR (400 MHz, DMSO-6): δ 1.25(d, 3 H, J = 6.82 Hz), 2.67-2.56 (m, 4 H), 2.88 (s. br, 4 H), 3.85 (s, 3 H), 3.53 (q, 1 H, J = 13.89, 6.82 Hz), 7.15(d, 2 H, / = 8.84), 7.34(t, 1 H, J = 7.33 Hz), 7.51(d, 1 H, 7= 8.34 Hz), 7.68-7.61 (m, 3 H), 8.00 (d, 1 H, 7 = 7.83 IIz). MS m/z calc. 428.15, found (ESI); 429.4(M + I)+. Retention time 2.68 minutes.
[00232] 4-Chloro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yI]-ethyl}- quinazoline
Figure imgf000290_0001
In a flask containing of 2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H- quinazolin-4-one (380.0 mg, 0.89 mmol) in phosphorus oxychloride (20 ml) was heated to 900C for 2 hours, then the solvent was concentrated under reduced pressure to give 4-Chloro-2-{ l-[4- (4-methoxy-benzenesulfonyl)-piperazin-l-yl] -ethyl }-quinazoline (Yield 394.2 mg, 100 %) that was used directly without further purification. 1H NMR (400 MHz, CDCl-3): δ 1.93(d, 3 VL, J = 6.82 Hz), 3.23-3.04 (m, 3 H), 3.54-3.34(m, 1 H), 3.87-3.65 (m, 4 H), 3.90(s, 3 H), 4.77 (q, 1 H, / = 14.15, 6.82 Hz), 7.05(d, 2 H, J= 8.84), 7.69(d, 2 H, J= 8.84), 7.87(t, H, J = 7.84), 8.10(t, 1 H, J = 8.34 Hz), 8.18(d, 1 H, 8.34 Hz), 8.35(d, 1 H, 8.34 Hz). MS m/z calc. 446.12, found (ESI); 447.4(M + I)+. Retention time 2.67 minutes.
[00233] 4-Methoxy-2-{l-[4-(4-methoxy-benzenesuIfonyI)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000290_0002
In a test tube containing of 4-Chloro-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-quinazoline (38.0 mg, 0.089 mmol) in THF (2 ml) was added MeOH (280.0 mg, 8.9 mmol). The reaction was heated at 60 0C for 0.5 hour. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was re-dissolvent in MeOH (2 ml) and purified by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 4- Methoxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline (Yield 4.43 mg, 11.13 %). MS m/z calc. 442.17, found (ESI); 443.4 (M + I)+. Retention time 2.40 minutes.
[00234] 4-Ethoxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline
Figure imgf000291_0001
4-Ethoxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl }-quinazoline compound was synthesized by using the same method as described in Scheme V (Yield 4.59 mg, 11.30 %). 1H NMR (400 MHz, CDCl3): δ 1.54 (t, 3 H, J = 7.07 Hz), 1.87 (d, 3 H, J = 7.07 Hz), 3.61- 3.31(m, 6 H), 3.76-3.61 (m, 2 H), 3.89 (s, 3 H), 4.73 (m, 1 H), 7.02 (d, 2 H, J = 9.09 Hz), 7.71- 7.62 (m, 3 H), 7.96 (d, 1 H, J= 1.26 Hz), 7.96(d, 2 H /= 1.26 Hz), 8.24 (d, 1 H, J = 8.08 Hz). MS m/z calc.456.18, found (ESI); 457.4 (M + I)+. Retention time 2.55 minutes.
[00235] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- propoxy-quinazoline
Figure imgf000291_0002
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-propoxy-quinazoline compound was synthesized by using the same method as described in Scheme V (Yield 4.15 mg, 9.92 %). 1H NMR (400 MHz, CDCl3): δ 1.01-1.09 (m, 3 H), 1.13 (t, 3 H, J = 7.33 Hz), 1.74-1.67 (m, 2 H), 1.95-1.88 (m, 2 H), 3.62-3.28 (m, 6 H), 3.74-3.62 (m, 2 H), 3.89 (s, 3 H), 4.68 (q, I R, J = 13.64, 7.07 Hz), 7.04-7.00 (m, 2 H), 7.70-7.64 (m, 3 H), 7.98-7.92 (m, 2 H), 8.24 (td, 1 H, / = 8.84, 1.01 Hz). MS m/z calc. 456.18, found (ESI); 457.4 (M + I)+. Retention time 2.55 minutes.
[00236] 4-Isopropoxy-2-{l-[4-(4-methoxy-benzenesuIfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000292_0001
4-Isopropoxy-2- { 1 -[4-(4-methoxy-benzenesulfonyl)-piperazin- 1 -yl]-ethyl } -quinazoline compound was synthesized by using the same method as described in Scheme V (Yield 1.89 mg, 4.51 %). MS m/z calc. 470.20, found (ESI); 471.2 (M + I)+. Retention time 2.84 minutes.
[00237] 4-Cyclopentyloxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-quinazoline
Figure imgf000292_0002
4-Cyclopentyloxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline was synthesized by using the same method as described in Scheme V (Yield 7.66 mg, 17.37 %). H NMR (400 MHz, CDCl3): δ 2.00-1.68 (m, 11 H), 2.15-2.04 (m, 2 H), 3.54-3.33 (m, 6 H), 3.73- 3.62 (m, 2 H), 3.89 (s, 3 H), 4.72 (q, 1 H, J = 13.39, 7.33 Hz), 7.02 (d, 2 H, 9.09 Hz), 7.68- 7.65(m, 3 H), 7.95 (td, 2 H, J = 8.08, 1.77 Hz), 8.19 (d, 1 H, J = 8.34 Hz). MS m/z calc. 496.21, found (ESI); 497.4 (M + I)+. Retention time 2.84 minutes.
[00238] (2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazolin-4-yl)-dimethyl-amine
Figure imgf000293_0001
(2- { 1 -[4-(4-Methoxy-benzenesulfonyl)-piperazin- 1 -yl]-ethyl } -quinazolin-4-yl)-dimethyl-amine was synthesized by using the same method as described in Scheme V. (Yield 26.25 mg, 66.86 %). 1H NMR (400 MHz, CDCl3): δ 1.74 (d, 3 H, J = 6.57 Hz), 3.33-3.31 (m, 6 H), 3.58-3.43 (m, 2 H), 3.87 (s, 3 H), 5.00(q, 1 H, J = 13.39, 6.82 Hz), 7.00 (d, 2 H, 8.84 Hz), 7.61 (d, 2 H, J = 8.84), 7.65 (td, 1 H, J= 8.34, 1.26 Hz), 7.92 (td, 1 H, J = 8.34, 1.26 Hz), 8.22 (dd, 1 H, 7 = 8.59, 1.01 Hz), 8.13 (dd, 1 H, /= 8.59, 1.01 Hz). MS m/z calc. 455.20, found (ESI); 456.4 (M + I)+. Retention time 2.15 minutes.
[00239] Ethyl-(2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazolin-4-yl)-amine
Figure imgf000293_0002
Ethyl-(2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-amine was synthesized by using the same method as described as Scheme V. (Yield 9.53 mg, 23.53 %). 1H NMR (400 MHz, MeOD-d4): δ 1.38 (t, 3 H, J = 7.33 Hz), 1.54 (d, 3 H, J = 6.82 Hz), 2.84- 2.77 (m, 2 H), 2.93-2.86 (m, 2 H), 3.16-3.10 (m, 4 H), 3.85 (s, 3 H), 3.97(q, I U, J = 13.39, 6.82 Hz), 7.15 (d, 2 H, J = 8.84 Hz), 7.76-7.72 (m, 3 H), 7.80 (d, 1 H J= 8.84 Hz), 7.98 (td, 1 H, J = 8.845 1-26 Hz), 8.28 (d, 1 H, J = 8.34 Hz). MS m/z calc. 455.20, found (ESI); 456.4 (M + I)+. Retention time 2.26 minutes.
[00240] Diethyl-(2-{l-[4-(4-methoxy-benzenesuIfonyI)-piperazin-l-yl]-ethyl}- quinazolin-4-yl)-amine
Figure imgf000294_0001
Diethyl-(2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -qύinazolin-4-yl)-amine was synthesized by using the same method as described in Scheme V (Yield 10.58 mg, 25.9 %). 1H NMR (400 MHz, CDCl3): δ 1.48 (t, 3 H, / = 6.82 Hz), 1.83 (d, 3 H, J = 6.82 Hz), 3.38-3.20 (m, 6 H), 3.69-3.52 (m, 2 H), 3.82-3.72 (m, 2 H), 3.85 (s, 3 H), 5.12 (q, I H, / = 14.15, 6.32 Hz), 7.00 (d, 2 H, J = 9.09 Hz), 7.63 (d, 2 H, J = 9.09 Hz), 7.95 (td, I H/= 8.59, 1.26 Hz), 7.95 (td, 1 H, / = 8.59, 1.26 Hz), 8.00 (d, 2 H, J = 8.08 Hz), 8.06 (dd, 1 H, J = 8.34, 1.26 Hz). MS m/z calc.483.23, found (ESI); 484.4 (M + I)+. Retention time 2.48 minutes.
[00241] 4-Methoxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000294_0002
4-Methoxy-2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazoline was synthesized by using the same method as described in Scheme V (Yield 8.23 mg, 13.33 %). 1H NMR (400 MHz, MeOD-4): δ 1.60 (d, 3 H, J = 6.82 Hz), 3.15-3.05 (m, 2 H), 3.27-3.18 (m, 6 H), 3.32 (s, 3 H), 3.99 (q, 1 H, J = 13.89, 6.32 Hz), 7.57 (t, 1 H, J = 8.08 H^), 7.77-7.69 (m, 3 H), 7.90-7.81 (m, 3 H), 8.22 (dd, 1 H, J = 8.08, 1.26Hz). MS m/z calc. 490.07, found (ESI); 493.2 (M + I)+. Retention time 2.95 minutes.
[00242] 2-{l-[4-(4-Bromo-benzenesulfonyI)-piperazin-l-yl]-ethyl}-4-ethoxy- quinazoline
Figure imgf000294_0003
2- { 1 -[4-(4-Bromo-benzenesulf onyl)-ρiperazin- 1 -yl] -ethyl } -4-ethoxy-quinazoline was synthesized by using the same method as described in Scheme V (Yield 8.59 mg, 13.52 %). 1H NMR (400 MHz, MeOD-4): δ 1.55 (t, 3 H, J = 7.07 Hz), 1.79 (d, 3 H, J= 6.57 Hz), 3.60-3.30 (m, 6 H), 3.76-3.63 (m, 2 H), 4.74-4.61 (m, 3 H), 7.72 (td, J = 8.34, 2.02 Hz), 7.81-7.76 (m, 2 H), 7.91-7.86 (m, 2 H), 8.00-7.93 (m, 1 H), 8.26 (d, 1 H, J = 7.58). MS m/z calc. 504.08, found (ESI); 507.2 (M + I)+. Retention time 3.09 minutes.
[00243] 2-{l-[4-(4-Bromo-benzenesulfonyI)-piperazin-l-yl]-ethyl}-4-propoxy- quinazoline
Figure imgf000295_0001
2- { 1 - [4-(4-Bromo-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-propoxy-quinazoline was synthesized by using the same method as described in Scheme V (Yield 8.89 mg, 11.24 %). MS m/z calc. 518.10, found (ESI); 521.0 (M + I)+. Retention time 2.91 minutes.
[00244] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- isopropoxy-quinazoline
Figure imgf000295_0002
2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-isopropoxy-quinazoline was synthesized by using the same method as described in Scheme V (Yield 9.29 mg, 14.23 0Io). MS m/z calc. 518.10, found (ESI); 521.0 (M + I)+. Retention time 2.91 minutes.
[00245] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- cyclopentyloxy-quinazoline
Figure imgf000296_0001
2- { 1 -[4-(4-Bromo-benzenesulfonyl)-piperazin- 1 -yl]-ethyl } -4-cyclopentyloxy-quinazoline was synthesized by using the same method as described in Scheme V (Yield 9.36 mg, 13.65 %). MS m/z calc. 544.11, found (ESI); 547.2 (M + I)+. Retention time 2.91 minutes.
[00246] (2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-
4-yI)-methyl-amine
Figure imgf000296_0002
(2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-methyl-amine compound was synthesized by using the same method as described in Scheme V (Yield 11.09 mg, 18.00 %). 1H NMR (400 MHz, MeOD-4): δ 1.58 (d, 3 H, J = 6.82 Hz), 2.91-2.84 (m, 2 H), 3.02-2.94 (m, 2 H), 3.32-3.14 (m, 4 H), 4.07 (q, 1 H, J = 14.40, 6.82 Hz), 7.76-7.70 (m, 3 H), 7.85-7.80 (m, 3 H), 7.99 (td, 1 H J= 8.59, 1.26 Hz), 8.24 (dd, I H1 J= 8.34, 0.76 Hz). MS m/z calc. 489.08, found (ESI); 492.2 (M + I)+. Retention time 2.34 minutes.
[00247] (2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-
4-yl)-dimethyl-amine
Figure imgf000296_0003
(2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-dimethyl-amine was synthesized by using the same method as described in Scheme V (Yield 16.78 mg, 26.47 0Io). 1H NMR (400 MHz, MeOD-4): δ 1.56 (d, 3 H, J = 6.57 Hz), 3.01-2.80 (m, 4 H), 3.23-3.08 (m, 4 H), 4.14-3.96 (m, 1 H), 7.75-7.63 (m, 3 H), 7.87-7.75 (m, 3 H), 8.01-7.90 (m, 1 H), 8.39 (dd, 1 H, J = 8.08 Hz). MS m/z calc. 503.10, found (ESI); 506.0 (M + I)+. Retention time 2.39 minutes.
[00248] (2-{l-[4-(4-Bromo-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-quinazolin-
4-yl)-ethyl-amine
Figure imgf000297_0001
(2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl }-quinazolin-4-yl)-ethyl-amine was synthesized by using the same method as described in Scheme V (Yield 20.60 mg, 32.49 %). 1H NMR (400 MHz, MeOD-4): δ 1.38 (t, 3 H, / = 7.33 Hz), 1.54 (d, 3 H, J - 7.07 Hz), 2.83-2.7 r4 (m, 2 H), 2.93-2.85 (m, 2 H), 3.20-3.08 (m, 4 H), 3.85 (q, 1 H, / = 14.40, 7.33 Hz), 7.76-7.69 (m, 3 H), 7.86-7.79 (m, 3 H), 7.99 (td, I HJ= 8.34, 1.26 Hz), 8.29 (d, 1 H, J= 8.34 Hz). MS m/z calc. 503.10, found (ESI); 506.0 (M + I)+. Retention time 2.39 minutes.
[00249] (2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyI}-quinazolin-
4-yl)-diethyl-amine
Figure imgf000297_0002
(2-{ l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl }-quinazolin-4-yl)-diethyl-amine was synthesized by using the same method as described in Scheme V (Yield 18.66 mg, 27.88 %). MS m/z calc. 531.13, found (ESI); 532.2 (M + I)+. Retention time 2.70 minutes.
[00250] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyI}-4- morpholin-4-yl-quinazoline
Figure imgf000298_0001
2- { 1 - [4-(4-Bromo-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-morpholin-4-yl-quinazoline was synthesized by using the same method as described in Scheme V (Yield 20.04 mg, 29.17 %). 1H NMR (400 MHz, MeOD-4): δ 1.58 (t, 3 H, J = 6.82 Hz), 3.01-2.92 (m, 2 H), 3.11-3.02 (m, 2 H), 3.7-3.15 (m, 4 H), 3.88 (t, 4 H, 5.05 Hz), 4.14 (q, I H, J= 13.64, 7.07 Hz), 4.30-4.18 (m, 4 H), 7.75-7.66 (m, 3 H), 7.87-7.81 (m, 3 H), 7.99 (td, 1 H J= 8.34, 1.77 Hz), 8.18 (d, 1 H, /= 8.59 Hz). MS m/z calc. 545.11, found (ESI); 548.4 (M + I)+. Retention time 2.43 minutes.
[00251] 2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyI}-4- cyclopentyloxy-quinazoline
Figure imgf000298_0002
2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl } -4-cyclopentyloxy-quinazoline was synthesized by using the same method as described in Scheme V (Yield 6.27 mg, 13.6 %). MS m/z calc. 500.16, found (ESI); 501.2 (M + I)+. Retention time 3.25 minrtes.
[00252] (2-{l-[4-(4-Chloro-benzenesulfonyI)-piperazin-l-yI]-ethyI}-quinazolin-
4-yI)-dimethyI-amine
Figure imgf000298_0003
(2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-dimethyl-amine was synthesized by using the same method as described in Scheme V (Yield 25.86 mg, 61.16 %). 1H NMR (400 MHz, MeOD-4): δ 1.56 (t, 3 H, /= 6.82 Hz), 2.93-2.86 (m, 2 H), 3.02-2.95 (m, 2 H), 3.22-3.11 (m, 4 H), 3.67(s, 6H), 4.08 (q, 1 H, 7 = 13.64, 6.82 Hz), 7.73-7.64 (m, 3 H), 7.83-7.76(m, 3 H), 7.97 (td, 1 H, J- 8.59, 1.26 Hz), 8.38 (dd, 1 H, J = 8.59, 0.76 Hz). MS m/z calc. 459.15, found (ESI); 460.2 (M + I)+. Retention time 2.66 minutes.
[00253] (2-{l-[4-(4-Chloro-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-quinazolin-
4-yl)-ethyl-amine
Figure imgf000299_0001
(2- { 1 -[4-(4-Chloro-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazolin-4-yl)-ethyl-amine was synthesized using the same method as described in Scheme V (Yield 20.27 mg, 47.9 %). 1H NMR (400 MHz, MeOD-4): δ 1.38 (t, 3 H, / = 7.07 Hz), 1.54(d, 3 H, J = 7.07 Hz), 2.83-2.75 (m, 2 H), 2.92-2.85 (m, 2 H), 3.19-3,11 (m, 4 H), 3.85(q, 2 H / = 14.65, 6.82 Hz), 3.98 (q, 1 H, J = 14.40, 6.82 Hz), 7.69-7.65 (m, 2 H), 7.73(dt, 1 H, J= 8.34, 1.26 Hz), 7.38-7.78(m, 1 H), 7.99 (td, I R, J= 8.34, 1.26 Hz), 8.29 (d, 1 H, / = 8.34 Hz). MS m/z calc. 459.15, found (ESI); 460.2 (M + I)+. Retention time 2.74 minutes.
[00254] (2-{l-[4-(4-ChIoro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-
4-yl)-diethyl-amine
Figure imgf000299_0002
(2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazm-l-yl]-ethyl}-qumazolin-4-yl)-diethyl-amine was synthesized using the same method as described in Scheme V (Yield 22.89 mg, 50.9 %). 1H NMR (400 MHz, MeOD-4): δ 1.51 (t, 9 H, J = 6.82 Hz), 2.81-2.71 (m, 2 H), 2.89-2.81 (m, 2 H), 3.20-3.05 (m, 4 H), 4.03(q, 5 H J= 14.65, 6.82 Hz), 7.68-7.65 (m, 2 H), 7.70(dt, 1 H, J = 8.34, 1.26 Hz), 7.83-7.77(m, 3 H), 7.97 (td, 1 H, J = 8.34, 1.26 Hz), 8.19 (d, 1 H, J = 8.34 Hz). MS m/z calc. 487.18, found (ESI); 488.4 (M + I)+. Retention time 2.93 minutes. [00255] 2-{l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- morphoIin-4-yl-quinazoline
Figure imgf000300_0001
2- { 1 -[4-(4-Chloro-benzenesulfonyl)-piperazin- 1 -yl] -ethyl } -4-morpholin-4-yl-quinazoline was synthesized using the same method as described in Scheme V (Yield 31.71 mg, 68.67 %). 1H NMR (400 MHz, MeOD-4): δ 1.58 (t, 3 H, J = 6.82 Hz), 3.02-2.92 (m, 2 H), 3.12-3.03(m, 2 H), 3.28-3.16(m, 4 H), 3.87(t, 4 H, J = 4.55 Hz), 4.14(q, I HJ= 13.89, 6.32 Hz), 4.30-4.19(m, 4 H), 7.71-7.64 (m, 3 H), 7.87-7.76(m, 3 H), 7.96(dt, 1 H, 7= 8.34, 1.26 Hz), 8.15 (d, 1 H, J= 8.59 Hz). MS mJz calc. 501.16, found (ESI); 502.21 (M + I)+. Retention time 2.66 minutes.
[00256] 2-{l-[4-(4-ChIoro-benzenesulfonyl)-piperazin-l-yl]-ethyI}-4-piperidin- 1-yl-quinazoline
Figure imgf000300_0002
2-{ l-[4-(4-Chloro-benzenesulfonyl)-piperazin-l-yl]-ethyl } -4-piperidin- 1-yl-quinazoline was synthesized by using the same method as described in Scheme V (Yield 14.10 mg, 30.6 %). 1H NMR (400 MHz, MeOD-4): δ 1.42 (t, 3 H, J = 6.82 Hz), 1.78(br, s, 6 H), 2.74-2.66 (m, 2 H), 2.85-2.75(m, 2 H), 3.05(br, s, 4 H), 3.89(q, 1 H, J= 14.15, 6.82 Hz), 4.10(br, s, 4 H), 7.60-7.54 (m, 3 H), 7.73-7.67(m, 3 H), 7.85(dt, 1 H, J = 8.59, 1.26 Hz), 8.03(d, 1 H, J = 8.59 Hz). '3C NMR (100 MHz, CD3OD): δ 16.84, 24.78, 25.99, 46.55, 48.71, 50.88, 66.02, 115.22, 124.65, 124.99, 128.31, 128.88, 129.24, 129.25, 129.53, 132.11, 133.80, 139.27, 151.93, 164.42, 164.64. MS m/z calc. 499.18, found (ESI); 500.2 (M + I)+. Retention time 2.95 minutes. [00257] 4-([l,3]Dioxolan-4-ylmethoxy)-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000301_0001
4-([ 1 ,3]Dioxolan-4-ylmethoxy)-2- { 1 -[4-(4-methoxy-benzenesulfonyl)-piperazin- l-yl]-ethyl } - quinazoline was synthesized by using the same method as described in Scheme V (Yield 14.0 mg, 38.8 %). MS m/z calc. 514.59, found (ESI); 515.4 (M + I)+. Retention time 2.69 minutes.
[00258] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(5- methyl- [1 ,3]dioxan-5-ylmethoxy)-quinazoline
Figure imgf000301_0002
-{ ylmethoxy)-quinazoline was synthesized by using the same method as described in Scheme V (Yield 8.9 mg, 23.4 %). MS m/z calc. 542.65, found (ESI); 543.2 (M + I)+. Retention time 2.76 minutes.
[00259] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-4-
(pyridin-4-yloxy)-quinazoIine
Figure imgf000302_0001
2-{l-[4-(4-Methoxy-benzenesulfonyl)-piρerazin-l-yl]-ethyl}-4-(pyridin-4-yloxy)-quinazoline was synthesized by using the same method as described in Scheme V (Yield 2.7 mg, 7.6 %). MS mJz calc. 505.59, found (ESI); 506.2 (M + I)+. Retention time 2.28 minutes.
[00260] 4-Cyclohexyloxy-2-{l-[4-(4-methoxy-benzenesuIfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000302_0002
4-Cyclohexyloxy-2- { 1 - [4-(4-methoxy-benzenesulfonyl)-piperazin- 1 -yl] -ethyl } -quinazoline was synthesized by using the same method as described in Scheme V (Yield 2.8 mg, 7.8 %). MS m/z calc. 510.65, found (ESI); 511.2 (M + I)+. Retention time 3.17 minutes.
[00261] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(2- pyrrolidin-l-yl-ethoxy)-quinazoline
Figure imgf000302_0003
2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(2-pyrrolidin-l-yl-ethoxy)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 26.7 mg, 72.6 %). MS m/z calc. 525.66, found (ESI); 526.2 (M + I)+. Retention time 2.20 minutes.
[00262] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-4-
(tetrahydro-pyran-4-yIoxy)-quinazoline
Figure imgf000303_0001
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-(tetrahydro-pyran-4-yloxy)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 7.8 mg, 21.7 %). MS m/z calc. 512.62, found (ESI); 526.2 (M + I)+. Retention time 2.65 minutes.
[00263] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(3- methyl-butoxy)-quinazoline
Figure imgf000303_0002
2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(3-methyl-butoxy)-quinazoline was synthesized by using the same method as described in Scheme V (Yield 29.6 mg, 84.6 %). MS m/z calc. 499.63, found (ESI); 500.2 (M + I)+. Retention time 2.09 minutes.
[00264] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yI]-ethyl}-4- piperidin- 1 -yl-quinazoline
Figure imgf000304_0001
2- { 1 - [4-(4-Methoxy-benzenesulfonyl)-ρiρerazin- 1 -yl] -ethyl } -4-piperidin- 1 -yl-quinazoline was synthesized by using the same method as described in Scheme V (Yield 30.2 mg, 84.8 %). MS m/z calc. 495.16, found (ESI); 496.4 (M + I)+. Retention time 2.76 minutes.
[00265] Cyclopentyl-(2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yI]- ethyl}-quinazolin-4-yl)-amine
Figure imgf000304_0002
Cyclopentyl-(2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl]-ethyl } -quinazolin-4-yl)- amine was synthesized by using the same method as described in Scheme V (Yield 29.6 mg, 84.6 %). MS m/z calc. 495.64, found (ESI); 496.4 (M + I)+. Retention time 2.86 minutes.
[00266] Cyclohexyl-(2-{l-[4-(4-methoxy-benzenesuIfonyl)-piperazin-l-yl]- ethyl}-quinazolin-4-yl)-amine
Figure imgf000304_0003
Cyclohexyl-(2- { 1 -[4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl]-ethyl } -quinazolin-4-yl)- amine was synthesized by using the same method as described in Scheme V (Yield 24.4 mg, 69.7 %). MS m/z calc. 509.66, found (ESI); 510.4 (M + I)+. Retention time 2.90 minutes. [00267] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(3- methyl-piperidin-l-yl)-quinazoline
Figure imgf000305_0001
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-(3-methyl-piperidin- 1 -yl)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 27.7 mg, 77.4 %). MS mJz calc. 509.66, found (ESI); 511.4 (M + I)+. Retention time 2.14 minutes.
[00268] 4-(3,5-Dimethyl-piperidin-l-yl)-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000305_0002
4-(3 ,5-Dimethyl-piperidin- 1 -yl)-2- { 1 -[4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } - quinazoline was synthesized by using the same method as described in Scheme V (Yield 58.9 mg, 80.3 %). MS tn/z calc. 523.7, found (ESI); 524.4 (M + I)+. Retention time 2.94 minutes.
[00269] 4-Azepan-l-yl-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000305_0003
4-Azepan- l-yl-2-{ 1 -[4-(4-methoxy-benzenesulfonyl)-ρiperazin- l-yl]-ethyl } -quinazoline was synthesized by using the same method as described in Scheme V (Yield 50.5 mg, 70.7 %). MS tn/z calc. 509.66, found (ESI); 510.4 (M + I)+. Retention time 2.83 minutes. [00270] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-4-(4- methyl-piperidin-l-yl)-quinazoline
Figure imgf000306_0001
2- { 1 - [4-(4-Methoxy-benzenesulfonyl)-piperazin- 1 -yl] -ethyl } -4-(4-methyl-piperidin- 1 -yl)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 55.9 mg, 78.3 %). MS mJz calc. 509.66, found (ESI); 510.2 (M + I)+. Retention time 2.83 minutes.
[00271] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- thiomorpholin-4-yI-quinazoline
Figure imgf000306_0002
2- { 1 - [4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-thiomorpholin-4-yl-quinazoline was synthesized by using the same method as described in Scheme V. (Yield 52.0 mg, 72.3 %). MS m/z calc. 513.67, found (ESI); 514.0 (M + I)+. Retention time 2.65 minutes.
[00272] l-(2-{l-[4-(4-Methoxy-benzenesulfonyI)-piperazin-l-yl]-ethyI}- quinazolin-4-yl)-piperidine-4-carboxylic acid ethyl ester
-Jk r,
Figure imgf000307_0001
■J-Drnx. I-N-'17V<;
"*'" MZ .\l ns : ~_ he
/ 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(2-methyl-pyrrolidin-l-yl)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 44.6 mg, 64.4 %). MS m/z calc. 595.63, found (ESI); 596.2 (M + I)+. Retention time 2.73 minutes.
[00275] 2-{l-[4-(4-Methoxy-benzenesulfonyI)-piperazin-l-yl]-ethyl}-4-(2-
1 t methyl-piperidin-l-yl)-quinazoline
Figure imgf000308_0001
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin~ 1 -yl] -ethyl } -4-(2-methyl-piperidin- 1 -yl)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 11.5 mg, 15.8 %). MS m/z calc. 509.66, found (ESI); 510.2 (M + I)+. Retention time 2.79 minutes.
[00276] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-
(octahydro-isoquinolin-2-yl)-quinazoline
Figure imgf000308_0002
2- { 1 - [4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-(octahydro-isoquinolin-2-yl)- quinazoline was synthesized by using the same method as described in Scheme V (Yield 63.3 mg, 81.9 %). MS m/z calc. 549.72, found (ESI); 550.2 (M + I)+. Retention time 3.09 minutes.
[00277] 9-(2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoIin-4-yI)-l,5-dioxa-9-aza-spiro[5.5]undecane
Figure imgf000309_0001
9-(2- { 1 -[4-(4-Methoxy-benzenesulfonyl)-piperazin- l-yl]-ethyl } -quinazolin-4-yl)- 1 ,5-dioxa-9- aza-spiro[5.5]undecane was synthesized by using the same method as described in Scheme V (Yield 33.8 mg, 42.6 %). MS m/z calc. 567.70, found (ESI); 568.2 (M + I)+. Retention time 2.64 minutes.
[00278] 4-tert-Butoxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000309_0002
4-tert-Butoxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl }-quinazoline was synthesized by using the same method as described in Scheme V (Yield 24.0 mg, 42.5 %). MS m/z calc. 484.22, found (ESI); 485.3 (M + I)+. Retention time 2.97 minutes.
[00279] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyI}-4- pyrrolidin-l-yl-quinazoline
Figure imgf000309_0003
2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin- l-yl]-ethyl }-4-pyrrolidin-l-yl-quinazoline was synthesized by using the same method as described in Scheme V (Yield 13.2 mg, 39.2 %). MS m/z calc. 481.0, found (ESI); 482.2 (M + I)+. Retention time 2.61 minutes. [00280] [l-(2-{l-[4-(4-Methoxy-benzenesulfonyl)-Pipera7in-l-yI]-ethyl}- quinazolin-4-yl)-piperidin-3-yl]-methanol
Figure imgf000310_0001
[ 1 -(2- { 1 - [4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazolin-4-yl)-piperidin-3- yl]-methanol was prepared by using the same method as described in Scheme V (Yield 26.3 mg, 69.9 %). MS m/z calc. 525.1, found (ESI); 526.2 (M + I)+. Retention time 2.46 minutes.
[00281] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyϊ}-4-(4- methyl-piperazin-l-yl)-quinazoline
Figure imgf000310_0002
2- { 1 - [4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-(4-methyl-piperazin- 1-yl)- quinazoline was prepared by using the same method as described in Scheme V (Yield 21.2 mg, 59.1 %). MS m/z calc. 510.2, found (ESI); 511.4 (M + I)+. Retention time 2.14 minutes.
[00282] [l-(2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyI} quinazolin-4-yl)-piperidin-4-yl]-methanol
Figure imgf000310_0003
[ 1 -(2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazolin-4-yl)-piperidin-4- yl]-methanol was prepared by using the same procedure as described in Scheme V (Yield 22.3 mg, 60.7 %). MS m/z calc. 525.2, found (ESI); 526.2 (M + I)+. Retention time 2.39 minutes.
[00283] 4-(3,4-Dimethyl-cyclohexyloxy)-2-{l-[4-(4-methoxy-benzenesulfonyI)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000311_0001
4-(3,4-Dimethyl-cyclohexyloxy)-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared by using the same procedure as described in Scheme V (Yield 3.2 mg, 8.5 %). MS m/z calc. 538.6, found (ESI); 539.4 (M + I)+. Retention time 3.45 minutes.
[00284] 4-(2-Aza-bicyclo[2.2.1]hept-2-yl)-2-{l-[4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000311_0002
4-(2-Aza-bicyclo[2.2.1]hept-2-yl)-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared by using the same method as described in Scheme V (Yield 30.2 mg, 84.8 %). MS m/z calc. 507.2, found (ESI); 508.4 (M + I)+. Retention time 2.71 minutes.
[00285] 2-[l-(2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yI]-ethyl}- quinazolin-4-yl)-piperidin-4-yl]-ethanol
Figure imgf000312_0001
2-[l-(2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-piperidin-4- yl]-ethanol was prepared by using the same method as described in Scheme V (Yield 3.9 mg, 10.3 %). MS m/z calc. 539.2, found (ESI); 540.2 (M + I)+. Retention time 2.45 minutes.
[00286] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyl}-4-(4- propyl-piperidin-l-yl)-quinazoline
Figure imgf000312_0002
2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(4-propyl-piperidin-l-yl)- quinazoline was prepared by using the same method as described in Scheme V (Yield 11.7 mg, 31.1 %). MS m/z calc. 537.3, found (ESI); 538.2 (M + I)+. Retention time 3.16 minutes.
[00287] (2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yI]-ethyl}- quinazolin-4-yl)-phenyl-amine
Figure imgf000312_0003
(2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-phenyl-amine was prepared by using the same procedure as described in Scheme V (Yield 27.8 mg, 78.9 %). MS m/z calc. 503.6 found (ESI); 504.2 (M + I)+. Retention time 2.73 minutes.
[00288] Benzyl-(2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazolin-4-yl)-amine
Figure imgf000313_0001
Benzyl-(2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-amine was prepared by using the same procedure as described in Scheme V (Yield 25.2 mg, 55.2 %). MS m/z calc. 517.6 found (ESI); 5518.2 (M + I)+. Retention time 2.78 minutes.
[00289] Benzyl-(2-{l-[4-(4-methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyl}- quinazolin-4-yl)-methyl-amine
Figure imgf000313_0002
Benzyl-(2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazolin-4-yl)-methyl- amine was prepared by using the same procedure as described in Scheme V (Yield 30.1 mg, 80.9 %). MS m/z calc. 531.7 found (ESI); 532.2 (M + I)+. Retention time 2.85 minutes.
[00290] l-[4-(2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yI]-ethyl}- quinazolin-4-yl)-piperazin-l-yl]-ethanone
Figure imgf000314_0001
1 -[4-(2- { 1 - [4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazolin-4-yl)-piperazin- 1 - yl]-ethanone was prepared by using the same method as described in Scheme V (Yield 15.3 mg, 40.7 %). MS m/z calc. 538.7 found (ESI); 539.2 (M + I)+. Retention time 2.36 minutes.
[00291] Preparation of 6-Fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-3H-quinazolin-4-one
Figure imgf000314_0002
Step 1: Preparation of 2-Aminό-5-fluoro-benzoic acid: A stirred solution of 5-fluoroisatin (39 g, 0.236 mol) in NaOH (5%, 500 mL) was treated dropwise over 10 min with 30% H2O2 (57 g, calculated to contain 17 g, 0.5 mol). After another 20 min of being stired, during which became warm and effervesced, the solution was cooled in an ice-bath and acidified to pH = 4 with 3 M HCl. The precipitated solid was collected and dried in air to obtain 2-amino-5-fluoro-benzoic acid 1 as a beige powder (29.6 g, 80%). 1H NMR (DMSO - d6) δ 7.3 - 8.2 (m, 2 H), 7.08 (d, J = 9 Hz, 1 H), 6.63 (d, J = 9 Hz, 2 H), 2.13 (s, 3 H).
Step 2: Preparation of 2-Ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one: A mixture of 2-amino-5- fluorobenzoic acid (23.3 g, 0.15 mol) and propionic acid anhydride (150 mL) was heated to reflux for 3 hr, then the propionic acid anhydride was removed in vacuo to afford 2-ethyl-6- fluoro-benzo[d][l,3]oxazin-4-one 2 as a gray solid, which was used directly in the next step.
Step 3: Preparation of 2-Ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one: A mixture of 2-ethyl-6- fluoro-benzo[d][l,3]oxazin-4-one (25 g) and ammonia (300 mL, 25-28%) was stirred overnight. The solid was filtered to give 2-ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one 3 as a white solid (23 g, 80%).
Step 4: Preparation of 2-(l-Bromo-ethyl)-6-fluoro-3H-quinazolin-4-one: To a solution of 2- ethyl-6-fluoro-benzo[d][l,3]oxazin-4-one 3 (19.2 g, 0.1 mol) and sodium acetate (8.2 g, 0.1 mol) in acetic acid (500 mL) was added dropwise a solution of bromine (16.0 g, 0.1 mol) in acetic acid (40 mL) at 10 0C. After stirred at r.t. for 2 days, the reaction mixture was gradually poured into cold water. The precipitated solid was filtered, washed with water, dried to give 2-(l-bromo- ethyl)-6-fluoro-3H-quinazolin-4-one (10 g, yield= 37%). 1H NMR (DMSO - d6) δ 12.6 (b, 1 H), 7.78 - 7.67 (m, 3 H), 5.07 (q, J = 6.8 Hz, 1 H), 1.97 (d, / = 6.8 Hz, 3 H). MS (ESI) m/e (M+H*1): 253.0.
Step 5: Preparation of 6-Fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-3H-quinazolin-4-one
6-Fluoro-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl }-3H-quinazolin-4-one was prepared by using the same method as described in Scheme I. (Yield 431.0 mg, 13.1 %). %). 1H NMR (400 MHz, CDCl3): δ 1.35(d, / = 6.82 Hz, 3 H), 2.58-2.47(m, 2 H), 2.69-2.58(m, 2 H), 3.10-2.84(m, 4 H), 3.53(q, / = 13.39, 6.82 Hz, 1 H), 3.85(s, 3 H), 6.98(d, J = 8.34, 2 H), 7.48- 7.34 (m, 1 H), 7.65-7.58(m, 3 H), 7.78 (d, J = 8.34, 3.03 Hz, 1 H). MS m/z calc. 446.5 found (ESI); 447.0 (M + I)+. Retention time 2.75 minutes.
[00292] 6-Fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-
4-piperidin-l-yl-quinazoIine
Figure imgf000315_0001
6-Fluoro-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-piperidin-l-yl- quinazoline was prepared using the same method as described in Scheme V (Yield 20.5 mg, 23.5 %). MS m/z calc. 413.0 found (ESI); 514.4 (M + I)+. Retention time 2.82 minutes.
[00293] 6-Fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-
4-(4-methyl-piperidin-l-yI)-quinazoline
Figure imgf000316_0001
6-Fluoro-2- { 1 -[4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -4-(4-methyl-piperidin- 1 - yl)-quinazoline was prepared by using the same method as described in Scheme V (Yield 50.2 mg, 57.3 %). MS m/z calc. 527.0 found (ESI); 528.0 (M + I)+. Retention time 2.96 minutes.
[00294] Cyclohexyl-(6-fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin- l-yl]-ethyl}-quinazolin-4-yI)-amine
Figure imgf000316_0002
Cyclohexyl-(6-fluoro-2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -quinazolin-4- yl)-amine was prepared using the same method as described in Scheme V (Yield 20.0 mg, 22.3 %). MS m/z calc. 527.0 found (ESI); 528.2 (M + I)+. Retention time 2.196 minutes.
[00295] 4-Cyclohexyloxy-6-fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyI}-quinazoUne
Figure imgf000317_0001
4-Cyclohexyloxy-6-fluoro-2-{ l-[4-(4-memoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared using the same method as described in Scheme V (Yield 2.8 mg, 3.1 %). MS m/z calc. 528.0 found (ESI); 529.2 (M + I)+. Retention time 3.29 minutes.
[00296] 4-Cydopentyloxy-6-fluoro-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000317_0002
4-Cyclopentyloxy-6-fluoro-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared using the same procedure described in Scheme V. (Yield 5.2 mg, 5.9%). MS m/z calc. 514.2 found (ESI); 515.4 (M + I)+. Retention time 3.17 minutes.
[00297] 4-(3,4-Dihydro-2H-quinolin-l-yl)-2-{l-[4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000317_0003
4-(3,4-Dihydro-2H-quinolin-l-yl)-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared using the same procedure described in Scheme V (Yield 16.0 mg, 41.5%). MS m/z calc. 543.6 found (ESI); 544.2 (M + I)+. Retention time 2.93 minutes. [00298] 4-(4-Benzyl-piperidin-l-yl)-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000318_0001
4-(4-Benzyl-piperidin- 1 -yl)-2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl]-ethyl } - quinazoline was prepared using the same procedure described in Scheme V (Yield 18.7 mg, 45.7%). MS m/z calc. 585.7 found (ESI); 586.4 (M + I)+. Retention time 3.20 minutes.
[00299] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(4- phenyl-piperazin-l-yl)~quinazoline
Figure imgf000318_0002
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl]-ethyl } -4-(4-phenyl-piperazin- 1 -yl)- quinazoline was prepared using the same procedure described in Scheme V (Yield 32.2 mg, 80.4%). MS m/z calc. 572.3 found (ESI); 573.2 (M + I)+. Retention time 2.96 minutes.
[00300] 4-(2,5-Dihydro-pyrrol-l-yI)-2-{l-[4-(4-methoxy-benzenesuIfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000319_0001
4-(2,5-Dihydro-pyrrol-l-yl)-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared using the same procedure described in Scheme V (Yield 28.7 mg, 85.6%). MS m/z calc. 479.3 found (ESI); 480.2 (M + I)+. Retention time 2.55 minutes.
[00301] 4-(3,6-Dihydro-2H-pyridin-l-yl)-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000319_0002
4-(3,6-Dihydro-2H-pyridin-l-yl)-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- quinazoline was prepared using the same procedure described in Scheme V (Yield 8.1 mg, 23.4%). MS m/z calc. 493.2 found (ESI); 494.4 (M + I)+. Retention time 2.68 minutes.
[00302] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- thiazolidin-3-yl-quinazoline
Figure imgf000319_0003
2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l~yl]-ethyl }-4-thiazolidin-3-yl-quinazoline was prepared using the procedure described in Scheme V (Yield 23.8 mg, 68.1%). MS m/z calc. 499.2 found (ESI); 500.0 (M + I)+. Retention time 2.61 minutes. [00303] [l,3]Dioxolan-2-ylmethyI-(2-{l-[4-(4-methoxy-benzenesulfonyI)- piperazin-l-yl]-ethyl}-quinazolin-4-yl)-methyI-amine
Figure imgf000320_0001
[ 1 ,3]Dioxolan-2-ylmethyl-(2- { 1 -[4-(4-methoxy-benzenesulfonyl)-piperazin- 1 -yl]-ethyl } - quinazolin-4-yl)-methyl-amine was prepared using the same method as described in Scheme V (Yield 34.3 mg, 92.9%). MS m/z calc. 527.6 found (ESI); 528.2 (M + I)+. Retention time 2.52 minutes.
[00304] 4-Cyclobutoxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-quinazoline
Figure imgf000320_0002
4-Cyclobutoxy-2-{ 1 -[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl] -ethyl }-quinazoline was prepared by using the procedure described in Scheme V (Yield 10.0 mg, 22.3%). MS m/z calc. 482.2 found (ESI); 483.4 (M + I)+. Retention time 2.86 minutes.
[00305] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-(4- methyl-cyclohexyloxy)-quinazoline
Figure imgf000320_0003
2- { 1 -[4-(4-Methoxy-benzenesulfonyl)-ρiperazin- 1 -yl]-ethyl } -4-(4-methyl-cyclohexyloxy)- quinazoline was prepared using the procedure described in Scheme V (Yield 10.0 mg, 20.5%). MS m/z calc. 4524.6 found (ESI); 525.2 (M + I)+. Retention time 3.31 minutes.
[00306] 4-(Bicyclo[2.2.1]hept-2-yloxy)-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000321_0001
4-(Bicyclo[2.2.1 ]hept-2-yloxy)-2- { 1 -[4-(4-methoxy-benzenesulfonyl)-piperazin- 1 -yl]-ethyl } - quinazoline was prepared using the procedure described in Scheme V (Yield 10.0 mg, 20.6%). MS m/z calc. 4524.6 found (ESI); 525.2 (M + I)+. Retention time 3.32 minutes.
r formation of diamine spacer analogs
Figure imgf000321_0003
Figure imgf000321_0002
N-Boc diamine
A mixture of 2-(l-bromo-ethyl)-3-methyl-3H-quinazolin-4-one (801 nig, 3 mmpl), the N-Boc amine (3.3 mmol), potassium iodide (498 mg, 3 mmol) and potassium carbonate (622 mg, 4.5 mmol) in acetonitrile (12 mL) was heated at 65°C for 3 days. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with saturated sodium thiosulphate solution and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in dichloromethane (5 mL) and TFA (5 mL) was added. The reaction was stirred at RT until deprotection was complete (as detected by LC- MS). IN NaOH solution was added until the solution was basic (pH 11-12). The organic layer was extracted and washed with water, dried over magnesium sulfate and concentrated in vacuo to yield the product which was used with no further purification. The deprotected amine (0.2 mmol) and triethylamine (167 μL, 0.4 mmol) were dissolved in dioxane (1 mL) and to this was added the corresponding sulfonyl chloride (0.3 mmol). The reaction was shaken at room temperature overnight. Dichloromethane (2 mL) and water (2 mL) were added and the reaction tube was shaken. The top aqueous layer was aspirated off and the organic layer was concentrated in vacuo. The residue was dissolved in DMSO and purified by HPLC to yield the final product.
[00308] 2-{l-[l-(4-Methoxy-benzenesulfonyl)-piperidin-4-ylamino]-ethyl}-3- methyl-3H-quinazolin-4-one
Figure imgf000322_0001
Step 1:
A mixture of 2-(l-bromo-ethyl)-3-methyl-3H-quinazolin-4-one (801 mg, 3 mmol), 4-amino-l- N-Boc piperidine (661 mg, 3.3 mmol), potassium iodide (498 mg, 3 mmol) and potassium carbonate (622 mg, 4.5 mmol) in acetonitrile (12 mL) was heated at 65°C for 3 days. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with saturated sodium thiosulphate solution and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo to yield 4-[l-(3-Methyl-4-oxo-3,4-dihydro- quinazolin-2-yl)-ethylamino]-piperidine-l-carboxylic acid tert-butyl ester (HPLC ret. time 2.20, 10-99%CH3CN, 5 min run, ESI-MS m/z 387.4 (MH+). Step 2:
The product was dissolved in dichloromethane (5 mL) and TFA (5 mL) was added. The reaction was stirred at room temperature until deprotection was complete (as detected by LC-MS). IN NaOH solution was added until the solution was basic (pH 11-12). The organic layer was extracted and washed with water, dried over magnesium sulfate and concentrated in vacuo to yield 3-Methyl-2-[l-(piperidin-4-ylamino)-ethyl]-3H-quinazolin-4-one,which was used with no further purification. (HPLC ret. time 1.19, 10-99%CH3CN, 5 min run, ESI-MS m/z 287.2 (M+l)+. Step 3: 3-Methyl-2-[l-(piρeridin-4-ylamino)-ethyl]-3H-quinazolin-4-one (57.2 mg, 0.2 mmol) and triethylamine (167 μL, 0.4 mmol) were dissolved in dioxane (1 mL) and to this was added 4- methoxybenzenesulfonyl chloride (62 mg, 0.3 mmol). The reaction was shaken at room temperature overnight. Dichloromethane (2 mL) and water (2 mL) were added and the reaction tube was shaken. The top aqueous layer was aspirated off and the organic layer was concentrated in vacuo. The residue was dissolved in DMSO and purified by HPLC to yield the final product, 2-{ l-[l-(4-Methoxy-benzenesulfonyl)-piperidin-4-ylamino]-ethyl}-3-methyl-3H- quinazolin-4-one. HPLC ret. time 2.23, 10-99%CH3CN, 5 min run; 1H NMR (CDCl3) 6 1.55 (d, 3H, J= 6.6 Hz), 1.66 (q, 2H, / = 12.1 Hz), 2.16 (m, 4H), 3.19 (m, IH), 3.53 (s, 3H), 3.68 (m, 2H), 3.80 (s, 3H), 4.86 (q, IH, J = 5.7 Hz), 7.12 (d, 2H, / = 9.0 Hz), 7.57 (t, IH, J = 8.1 Hz), 7.63 (d, 2H, J = 8.9 Hz), 7.69 (d, IH, J = 7.7 Hz), 7.86 (t, IH, J = 8.4 Hz), 8.15 (dd, IH, J = 8.0, 1.2 Hz); ESI-MS m/z 457.4 (M+l) +.
[00309] 2-(l-{[l-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-methyl-amino}- ethyl)-3-methyl-3H-quinazolin-4-one
Figure imgf000323_0001
To a mixture of 2-{ l-[l-(4-methoxy-benzenesulfonyl)-piperidin-4-ylamino]-ethyl}-3-methyl- 3H-quinazolin-4-one (183 mg, 0.4 mmol), formaldehyde (39 μL, 0.48mmol, 37 %wt. solution in water) and DMF (1 mL) was added MP-Cyanoborohydride (300 mg, 2-3 mmol/g) and the reaction was stirred overnight at room temperature. The reaction mixture was then filtered and purified by HPLC to yield the product. HPLC ret. time 2.41 min, 10-99%CH3CN, 5 min run; 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.0 Hz, IH), 7.93 (t, J = 7.2 Hz, IH), 7.68 (m, 4H), 7.03 (d, J = 8.6 Hz, 2H), 4.93 (m, IH), 3.98 (s, IH), 3.89 (s, 3H), 3.69 (s, 3H), 3.10 (s, 3H), 2.58 (m, 2H), 2.21 (m, 2H), 1.78 (d, J = 6.6 Hz, 3H), 1.31 (m, 4H); ESI-MS m/z 471.3 (M+l) +.
[00310] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline
[00311] Step 1: N-(2-Formyl-phenyl)-propionamide
Figure imgf000324_0001
[00312] To a solution of 2-aminobenzaldehyde (1.21g, 10 mmol), and triethylamine (1.39 mL, 10 mmol) in dichloromethane (50 mL) was added propionyl chloride (1.04 mL, 12 mol). The reaction was stirred at room temperature for 3 days. The reaction solution was washed with water and then dried over magnesium sulfate and concentrated in vacuo to yield the crude product (1.65g, 93%). The product was used without further purification. 1H NMR (400 MHz, CDC13) δ 11.16 (s, IH), 9.93 (s, IH), 8.77 (d, J = 8.5 Hz, IH), 7.67 (d, / = 7.7 Hz, IH), 7.62 (t, / = 7.1 Hz, IH), 7.22 (t, J = 7.5 Hz, IH), 2.51 (q, J = 7.6 Hz, 2H), 1.29 (t, J = 7.6 Hz, 3H); HPLC ret. time 1.34 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 177.2 (M+l)+.
[00313] Step 2: 2-Ethyl-quinazolinc
Figure imgf000324_0002
[00314] N-(2-Formyl-phenyl)-propionamide (1.65g, 9.3 mmol) was combined with
> ammonia (24 mL, 2M solution in methanol) in a flask fitted with a condenser and stopper with a needle to vent. The reaction was heated to 100°C for 1 day. The reaction mixture was concentrated in vacuo to yield the crude product as an orange oil (1.47g, 100%). This product was used without further purification. 1H NMR (400 MHz, CDC13) δ 9.36 (s, IH), 7.99 (d, J = 10.0 Hz, IH), 7.89 (m, 2H), 7.60 (t, J = 8.1 Hz, IH), 3.16 (q, J = 7.6 Hz, 2H), 1.47 (t, J = 7.6 Hz, 3H); HPLC ret. time 0.61 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 159.0 (MH+).
[00315] Step 3: 2-(l-Bromo-ethyl)-quinazoline
Figure imgf000324_0003
[00316] A solution of 2-ethyl-quinazoline (316mg, 2 mmol), iV-bromosuccinimide
(356mg, 2 mmol) and benzoyl peroxide (48mg, 0.2 mmol) in chloroform (10 mL) was heated to reflux for 2 hours. The reaction solution was concentrated in vacuo and purified by column chromatography (0 - 25% ethyl acetate - hexanes) to yield the pure product (130mg, 28%). 1H NMR (400 MHz, CDC13) δ 9.45 (s, IH), 8.04 (d, J = 9.0 Hz, IH), 7.94 (m, 2H), 7.68 (t, J = 8.1 Hz, IH), 5.47 (q, J = 6.9 Hz, IH), 2.23 (d, J = 6.9 Hz, 3H); HPLC ret. time 2.79 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 236.9 (M+l)+.
[00317] Ste2_4: 2-{l-[4-(4-Bromo-benzenesuIfonyl)-piperazin-l-yl]-ethyl}- quinazoline
Figure imgf000325_0001
A mixture of 2-(l-Bromo-ethyl)-quinazoline (43mg, 0.18 mmol) and l-(4-Bromo- benzenesulfonyl)-piperazine (67mg, 0.22 mmol), potassium iodide (30g, 0.18mmol) and potassium carbonate (37mg, 0.27 mmol) in acetonitrile (1 mL) was heated at 650C for 1 day. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with saturated sodium thiosulphate solution, saturated sodium bicarbonate solution and then with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was dissolved in DMSO and purified by HPLC. 1H NMR (400 MHz, CDC13) δ 9.45 (s, IH), 8.06 (m, 3H), 7.80 (t, J = 7.9 Hz, IH), 7.72 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.5 Hz, 2H), 4.86 (q, J = 7.0 Hz, IH), 3.65 (m, 2H), 3.43 (m, 6H), 1.88 (d, J = 7.0 Hz, 3H) HPLC ret. time 2.45 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 461.1 (M+l)+. [00318] Methyl 2-(diethoxyphosphoryl)-propionate
Figure imgf000325_0002
Methyl 2-bromo propionate (181 g, 1 mol) was preheated at 140°C and then the triethyl phosphite was added dropwise over a period of 2 hours. Ethyl bromide was removed from the system and the temperature was raised to 160°C. After the addition was complete, the temperature was raised to 1900C for 1 hr. The mixture was fractionated to give the product as a colorless liquid (185 g, 82.6%, Bp16mmHg 142-146°C). 1HNMR (CDCl3) δ 4.16-4.08(m, 4 H), 3.73 (s, 3 H), 3.07-2.96 (dq, 1 H, JH-H = 7.2 Hz, JP.H = 23.6 Hz), 1.44-1.38 (dd, 3 H, JH-H = 7.2 Hz, Jp.H = 16 Hz), 1.32-1.25 (m, 3 H). [00319] 2-(l-benzylpiperidin-4-ylidene)-propionic acid methyl ester
Figure imgf000326_0001
To a suspension of NaH (60% in mineral oil, 6 g, 0.15 mol) in dry THF (300 mL), under N2 atmosphere, was added a solution of methyl 2-(diethoxyphosphoryl)-propionate (33.6 g, 0.15 mol) in dry THF (150 mL) at such a rate to keep the temperature below 30°C. After being stirred at r.t for 40 min, a solution of N-benzyl-4-piperidone (28.35 g, 0.15 mol) in dry THF (100 mL) was added dropwise keeping the temperature below 30°C. After the addition was completed, the mixture was stirred at r.t for 30 min. The reaction was quenched with NH4Cl (sat. aq., 400 mL). The mixture was extracted with Et2O (300 mL x 2) and the combined extracts were washed with brine, dried and concentrated to give the crude product as a red oil, which was used directly in the next step.
[00320] 4-(l-Methoxycarbonyl-ethyl)-piperidine-l-carboxylic acid tert-butyl ester
Figure imgf000326_0002
A mixture of 2-(l-benzylpiperidin-4-ylidene)-propionic acid methyl ester (45 g crude from last step, about 0.15 mol), BoC2O (32.7 g, 0.15 mol) and 10% Pd/C (4 g) in EtOH (600 mL) was stirred overnight at 55°C under a H2 atmosphere (PH2 =55 PSI). The catalyst was filtered off and the filtrate was concentrated in vacuo to give the crude product as light yellow oil, which was directly used in next step.
[00321] 4-(l-Carboxy-ethyl)-piperidine-l-carboxylic acid tert-butyl ester
Figure imgf000326_0003
A mixture of 4-(l-methoxycarbonylethyl)-piperidine-l-carboxylic acid terr-butyl ester (40 g crude from last step, about 0.15 mol), LiOH (12.6 g, 0.3 mol) in water (200 mL) and THF (400 mL) was heated to reflux for 4 hours. The cooled mixture was diluted with water (200 mL) and washed with Et2O (200 mL x 2). The aqueous layer was acidified with HCl (10%) at 0°C to pH3 - 4. The mixture was extracted with Et2O (200 mL x 3) and the combined extracts were washed with brine, dried and concentrated to give the product as a white solid (28 g, 73% from N- benzyl-4-piperidone). 1HNMR (CDCl3) δ 4.11 (m, 2 H), 2.69-2.63 (m, 2 H), 2.30 (p, 1 H, J = 7.2 Hz), 1.72-1.62 (m, 3 H), 1.44 (s, 9 H), 1.27-1.18 (m, 2 H), 1.16 (d, 3 H, J = 7.2 Hz).
[00322] Preparation of 4-[l-(2-carbamoylphenylcarbamoyl)-ethyl]-piperidine-
1-carboxylic acid tert-butyl ester
Figure imgf000327_0001
A mixture of 4-(l-carboxy-ethyl)-piperidine-l-carboxylic acid tert-butyl ester (28.6 g, 0.11 mol), 2-aminobenzamide (13.7 g, 0.1 mol), EDCI (21.3 g, 0.11 mol), HOBT (15 g, 0.11 mol) and Et3N (25 mL) in CH2Cl2 (500 mL) was stirred for 48 hr. The reaction mixture was diluted with CH2Cl2 (1000 mL) and washed with NaHCO3 (aq), the organic layer was dried with Na2SO4 and concentrated in vacuo to give the product a yellow solid (20 g, 48%) which was used directly for the next step.
[00323] 4-[l-(4-oxo-3,4-dihydro-quinazoIin-2-yl)-ethyl]-piperidine-l- carboxylic acid tert-butyl ester
Figure imgf000327_0002
A solution of 4-[l-(2-carbamoyl-phenylcarbamoyl)-ethyl]- piperidine-1-carboxylic acid tert- butyl ester (20 g, 0.05mmol, crude from the last step) and MeONa (10 g, 0.19 mol) in MeOH (500 mL) was heated to reflux for 6 hr and the solvent was removed in vacuo. The residue was diluted with water and extracted with EtOAc (300 mL x 3), the organic layer was dried with Na2SO4, concentrated and purified by column chromatography to afford the product (2g, 5%).
[00324] 2-(l-piperidin-4-yl-ethyI)-3H-quinazolin-4-one
Figure imgf000328_0001
A solution of 4-[l-(4-oxo-3,4-dihydro-quinazolin-2-yl)-ethyl]-piperidine-l-carboxylic acid tert- butyl ester and TFA in CH2Cl2 was stirred at r.t. for 6 hr. The precipitated solid was filtered and dried to afford the product as a white solid. (2g, 90%). 1H NMR (DMSO-de) δ 8.51 (br, s, 1 H), 8.18 (br, s, 1 H), 8.06 (d, I B, J= 7.6), 7.74 (t, 1 H, / = 8.0), 7.57 (d, 1 H, J = 8.0), 7.44 (t, 1 H, J = 8.0), 3.29-3.18 (m, 2 H), 2.88-2.76 (m, 2 H), 2.61-2.57 (m, 1 H), 1.95-1.92 (m, 2 H), 1.61-1.57 (m, 1 H), 1.42-1.25 (m, 2 H), 1.25 (d, 3 H, J = 6.8); ESI-MS m/z 258.1 (M+l)+.
[00325] 2-{l-[l-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-ethyI}-3H- quinazolin-4-one
Figure imgf000328_0002
To a mixture of 2-(l-piperidin-4-yl-ethyl)-3H-quinazolin-4-one (971mg, 2 mmol) and triethylamine (976 μL, 7 mmol) in 1,4-dioxane (10 mL) was added 4-methoxysulfonyl chloride (537mg, 2.6 mmol). The reaction was stirred at room temperature for 3 hours, the filtered and the solute was concentrated in vacuo. The residue was dissolved in dichloromethane and extracted with water. The organic layer was concentrated in vacuo and purified by column chromatography (25 - 50% ethyl acetate - hexanes) to yield the product as a white solid (70mg, 8%). 1H NMR (400 MHz, CDC13) δ 11.11 (s, IH), 8.24 (dd, J = 7.9, 1.1 Hz, IH), 7.79 (t, / = 8.4 Hz, IH), 7.68 (m, 3H), 7.48 (t, J = 7.5 Hz, IH), 6.98 (d, J = 8.9 Hz, 2H), 3.89 (s, 3H), 3.75 (d, J = 11.7 Hz, IH), 2.62 (quintet, J = 7.4 Hz, IH), 2.24 (m, 2H), 1.71 (m, 4H), 1.50 (m, 2H), 1.39 (d, / = 7.0 Hz, 3H); HPLC ret. time 2.89 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 428.1 (M+l)+.
[00326] 4-CycIopentyIoxy-2-{l-[l-(4-methoxy-benzenesuIfonyl)-piperidin-4- yl]-ethyl}-quinazoline
Figure imgf000329_0001
A mixture of 2-{ l-[l-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-ethyl}-3H-quinazolin-4-one (34mg, 0.08 mmol), cyclopentyl iodide (18 μL, 0.16 mmol), and potassium carbonate (55mg, 0.4 mmol) in DMF (1 mL) was heated to 70°C for 1 day. The reaction mixture was partitioned between dichloromethane and water. The organic layer was concentrated in vacuo and the residue was purified by HPLC (in the absence of TFA) to yield the product. 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, / = 7.6 Hz, IH), 7.81 (d, J = 8.3 Hz, IH), 7.75 (t, J = 7.0 Hz, IH), 7.67 (d, J = 8.9 Hz, 2H), 7.46 (t, J = 7.5 Hz, IH), 6.97 (d, J = 8.9 Hz, 2H), 5.63 (m, IH), 3.86 (s, 3H), 3.80 (d, J = 11.6 Hz, IH), 3.67 (dd, J = 11.2, 1.6 Hz, IH), 2.81 (quintet, J = 7.3 Hz, IH), 2.28 (t, J= 11.8 Hz, IH), 2.17 (m, IH), 1.93 (m, 10H), 1.44 (m, 3H), 1.29 (d, J = 6.9 Hz, 3H); HPLC ret. time 3.24 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 496.3 (M+l) +
[00327]
Na2CO3
Figure imgf000329_0002
Preparation of S-propionylamino-pyrazine-Z-carboxylic acid amide. A mixture of 3-amino- ρyrazine-2-carboxylic acid (20.9 g, 0.15 mol), pyridine (29.6 g, 0.375 mol) and DMAP (1.83 g, 15 mmol) in propionic acid anhydride (100 mL) was stirred at room temperature overnight. The reaction mixture was poured into NH3-H2O (500 mL) partially at 0 0C. After stirred for 30 min at 0 0C, the precipitated solid was filtered, washed with water , dried in air to give 3- propionylamdno-pyrazine-2-carboxylic acid amide as a beige solid (12.4 g, 43%), which was used directly in the next step. [00328] Preparation of 2-Ethyl-3H-pteridin-4-one. A mixture of 3- propionylamino-pyrazine-2-carboxylic acid amide (9.7 g, 50 mmolj and Na2CO3 (100 mL, 10%) was refluxed overnight. The water was removed in vacuo and the residue was treated with CH3OH (200 mL). The insoluble salt was filtered and the filtrate was evaporated to give 2- Ethyl-3H-pteridin-4-one as a yellow solid (6.1 g, 69%). 1H NMR (DMSO - d6) δ 8.64 (d, J = 2 Hz, 1 H), 8.36 (d, J = 2 Hz , 1 H), 2.52 (q, / = 4.5 Hz , 2 H), 1.18 (t, / = 4.5 Hz, 3 H). MS (ESI) m/e (M+l)+: 177.3.
[00329] 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H-pteridin-
4-one
Figure imgf000330_0001
[00330] 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl }-3H-pteridin-
4-one by using the same method as described in Scheme IA or Scheme IB. (Yield 249.0 mg, 24.4%). 1Η NMR (400 MHz, CDCl3): δ 1.44 (d, J = 7.33 Hz, 3 H), 2.71-2.56(m, 4 H), 3.13-2.84 (m, 4 H), 3.85(s, 3 H), 4.05(q, I H, J = 14.15, 7.33 Hz), 6.99 (d, J = 8.84, 1 H), 7.63 (d, J = 8.84, 2 H), 8.74(d, / = 2.02, 1 H), 8.88 (d, J = 2.02, 1 H). MS m/z calc. 430.4 found (ESI); 431.2 (M + I)+. Retention time 2.30 minutes.
[00331] 4-Cyclohexyloxy-2-{l-[4-(4-methoxy-benzenesuIfonyI)-piperazin-l-yl]- ethyl}-pteridine
Figure imgf000330_0002
[00332] 4-Cyclohexyloxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethylj-pteridine by using the procedure described in Scheme V. (Yield 10.0 mg, 27.9%). MS m/z calc. 512.6 found (ESI); 513.2 (M + I)+. Retention time 3.67 minutes.
[00333] 4-Cyclopentyloxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-pteridine
Figure imgf000331_0001
[00334] 4-Cyclopentyloxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]- ethyl}-pteridine by using the procedure described in Scheme V (Yield 10.0 mg, 27.9%). MS m/z calc. 498.6 found (ESI); 499.2 (M + I)+. Retention time 3.56 minutes.
[00335] Sythesis of pyrimidines:
Figure imgf000331_0002
[00336] 2-ethyl-3H-pyrimidin-4-one:
[00337] Step 1:
[00338] Dry HCl (g) is passed into a cold solution (-20 °C) of dry propionitrile
(406 g, 7.38 mol) in absolute alcohol (347 g, 7.56 mol) until an increase of 284 g (7.78 mol) in weight. It was stirred overnight and a solid mass of white crystals of propionimidic acid ethyl ester hydrochloride came out which were used directly in the next step without further purification.
[00339] Step 2:
[00340] The propiorάmidic acid ethyl ester hydrochloride from step 1 (171 g, 1.69 mol) was dissolved in a solution of ammonia in alcohol (350 g, 9.15 %). The resulting mixture was allowed to stir overnight and the small amount of salt was filtered off. Removal of the solvent in vacuo gave 116 g (86 %) of white solid, which can be used directly in the next step.
[00341] Step 3:
[00342] To a hot (60 0C) solution of propionamidine hydrochloride prepared in step 2 (54.3 g, 0.5mol) and propynoic acid ethyl ester (53.9 g, 0.55 mol) in absolute alcohol (IL) was added dropwise a solution of KOH (70 g, 80%, 1 mol) in absolute alcohol (300 mL) during 3 hours. The temperature was kept between 60 0C and 70 °C during the addition. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was acidified to pH 5 with HCl (6 M), extracted with ethyl acetate for at least 15 times. The organic layer was dried over Na2SO4 and then filtered. The filtrate was evaporated under reduced pressure and the residue was recrystallized with acetonitrile to afford 2-ethyl-3H-pyrimidin-4- one as light yellow crystals (14 g, 23 %).
[00343] 1H-NMR(CDCB) δ 8.00-7.98 (d, IH, J = 6.8 Hz), 6.34-6.33 (d, IH, J =
6.8 Hz), 2.77-2.71 (q, 2H), 1.37-1.33 (t, 3H). MS (ESI) m/e (M+l) 125.2.
[00344] 5-Bromo-2-(l-bromo-ethyI)-3H-pyrimidin-4-one
Figure imgf000332_0001
To a solution of 2-ethyl-3H-pyrimidin-4-one (3.0 g, 24.2 mmol) in chloroform (50 ml) were added NBS (4.3 g, 24.2 mmol) and benzoyl peroxide (5.8 g, 24.2 mmol) and the mixture was heated at 60 0C for 2 hours. The reaction was cooled to room temperature and the solvent was evaporated. The solid residue was washed with ether 3 times to give 5-Bromo-2-(l-bromo- ethyl)-3Η-pyrimidin-4-one (Yield 3.6 g, 52.3%) that was used in next step without further purification. 1H NMR (400 MHz, CDCl3): δ 1.98 (d, / = 7.1 Hz, 3 H), 4.88 (q, J = 7.1 Hz, 1 H), 8.22 (s, 1 H). MS m/z calc. 281.9 found (ESI); 283.0 (M+l)+. Retention time 1.97 minutes.
[00345] 5-Bromo-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-
3H-pyrimidin-4-one
Figure imgf000332_0002
In a round bottom flask containing 5-bromo-2-(l-bromo-ethyl)-3H-pyrimidin-4-one (1.0 g, 3.5 mmol) in acetonitrile (30 ml) was added KI (0.9 g, 5.3 mmol), K2CO3 (1.2 g, 5.3 mmol), and (1- (4-Methoxy-benzenesulfonyl)-piperazine (983 mg, 3.5 mmol). The reaction was heated at reflux for 12 hours. The solution was concentrated under reduced pressure. The residue was partitioned between water (10 ml) and dichloromethane (15 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue purified by column chromatography (ethyl acetate: hexanes 1:1) to give 5-bromo-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H- pyrimidin-4-one (Yield 854 mg, 53 %). 1H NMR (400 MHz, CDCl3): δ 1.28 (d, J = 7.0 Hz, 3 H), 2.62-2.49 (m, 4H), 3.00-2.94 (m, 4H), 3.84(s, 3H), 4.05 (q, I HJ = 7.0 Hz), 6.97 (d, J = 11.8 Hz, 2 H), 7.62 (d, J = 11.8 Hz, 2 H), 8.11 (s, 1 H). MS m/z calc. 457.3, found (ESI); 457.2 (M +I)+. Retention time 2.50 minutes.
[00346] 5-Bromo-4-cyclopentyIoxy-2-{l-[4-(4-methoxy-benzenesulfonyl)- piperazin-l-yl]-ethyl}-pyrimidine
Figure imgf000333_0001
To a solution of 5-Bromo-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H- pyrimidin-4-one(100 mg, 0.22 mmol) in 2 ml DMF was added iodo-cyclopentane (85.7 mg, 0.22 mmol) and potassium carbonate (152.0 mg, 1.1 mmol). This reaction was heated to 900C for 18 hours. After cooling down to room temperature, the K2CO3 was filtrated. Purification was accomplished by ΗPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 5-bromo-4- cyclopentyloxy-2- { 1 - [4-(4-methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -pyrimidine. (Yield 11.5 mg, 9.9%). 1Η NMR (400 MHz, CDCl3): δ 1.30(d, / = 6.82 Hz, 3 H), 1.64-1.5 l(m, 2 H), 1.82-1.67 (m, 4 H), 1.96-1.82 (m, 2 H), 2.65-2.52 (m, 4 H), 3.00-2.85 (m, 4 H), 3.67 (q, J = 6.82 Hz, 1 H), 3.78 (s, 3 H), 5.41 (m, 1 H), 6.90 (d, J = 9.09, 2 H), 7.59 (d, / = 9.09, 2 H), 8.39(s, 1 H). MS m/z calc. 525.2 found (ESI); 526.2 (M + I)+. Retention time 2.91 minutes.
[00347] 4-Cyclopentyloxy-2-{l-[4-(4-methoxy-benzenesulfonyI)-piperazin-l- yl]-ethyl}-pyrimidine
Figure imgf000334_0001
To a solution of 5-Bromo-4-cyclopentyloxy-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-pyrimidine (30.0 g, 0.06 mmol) in ethanol (10 ml) was added 10 mg platinum on carbon (0.5% wt). The solution was degassing three times and the hydrogen gas was introduced through a hydrogen balloon. The reaction was heated to reflux for 18 hours at room temperature. The solution was filtrated through a celite column and the solvent was evaporated. Water (5 ml) was then added to the solution and the mixture was extracted with dichloromethane (10 ml). The organic layer was then washed with 10% sodium bisulfite solution, and then washed with saturated brine (2 x 30 ml). The combined organic phase was collected and dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a brown crude product. The resulting residue was purified by silica gel chromatography with 50% dichloromethane in hexane. The product was collected and was dried under reduced pressure to give the 4-Cyclopentyloxy-2- { 1 - [4-(4-methoxy-benzenesulfonyl)-piperazin- 1 -yl] -ethyl } - pyrimidine (Yield 15 mg, 60%. 1H NMR (400 MHz, CDCl3): 5 1.60-1.54(m, 2 H), 1.64(d, J = 6.82 Hz, 3 H), 1.76-1.67(m, 4 H), 1.96-1.84 (m, 2 H), 3.35-3.12(m, 4 H), 3.50-3.35(m, 2 H), 3.05(s, 3 H), 4.41(q, 1 H, J = 13.64, 7.33 Hz), 5.38(m, 1 H), 6.60 (d, J = 5.81, 1 H), 6.94 (d, J = 8.84, 2 H), 7.56 (d, J = 8.84, 2 H), 8.32 (d, J = 5.81, 1 H). MS m/z calc. 446.2 found (ESI); 447.2 (M + I)+. Retention time 2.76 minutes.
[00348] 5-Bromo-2-{l-[4-(4-methoxy-benzenesulfonyI)-piperazin-l-yl]-ethyl}-
4-piperidin-l-yl-pyrimidin
Figure imgf000334_0002
In a flask containing of 5-bromo-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}- 3H-pyrnr.idin-4-one (150.0 mg, 0.33 mmol) in phosphorus oxychloride (2 ml) was heated to 90 0C for 2 hours, then the solvent was concentrated under reduced pressure to give the 5-bromo-4- chloro-2-{ l-[4-(4-methoxy-benzenesulfonyl)-ρiperazin-l-yl]-ethyl}-pyrimidine that was used in the next step without any purification. MS m/z calc. 524.2 found (ESI); 526.2 (M + I)+. Retention time 2.91 minutes.
[00349] Step2:
[00350] To the sample of step 1 dissolved in THF (5ml) was added piperidine (278 mg, 3.28 mmol) and the reaction was heated at 60 0C for 0.5 hour. The solution was concentrated under reduced pressure. The residue was partitioned between water (2 ml) and dichloromethane (5 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The solvent was removed under vacuum. The resulting residue was re- dissolvent in MeOH (2 ml) and purified by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product 5-Bromo-2-{ l-[4-(4-methoxy-benzenesulfonyl)- piperazin-1-yl] -ethyl }-4-piperidin-l-yl-pyrimidine was collected and dried under reduced pressure (Yield 135 mg, 78.5 %). 1H NMR (400 MHz, CDCl3): δ 1.29 (d, /= 7.1 Hz, 3 H), 1.61- 1.52 (m, 9 H), 2.6-2.5(m, 4 H), 3.00-2.90 (m, 4 H), 3.11-3.04 (m, 2 H), 3.81 (s, 3 H), 3.82 (q, J = 7.1 Hz, 1 H), 6.89(d, J = 9.1, 2 H), 7.62 (d, J = 9.1, 2 H), 8.26 (s, 1 H). MS m/z calc. 524.4, found (ESI); 526.2 (M +I)+. Retention time 2.91 minutes.
[00351] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-5-phenyl-
4-piperidin-l-yl-pyrimidine
Figure imgf000335_0001
In a flask containing of 5-bromo-2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- piperidin-1-yl-pyrimidine (100.0 mg, 0.19 mmol) in DMF (5 ml) was added phenylbroronic acid (23.2 mg, 0.19 mmol), triphenylphosphine polymer supported (63.0 mg, 3 mmol/g), palladium (II) acetate (42.6 mg, 0.19 mmol) and K2CO3 (52.5 mg, 0.38 mmol). The mixture was heated at 90 0C for 2 hours with stirring. After cooling down to room temperature, the excess K2CO3 was filtrated. Purification was accomplished by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-5-phenyl-4-piperidin-l-yl- pyrimidine (Yield 4.0 mg, 4.1 %). MS mJz calc. 521.2 found (ESI); 522.4 (M + I)+. Retention time 3.06 minutes.
[00352] Preparation of 2-ethyl-6-oxo-l,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000336_0001
To a cold (0 0C) solution of NaOEt (0.2 mol) in absolute alcohol (150 mL) was added propionamidine hydrochloride (10.9 g, 0.1 mol) in one portion. A solution of 2- ethoxymethylene-malonic acid diethyl ester (21.6 g, 0.1 mol) in absolute alcohol (60 mL) was added dropwise to the above mixture during 20 minutes. After the addition was completed, the whole mixture was heated to reflux for 2.5 hours, then cooled and poured to ice water. The aqueous solution was acidified to pH 5 with HCl (6 M), extracted with ethyl acetate (4 100 mL). The organic layer was washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was re-crystallized with acetonitrile to afford 2-ethyl-6- oxo-l,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester as white crystals (17 g, 86 %). IH NMR(CDCl3) 8 8.71 (s, IH), 4.37-4.32 (q, 2H), 2.84-2.78 (q, 2H), 1.38-1.34 (m, 6H). MS (ESI) m/e (M+l)+ 197.2.
[00353] 2-(l-Bromo-ethyl)-6-oxo-l,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000336_0002
To a solution of 2-Ethyl-6-oxo-l,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester (3.92 g, 20 mmol) and sodium acetate (1.64 g, 20 mmol) in glacial acetic acid (80 mL) heated to 50°C was added dropwise a solution of bromine (1.03 mL, 20 mmol) in glacial acetic acid (40 mL). After addition was complete the reaction was heated to reflux for 1 hour. The reaction was then cooled to room temperature and then concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water then dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was then purified by column chromatography (35-75% ethyl acetate - hexanes) to yield the product as a white solid (2.29g, 42%). 1H NMR (400 MHz, CDC13) δ 12.32 (br s, IH), 8.87 (s, IH), 5.08 (q, J = 6.9 Hz, IH), 4.44 (q, J = 7.1 Hz, 2H), 2.08 (d, J = 6.9 Hz, 3H), 1.43 (t, J = 7.1 Hz, 3H); HPLC ret. time 2.13 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 276.9 (M+l)+.
[00354] 2-{l-[4-(4-Methoxy-benzenesuIfonyl)-piperazin-l-yl]-ethyI}-6-oxo-l,6- dihydro-pyrimidine-S-carboxylic acid ethyl ester
Figure imgf000337_0001
A mixture of 2-(l-Bromo-ethyl)-6-oxo-l,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester (2.29g, 8.3 mmol) and l-(4-Methoxy-benzenesulfonyl)-piperazine (2.55g, 10 mmol), potassium iodide (1.38g, 8.3mmol) and potassium carbonate (1.72g, 12.5 mmol) in acetonitrile (35 mL) was heated at 65°C for 1 day. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with saturated sodium thiosulphate solution, saturated sodium bicarbonate solution and then with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was then purified by column chromatography (60 - 100% ethyl acetate - hexanes) to yield the product as a pale yellow solid (2.15g, 57%). 1H NMR (400 MHz, CDC13) δ 10.34 (s, IH), 8.63 (s, IH), 7.71 (d, J = 8.9 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.93 (s, 3H), 3.63 (q, J = 6.6 Hz, IH), 3.06 (m, 4H), 2.65 (m, 4H), 1.38 (m, 6H); HPLC ret. time 2.46 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 451.5 (MH+). [00355] 2- { 1 - [4-(4-Methoxy-benzenesulf ony l)-piperazin- 1 -yl] -ethyl } -4-piperidin- l-yl-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000338_0001
2- { 1 -[4-(4-Methoxy-benzenesulf onyl)-piperazin- 1 -yl] -ethyl } -6-oxo- 1 ,6-dihydro-pyrimidine-5- carboxylic acid ethyl ester (1.55g, 3.4 mmol) in POCl3 (10 mL) was heated to 90°C for 2 hours. Then the excess POCI3 was removed in vacuo. The residue was dissolved in toluene (5 mL) and then the solvent was removed in vacuo. This step was repeated twice more. The residue was then dissolved in THF (10 mL) and piperidine (3.36 mL, 34 mmol) was added. The reaction was stirred at room temperature for 1 day. The reaction mixture was partitioned between dichloromethane and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (30 - 80% ethyl acetate - hexanes) to yield the product as a pale yellow solid (1.6 Ig, 91%). 1H NMR (400 MHz, CDCl3) δ 8.60 (s, IH), 7.68 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 3.69 (m, IH), 3.54 (m, 4H), 3.02 (m, 4H), 2.69 (m, 4H), 1.68 (m, 6H), 1.38 (m, 6H); HPLC ret. time 2.66 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 518.1 (M+l)+.
[00356] (2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- piperidm-l-yl-pyrimidin-5-yl)-methanol
Figure imgf000338_0002
To a solution of 2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-piperidin-l-yl- pyrimidine-5-carboxylic acid ethyl ester (104 mg, 0.2 mmol) in ethanol (1 mL) was added sodium borohydride (38 mg, 1.0 mmol) and the reaction mixture was heated to reflux for 1 day. The reaction was then partition between dichloromethane and saturated sodium bicarbonate solution. The organic layer was concentrated in vacuo and then the residue was dissolved in DMSO (1 mL) and purified by LC-MS to yield the product. 1H NMR (400 MHz, CDC13) δ 8.26 (s, IH), 7.65 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 4.62 (s, 2H), 4.53 (q, J = 6.6 Hz, IH), 3.93 (m, 7H), 3.25 (m, 8H), 1.77 (m, 6H), 1.67 (d, J = 6.8 Hz, 3H); HPLC ret. time 2.49 min, 10- 99% CH3CN, 5 min run; ESI-MS m/z 476.1 (M+l)+.
[00357] 4-Cyclopentyloxy-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l- yl]-ethyl}-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000339_0001
A mixture of 2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6-oxo-l,6-dihydro- pyrimidine-5-carboxylic acid ethyl ester (90 mg, 0.2 mmol), cyclopentyl iodide (46 μL, 0.4 mmol), and potassium carbonate (138 mg, 1 mmol) in DMF (1 mL) was heated to 90°C for 1 day. The reaction mixture was then filtered and purified by HPLC (in the absence of TFA) to yield the product. 1H NMR (400 MHz, CDC13) δ 8.91 (s, IH), 7.68 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 5.58 (m, IH), 4.36 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.84 (m, IH), 3.04 (m, 4H), 2.73 (m, 4H), 1.83 (m, 8H), 1.40 (m, 6H); HPLC ret. time 2.80 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 519.5 (M+l)+.
[00358] 2-{l-[4-(4-Methoxy-benzenesuIfonyI)-piperazin-l-yl]-ethyl}-4- piperidin-l-yl-pyrimidine-5-carboxylic acid
Figure imgf000339_0002
A mixture of l-l l-^-C^methoxy-benzenesulfonyO-piperazin-l-yli-ethylJ^-piperidin-l-yl- pyrimidine-5-carboxylic acid ethyl ester (518mg, 1.0 mmol), ethanol (3.75 mL) and 25M aqueous potassium hydroxide solution (1.25 mL) was heated to 8O0C for 30 minutes. The reaction solution was neutralized with concentrated hydrochloric acid to pH 7 and extracted with dichloromethane. The aqueous solution was then made basic again with IN NaOH solution at which time a precipitate formed. The solution was filtered to yield the product as a white solid (180 mg, 37%). 1H NMR (400 MHz, CDC13) δ 7.99 (s, IH), 7.63 (d, J = 8.9 Hz, 2H), 7.15 (d, J = 8.9 Hz, 2H), 3.86 (s, 3H), 3.53 (m, 5H), 2.78 (m, 4H), 2.56 (m, 4H), 1.58 (m, 2H), 1.48 (m, 4H), 1.22 (d, J = 6.9 Hz, 3H); HPLC ret. time 2.41 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 490.1 (M+l)+.
[00359] 2-{l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4- piperidin-l-yl-pyrimidine-5-carboxylic acid dimethylamide
Figure imgf000340_0001
To a mixture of 2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-4-piperidin-l-yl- pyrimidine-5-carboxylic acid (60 mg, 0.12 mmol), HATU (68mg, 0.18 mmol), DlEA (42 μL, 0.24 mmol) in DMF (1 mL) was added dimethyl amine (120μL, 0.24 mmol, 2M solution in THF). The reaction was stirred at room temperature for 3 hours. The solution was then filtered and purified by HPLC to yield the desired product. HPLC ret. time 2.41 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 517.3 (M+l)+.
[00360] 4-CycIopentyloxy-2-{l-[4-(4-methoxy-benzenesuIfonyl)-piperazin-l- yl]-ethyl}-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000341_0001
A mixture of 2-{ l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-6-oxo-l,6-dihydro- pyrimidine-5-carboxylic acid ethyl ester (90 mg, 0.2 mmol), cyclopentyl iodide (46 μL, 0.4 mmol), and potassium carbonate (138 mg, 1 mmol) in DMF (1 mL) was heated to 90°C for 1 day. The reaction mixture was then filtered and purified by HPLC (in the absence of TFA) to yield the product. 1H NMR (400 MHz, CDC13) δ 8.91 (s, IH), 7.68 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 5.58 (m, IH), 4.36 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.84 (m, IH), 3.04 (m, 4H), 2.73 (m, 4H), 1.83 (m, 8H), 1.40 (m, 6H); HPLC ret. time 2.80 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 519.5 (MH+).
[00361] 4-Isopropyl-2-{l-[4-(4-methoxy-benzenesulfonyl)-piperazin-l-yI]- ethyl}-quinazoline
Figure imgf000341_0002
In a flask containing of 2-{ l-[4-(4-Methoxy-benzenesulfonyl)-piperazin-l-yl]-ethyl}-3H- quinazolin-4-one (100.0 mg, 0.233 mmol) in POCl3 (3 ml) was heated for 2 hours with stirring. The excess of POCl3 was then removed under reduced pressure. The residue was redissolved in 5 ml dry THF. The isopropyllithium (3.4 ml, 23.3mmol of 0.7 M in pentane) was added to the reaction at -780C with stirring for 30 min. and allow the reaction warm to the room temperature. 0.5 ml of water were slowly added to quench the excess of isopropyllithium. The solution was evaporated and extracted with water and ethyl acetate. Purification was accomplished by HPLC (Gilson-215, 0.035% TFA in acetonitrile and 0.05% water as mobile phase). The product was collected and dried under reduced pressure to give the 4-Isopropyl-2-{ l-[4-(4-methoxy- benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoline (Yield 42.3 mg, 40.28 %). 1H NMR (400 MHz, DMSO-e): D 1.35(d, 6 H, J = 6.82 Hz), 1.78(d, 3 H, J = 7.07 Hz), 3.47-2.82 (m, 6 H), 3.65-3.43(m, 2 H), 3.80 (s. 3 H), 3.91-3.82 (m, 1 H), 4.75 (q, I H, J = 13.89, 7.07 Hz), 6.93(d, 2 H, / = 9.35 Hz), 7.56(d, 2 H, 7 = 8.84 Hz), 7.65(dt, 1 H, J = 8.34, 1.77 Hz), 7.88(dt, 1 H, J = 8.59, 1.77 Hz), 7.96 (d, 1 H, 8.08 Hz), 8.14 (d, 1 H, J = 8.59 Hz). M3 m/z calc. 454.20, found (ESI); 455.3 (M + I)+. Retention time 2.75 minutes.
[00362] 2-{l-[4-(4-Bromo-benzenesulfonyl)-piperazin-l-yl]-ethyl}-quinazoIine
Step 1: Λ/r-(2-Formyl-phenyl)-propionamide
Figure imgf000342_0001
To a solution of 2-aminobenzaldehyde (1.21g, 10 mmol), and triethylamine (1.39 mL, 10 mmol) in dichloromethane (50 mL) was added propionyl chloride (1.04 mL, 12 mol). The reaction was stirred at room temperature for 3 days. The reaction solution was washed with water and then dried over magnesium sulfate and concentrated in vacuo to yield the crude product (1.65g, 93%). The product was used without further purification. 1H NMR (400 MHz, CDC13) δ 11.16 (s, IH), 9.93 (s, IH), 8.77 (d, J= 8.5 Hz, IH), 7.67 (d, J = 7.7 Hz, IH), 7.62 (t, J= 7.1 Hz, IH), 7.22 (t, J = 7.5 Hz, IH), 2.51 (q, J = 7.6 Hz, 2H), 1.29 (t, / = 7.6 Hz, 3H); HPLC ret. time 1.34 min, 10- 99% CH3CN, 5 min run; ESI-MS m/z 177.2 (M+l)+.
Step 2: 2-Ethyl-quinazoline
Figure imgf000342_0002
iV-(2-Formyl-phenyl)-propionamide (1.65g, 9.3 mmol) was combined with ammonia (24 mL, 2M solution in methanol) in a flask fitted with a condenser and stopper with a needle to vent. The reaction was heated to 1000C for 1 day. The reaction mixture was concentrated in vacuo to yield the crude product as an orange oil (1.47g, 100%). This product was used without further purification. 1H NMR (400 MHz, CDC13) δ 9.36 (s, IH), 7.99 (d, / = 10.0 Hz, IH), 7.89 (m, 2H), 7.60 (t, J = 8.1 Hz, IH), 3.16 (q, J = 7.6 Hz, 2H), 1.47 (t, J = 7.6 Hz, 3H); HPLC ret. time 0.61 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 159.0 (MH+). Step 3: ?-(l-Bromo-ethyl)-qumazoline
Figure imgf000343_0001
A solution of 2-ethyl-quinazoline (316mg, 2 mmol), iV-bromosuccinimide (356mg, 2 mmol) and benzoyl peroxide (48mg, 0.2 mmol) in chloroform (10 mL) was heated to reflux for 2 hours. The reaction solution was concentrated in vacuo and purified by column chromatography (0 - 25% ethyl acetate - hexanes) to yield the pure product (130mg, 28%). 1H NMR (400 MHz, CDC13) δ 9.45 (s, IH), 8.04 (d, J = 9.0 Hz, IH), 7.94 (m, 2H), 7.68 (t, J = 8.1 Hz, IH), 5.47 (q, J = 6.9 Hz, IH), 2.23 (d, J = 6.9 Hz, 3H); HPLC ret. time 2.79 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 236.9 (M+l)+.
Step 4: 2-{l-[4-(4-Bromo-benzenesulfonyI)-piperazin-l-yl]-ethyl}-quinazoline
Figure imgf000343_0002
A mixture of 2-(l-Bromo-ethyl)-quinazoline (43mg, 0.18 mmol) and l-(4-Bromo- benzenesulfonyl)-piperazine (67 mg, 0.22 mmol), potassium iodide (3Og, 0.18mmol) and potassium carbonate (37mg, 0.27 mmol) in acetonitrile (1 mL) was heated at 65°C for 1 day. The reaction mixture was then concentrated in vacuo. The residue was dissolved in dichloromethane and washed with saturated sodium thiosulphate solution, saturated sodium bicarbonate solution and then with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was dissolved in DMSO and purified by HPLC. 1H NMR (400 MHz, CDC13) δ 9.45 (s, IH), 8.06 (m, 3H), 7.80 (t, J = 7.9 Hz, IH), 7.72 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.5 Hz, 2H), 4.86 (q, J = 7.0 Hz, IH), 3.65 (m, 2H), 3.43 (m, 6H), 1.88 (d, J = 7.0 Hz, 3H) HPLC ret. time 2.45 min, 10-99% CH3CN, 5 min run; ESI-MS m/z 461.1 (M+l)+. [00363] Other compounds of formula I have been prepared by methods substantially similar to those described above. Depicted below in Table 2 are LC Mass Retention Time, and LC Mass Plus values for compounds as depicted in Table 1, along with NMR data for selected compounds.
[00364] Table 2
Figure imgf000344_0001
Figure imgf000345_0001
Figure imgf000346_0001
Figure imgf000347_0001
Figure imgf000348_0001
Figure imgf000349_0001
Figure imgf000350_0001
Figure imgf000351_0001
Figure imgf000352_0001
Figure imgf000353_0001
Figure imgf000354_0001
Figure imgf000355_0001
Figure imgf000356_0001
Figure imgf000357_0001
Figure imgf000358_0001
Figure imgf000359_0001
Figure imgf000360_0001
Figure imgf000361_0001
Figure imgf000362_0001
Figure imgf000363_0001
Figure imgf000364_0001
[00365] B) Assays for Detecting and Measuring ΔF508-CFTR Correction
Properties of Compounds
[00366] I) Membrane potential optical methods for assaying ΔF508-CFTR modulation properties of compounds [00367] The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00368] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission were monitored using VIPR™ π, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
[00369] Identification of Correction Compounds
[00370] To identify small molecules that correct the trafficking defect associated with ΔF5O8-CFTR; a single-addition HTS assay format was developed. The cells were incubated in serum-free medium for 16 hrs at 37 °C in the presence or absence (negative control) of test compound. As a positive control, cells plated in 384-well plates were incubated for 16 hrs at 27 0C to "temperature-correct" ΔF5O8-CFTR. The cells were subsequently rinsed 3X with Krebs Ringers solution and loaded with the voltage-sensitive dyes. To activate ΔF508-CFTR, 10 μM forskolin and the CFTR potentiator, genistein (20 μM), were added along with Cl"-free medium to each well. The addition of Cl"-free medium promoted Cl" efflux in response to ΔF508-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET-based voltage-sensor dyes. ,
[00371] Identification of Potentiator Compounds
[00372] To identify potentiators of ΔF5O8-CFTR, a double-addition HTS assay format was developed. During the first addition, a Cl"-free medium with or without test compound was added to each well. After 22 sec, a second addition of Cl"-free medium containing 2 - 10 μM forskolin was added to activate ΔF508-CFTR. The extracellular Cl' concentration following both additions was 28 mM, which promoted Cl" efflux in response to
ΔF5O8-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET-based voltage-sensor dyes.
Solutions
Bath Solution #1: (in mM) NaCl 160, KCl 4.5, CaCl2 2, MgCl2 1, HEPES 10, pH 7.4 with
NaOH.
Chloride-free bath solution: Chloride salts in Bath Solution #1 are substituted with gluconate salts.
CC2-DMPE: Prepared as a 10 mM stock solution in DMSO and stored at -20°C.
DiSBAC2(3): Prepared as a 10 mM stock in DMSO and stored at -20°C.
[00373] Cell Culture
[00374] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for optical measurements of membrane potential. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 °C before culturing at 27 0C for 24 hrs. for the potentiator assay. For the correction assays, the cells are cultured at 27 °C or 37 °C with and without compounds for 16 - 24 hoursB) Electrophysiological Assays for assaying ΔF508-CFTR modulation properties of compounds
[00376] l.Ussing Chamber Assay
[00377] Ussing chamber experiments were performed on polarized epithelial cells expressing ΔF5O8-CFTR to further characterize the ΔF5O8-CFTR modulators identified in the optical assays. pRχΔF508'CFTR epithelial cells grown on Costar Snapwell cell culture inserts were mounted in an Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of Iowa, IA, and, Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2-mV pulse. Under these conditions, the FRT epithelia demonstrated resistances of 4 KΩ/ cm2 or more. The solutions were maintained at 27 0C and bubbled with air. The electrode offset potential and fluid resistance were corrected using a cell-free insert. Under these conditions, the current reflects the flow of Cl" through ΔF5O8-CFTR expressed in the apical membrane. The Isc was digitally acquired using an MPlOOA-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
[00378] Identification of Correction Compounds
[00379] Typical protocol utilized a basolateral to apical membrane Cl" concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOET) to give a large Cl" concentration gradient across the epithelium. All experiments were performed with intact monolayers. To fully activate ΔF508-CFTR, forskolin (10 μM) and the PDE inhibitor, IBMX (100 μM), were applied followed by the addition of the CFTR potentiator, genistein (50 μM).
[00380] As observed in other cell types, incubation at low temperatures of FRT cells stably expressing ΔF5O8-CFTR increases the functional density of CFTR in the plasma membrane. To determine the activity of correction compounds, the cells were incubated with 10 μM of the test compound for 24 hours at 37°C and were subsequently washed 3X prior to recording. The cAMP- and genistein-mediated Isc in compound-treated cells was normalized to the 27°C and 37°C controls and expressed as percentage activity. Preincubation of the cells with the correction compound significantly increased the cAMP- and genistein-mediated Isc compared to the 37°C controls.
[00381] Identification of Potentiator Compounds
[00382] Typical protocol utilized a basolateral to apical membrane Cl" concentration gradient. To set up this gradient, normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 μg/ml), whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl" concentration gradient across the epithelium. All experiments were performed 30 min after nystatin permeabilization. Forskolin (10 μM) and all test compounds were added to both sides of the cell culture inserts. The efficacy of the putative ΔF508-CFTR potentiators was compared to that of the known potentiator, genistein. [00383] Solutions
Basolateral solution (in mM): NaCl (135), CaCl2 (1.2), MgCl2 (1.2), K2HPO4 (2.4),
1 KHPO4 (0.6), N-2-hydroxyethylpiρerazine-N'-2- ethanesulfonic acid (HEPES) (10), and dextrose (10). The solution was titrated to pH 7.4 with NaOH.
Apical solution (in mM): Same as basolateral solution with NaCl replaced with Na
Gluconate (135).
[00384] Cell Culture
[00385] Fisher rat epithelial (FRT) cells expressing ΔF5O8-CFTR (FRT^508-01™) were used for Ussing chamber experiments for the putative ΔF508-CFTR modulators identified from our optical assays. The cells were cultured on Costar Snapwell cell culture inserts and cultured for five days at 37 °C and 5% CO2 in Coon's modified Ham's F- 12 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Prior to use for characterizing the potentiator activity of compounds, the cells were incubated at 27 °C for 16 - 48 hrs to correct for the ΔF508-CFTR. To determine the activity of corrections compounds, the cells were incubated at 27 °C or 37 °C with and without the compounds for 24 hours.
[00386] 2. Whole-cell recordings
[00387] The macroscopic ΔF508-CFTR current (IΔFSOS) in temperature- and test compound-corrected NIH3T3 cells stably expressing ΔF508-CFTR were monitored using the perforated-patch, whole-cell recording. Briefly, voltage-clamp recordings of IΔFSOS were performed at room temperature using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). All recordings were acquired at a sampling frequency of 10 kHz and low-pass filtered at 1 kHz. Pipettes had a resistance of 5 - 6 MΩ when filled with the intracellular solution. Under these recording conditions, the calculated reversal potential for Cl" (Eci) at room temperature was -28 mV. AU recordings had a seal resistance > 20 GΩ and a series resistance < 15 MΩ. Pulse generation, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A/D interface in conjunction with Clampex 8 (Axon Instruments Inc.). The bath contained < 250 μl of saline and was continuously perifused at a rate of 2 ml/min using a gravity-driven perfusion system.
[00388] Identification of Correction Compounds
[00389] To determine the activity of correction compounds for increasing the density of functional ΔF508-CFTR in the plasma membrane, we used the above-described perforated-patch-recording techniques to measure the current density following 24-hr treatment with the correction compounds. To fully activate ΔF508-CFTR, 10 μM forskolin and 20 μM genistein were added to the cells. Under our recording conditions, the current density following 24-hr incubation at 27°C was higher than that observed following 24-hr incubation at 37 0C. These results are consistent with the known effects of low-temperature incubation on the density of ΔF508-CFTR in the plasma membrane. To determine the effects of correction compounds on CFTR current density, the cells were incubated with 10 μM of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 μM of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C controls.
[00390] Identification of Potentiator Compounds
[00391] The ability of ΔF508-CFTR potentiators to increase the macroscopic
ΔF508-CFTR Cl" current (IΔFSOS) in NIH3T3 cells stably expressing ΔF508-CFTR was also investigated using perforated-patch-recording techniques. The potentiators identified from the optical assays evoked a dose-dependent increase in IΛFSOS with similar potency and efficacy observed in the optical assays. In all cells examined, the reversal potential before and during potentiator application was around -30 mV, which is the calculated EQ (-28 mV).
[00392] Solutions
Intracellular solution (in mM): Cs-aspartate (90), CsCl (50), MgCl2 (1), HEPES (10), and
240 μg/ml amphotericin-B (pH adjusted to 7.35 with CsOH).
Extracellular solution (in mM): JV-methyl-D-glucamine (NMDG)-Cl (150), MgCl2 (2),
CaCl2 (2), HEPES (10) (pH adjusted to 7.35 with HCl). [00393] Cell Culture
[00394] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for whole-cell recordings. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For whole-cell recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 0C for measuring the activity of correctors.
[00395] 3. Single-channel recordings
[00396] The single-channel activities of temperature-corrected ΔF5O8-CFTR stably expressed in NIH3T3 cells and activities of potentiator compounds were observed using excised inside-out membrane patch. Briefly, voltage-clamp recordings of single-channel activity were performed at room temperature with an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc.). All recordings were acquired at a sampling frequency of 10 kHz and low-pass filtered at 400 Hz. Patch pipettes were fabricated from Corning Kovar Sealing #7052 glass (World Precision Instruments, Inc., Sarasota, FL) and had a resistance of 5 - 8 MΩ when filled with the extracellular solution. The ΔF508-CFTR was activated after excision, by adding 1 mM Mg-ATP, and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI). After channel activity stabilized, the patch was perifused using a gravity- driven microperfusion system. The inflow was placed adjacen* to the patch, resulting in complete solution exchange within 1 - 2 sec. To maintain ΔF5O8-CFTR activity during the rapid perifusion, the nonspecific phosphatase inhibitor F" (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipette potential (Vp) was maintained at 80 mV.
[00397] Channel activity was analyzed from membrane patches containing < 2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To determine the single-channel current amplitude, the data recorded from 120 sec of ΔF508-CFTR activity was filtered "off-line" at 100 Hz and then used to construct all-point amplitude histograms that were fitted with multigaussian functions using Bio-Patch Analysis software (Bio-Logic Comp. France). The total microscopic current and open probability (P0) were determined from 120 sec of channel activity. The P0 was determined using the Bio-Patch software or from the relationship P0 = M(N), where I = mean current, i = single-channel current amplitude, and N = number of active channels in patch.
[00398] Solutions
Extracellular solution (in mM): NMDG (150), aspartic acid (150), CaCl2 (5), MgCl2 (2), and HEPES (10) (pH adjusted to 7.35 with Tris base).
Intracellular solution (in mM): NMDG-Cl (150), MgCl2 (2), EGTA (5), TES (10), and Tris base (14) (pH adjusted to 7.35 with HCl).
[00399] Cell Culture
[00400] NIH3T3 mouse fibroblasts stably expressing ΔF5O8-CFTR are used for excised-membrane patch-clamp recordings. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For single channel recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use.
[00179] Compounds of the invention are useful as modulators of ATP binding cassette transporters. Table 3 below illustrates the EC50 and relative efficacy of certain embodiments in Table 1.
[00180] In Table 3 below, the following meanings apply:
EC50: "+++" means <10 uM; "++" means between lOuM to 25 uM; "+" means between 25 uM to 6OuM.
% Efficacy: "+" means < 25%; "++" means between 25% to 100%; "+++" means > 100%.
Table 3
Figure imgf000371_0001
Figure imgf000372_0001
Figure imgf000373_0001
Figure imgf000374_0001
Figure imgf000375_0001
Figure imgf000376_0001
Figure imgf000377_0001
Figure imgf000378_0001
Figure imgf000379_0001
Figure imgf000380_0001
Figure imgf000381_0001
Figure imgf000382_0001
Figure imgf000383_0001
Figure imgf000384_0001

Claims

1. A method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compound of formula (I):
Figure imgf000385_0001
I or a pharmaceutically acceptable salt thereof, wherein:
G1 is =O, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR'CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR5SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RA and RB, or any ring formed by RA and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, - NR5CONR5-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR7SO2-, -NR'S02NR'-, and each occurrence of Ru is independently R', halogen, NO2, or CN,
R1 is absent or is Y-Rγ;
Y is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR', SR', N(R' )2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is 0- 5;
T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R', halogen, NO2, or CN;
Q is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of Q are optionally and independnetly replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rx is independently R', halogen, NO2, or CN;
Figure imgf000386_0001
wherein G2 and G3 are each independently absent or an optionally substituted C1- C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
B is absent or is an optionally substituted C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C1-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rv is independently R', halogen, NO2, or CN; provided that G2, B, G3, and Ar1 are not simultaneously absent.
2. The method of claim 1, wherein compounds have one of the following general structures I-A, I-B, I-C, I-D and I-E, as depicted below.
Figure imgf000387_0001
I A I B I-C
Figure imgf000388_0001
I D I E
3. The method of claim 1, wherein in the compound RA and RB are each independently hydrogen, an optionally substituted Q-Cgalkyl group, or V-Rv, where V is as defined generally above, and Rv is an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
4. The method of claim 1, wherein in the compound RA and RB, taken together with the nitrogen atom, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring.
5. The method of claim 1, wherein in the compound RA and RB are each independently hydrogen; an optionally substituted group selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or pentyl; an optionally substituted ring selected from:
Figure imgf000388_0002
i ii iii iv
Figure imgf000388_0003
Vl VU VlIl
Figure imgf000389_0001
IX Xl xii
Figure imgf000389_0002
XlU XlV XV XVl
Figure imgf000389_0003
XVU xviϊi XlX XX
Figure imgf000389_0004
xxi XXU XXUl XXlV
Figure imgf000389_0005
XXV XXVl XXVU XXVlH
Figure imgf000389_0006
XXlX XXX XXXl XXXH
Figure imgf000390_0001
xxxiii XXXlV XXXV
Figure imgf000390_0002
XXXVl XXXVU XXXVUl XXXlX
Figure imgf000390_0003
XL xLi XLU xLiii
Figure imgf000390_0004
XLiv XLV XLvl
nd R , taken together are optionally substituted group selected from:
Figure imgf000390_0005
b
Figure imgf000390_0006
g
Figure imgf000390_0007
Figure imgf000391_0001
m n or o
6. The method of claim 1, wherein in the compound q is 0, 1, 2, or 3, and each occurrence of U-Ru is independently hydrogen, R', -CH2R', halogen, CN, NO2, -N(R')2, -CH2N(R')2, -OR', -CH2OR', -SR', -CH2SR', -COOR', -NR'COR', -NR'COOR', -CON(R')2, -SO2N(R')2, - CONR'(CH2)2N(R')2, -CONR(CH2)3N(R')2, -CONR'(CH2)4N(R')2, -O(CH2)2OR\ O(CH2)3OR', O(CH2)4OR', -O(CH2)2N(R')2, -O(CH2)3N(R')2, -O(CH2)4N(R')2, -NR' CH(CH2OH)R', - NR5CH(CH2CH2OH)R', -NR'(CH2)R', -NR'(CH2)2R', -NR'(CH2)3R', -NR'CCEb)^', - NR'(CH2)N(R')2, -NR' (CH2)2N(R' )2, -NR'(CH2)3N(R')2, -NR' (CH^4N(R' )2, -NR'(CH2)0R', - NR' (CH2)2OR' , -NR' (CH2)3OR' , or -NR' (CH2)4OR' .
7. The method of claim 1, wherein in the compound q is 1, 2, or 3 and each occurrence of U-Ru is independently F, Cl, Br, CN, -OH, -NH2, -CH2OH, -d-C6alkyl, -O(d-C6alkyl), - CH2θ(d-C6alkyl), -CO(d-C6alkyl), -COO(d-C6alkyl), -NHSO2(C1-C6^yI), -SO2NH2, - CONH2, -CON(Cj-C6alkyl), -SO2(CrC6alkyl), -S02phenyl, phenyl, benzyl, -N(d-C6alkyl)2, or - S(C!-C6alkyl), wherein each of the foregoing phenyl, benzyl, and d-Cealkyl groups is independently and optionally substituted, and wherein each of the foregoing Ci-C6alkyl groups is linear, branched, or cyclic.
8. The method of claim 1, wherein R1 is Y-Rγ, wherein Y is a Ci-C4alkylidene chain, wherein one or two non- adjacent methylene units of Y are optionally replaced by CO, CONR, SO2, NRSO2, SO2NR, O, S, or NR; and each occurrence of Rγ is independently selected from R', OR', SR', or N(R')2.
9. The method of claim 1, wherein R1 is optionally substituted C1-C4alkyl.
10. The method of claim 1, wherein R1 is -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -(CHz)2OR', -(CH2)3OR\ -(CH2)2N(R')2, -(CH2)3N(R')2, -(CH2)2NRCOR\ or -(CH2)3NRCOR' .
11. The method of claim 1, wherein R2 and R3 are each independently hydrogen, halogen, or an optionally substituted group selected from C1-6alkyl, aryl, aryl(C1-6)alkyl, -N(R')2, - CH2N(R')2, OR', -CH2OR', SR', -CH2SR', COOR', -NRCOR', -(CH2)2N(R')2, -(CH2)2OR\ - (CH2)2SR\ -COR', -CON(R')2, SO2R', or -SO2N(R')2.
12. The method of claim 1, wherein R2 and R3 are each independently H, Cl, Br, F, CF3, Me, Et, -COOH, NH2, -N(CH3)2, -N(Et)2, -N(IPr)2, -O(CH2)2OCH3, -COtQ-Qalkyl), -CONH2, - COOCH3, -OH, -CH2OH, -NHCOCH3, -SO^Q-Qalkyl), -SO2NH2, -SO2N(CH3)2, or an optionally substituted group selected from C1-4alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.
13. The method of claim 1, wherein R2 and R3 taken together form a ring selected from:
Figure imgf000392_0001
Figure imgf000392_0002
g
Figure imgf000392_0003
i j k 1
Figure imgf000392_0004
m n o
Figure imgf000393_0001
Figure imgf000393_0002
U V W
Figure imgf000393_0003
aa bb
Figure imgf000393_0004
cc dd ee ff
Figure imgf000393_0005
gg hh
wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom may optionally be substituted with one or more independent occurrences of Q-Rx.
14. The method of claim 1, wherein R2 and R3, taken together form an optionally substituted phenyl group and compounds have the formula II:
Figure imgf000394_0001
II
15. The method of claim 1, wherein compounds have one of formulas II- A, H-B, H-C, H-D, orll-E:
Figure imgf000394_0002
II-A II-B II-C
Figure imgf000394_0003
II-D II-E
16. The method of claim 15, wherein x is 0-4, and each occurrence of Q-Rx, when present, is independently halogen, CN, NO2, or an optionally substituted group selected from C1-4alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, -N(R')2, - CH2N(R' )2, -OR', -CH2OR', -SR', SO2R', -CH2SR', -COOR', -NRCOR', -CON(R' )2, or - S(O)2N(R')2.
17. The method of claim 15, wherein each occurrence of Q-Rx, when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, -N(CH3)2, -N(Et)2, -N(iPr)2, -O(CH2)2OCH3, - CONH2, -COOCH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, - NHCOCH3, -SO2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole.
18. The method of claim 1, wherein G2 is a Ci-C3alkylidene chain or a C3-C6 spiroalkylidene ring, wherein one or two methylene units are optionally replaced by -NR'-, - N(SO2R')-, N(COR')-, -O-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the C1- C3alkylidene chain is optionally and independently substituted with R', and G3 is a C1- C3alkylidene chain wherein one or two methylene units are optionally replaced by -NR'-, - N(SO2R')-, N(COR')-, -O-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the C1- C3alkylidene chain is optionally and independently substituted with R' .
19. The method of claim 1, wherein G2 is-CHR', wherein R' is hydrogen, or optionally substituted CrC4alkyl and G3 is -(C(R')2)1-3-, -NR'-, -CO-, -SO2-, or -CONR-.
20. The method of claim 1, wherein B is -NR'C(R')2NR'-, -NR'(C(R')2)2NR'-, -
NR'(C(R')2)3NR'-, -NR'(C(R')2)4NR'-, or is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure
Figure imgf000395_0001
wherein n is O, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R' )2, -0-, -NR-, S, C=O, or C=S.
21. The method of claim 20, wherein at least one of X1, X2, X3, X4, X5 or X6 is a nitrogen atom.
22. The method of claim 20, wherein at least one of X2 or X5 is a nitrogen atom, and X1, when present, X3, X4, and X6 are each C(R' )2.
23. The method of claim 1, wherein B is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure \. * 'n and compounds have the structure of formula III:
Figure imgf000396_0001
III wherein n is 0, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R')2, -O-, -NR-, S, C=O, or C=S.
24. The method of claim 23, wherein compounds have one of the structures IH-A, III-B, III- C III-D or IH-E:
Figure imgf000396_0002
III-A IH-B
Figure imgf000396_0003
III-C III-D
Figure imgf000396_0004
III-E
25. The method of claim 23, wherein compounds have one of the structures IV-A, IV-B, IV- C, IV-D, or IV-E:.
Figure imgf000397_0001
IV-A IV-B
Figure imgf000397_0002
IV-C IV-D
Figure imgf000397_0003
IV-E
26. The method of claim 23, wherein compounds have one of the structures V-A, V-B, V-C, V-D, orV-E:
Figure imgf000397_0004
V-A V-B
Figure imgf000397_0005
V-C V-D
Figure imgf000397_0006
V-E
27. The method of claim 1 , wherein Ar1 is selected from:
Figure imgf000398_0001
U Hl IV
N.
• N
-(WRw)m |-n fTV'% -(WRw)π (WRw)m
Vl VIl
Figure imgf000398_0002
VUl IX Xl
Figure imgf000398_0003
XU XlU XlV XV
Figure imgf000398_0004
XVl XVH XVHl XlX
Figure imgf000399_0001
XX XXl XXU XXlU
Figure imgf000399_0002
XXlV XXV XXVl xxvii
Figure imgf000399_0003
XXVHl XXlX XXX XXXl
Figure imgf000399_0004
xxxii XXXlU XXXlV XXXV
Figure imgf000399_0005
XXXVl xxxvii XXXVlH
Figure imgf000399_0006
XXXlX XL XLl XLIl
Figure imgf000400_0001
xLiii xLiv xLv xLvi
wherein m is 0, 1, 2, 3, 4 or 5, and wherein any Ar1 is bonded to G3 through any substitutable nitrogen or carbon atom, and wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom is substituted with one or more independent occurrences of W-Rw
28. The method of claim 1, wherein Ar1 is an optionally substituted group selected from i, ii, v, vi, vii, xx, xLii, xLiii, XLiv, xLv, or xLvi.
29. The method of claim 1, wherein Ar1 is an optionally substituted phenyl group (i).
30. The method of claim 22, wherein W is a bond or is an optionally substituted Ci-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by O, NR, S, SO2, or COO, CO, and Rw is R' or halogen.
31. The method of claim 27, wherein each occurrence of WRW is independently -C1-3alkyl, - O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), - 0(CH2)N(R)(R'), -CON(R)(R'), -(CH2)2OR\ -(CH2)OR', optionally substituted phenyl, - N(R)(R'), -(CH2)2N(R)(R'), or -(CH2)N(R)(R').
32. The method according to claim 1, wherein said ABC-transporter or a fragment thereof is in vivo.
33. The method according to claim 1, wherein said ABC-transporter or a fragment thereof is in vitro.
34. The method according to claim 1, wherein said ABC-transporter is CFTR.
35. A method of treating an ABC transporter mediated disease in a mammal, comprising the step of administering to said mammal a composition comprising a compound according to claim 1.
[00401] 36. The method according to claim 35, wherein said disease is selected from Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type π, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma. The diseases associated with the latter class of ER malfunction are Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, SpinocerebuUar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease (due to Prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
37. The method according to claim 35, wherein said disease is cystic fibrosis.
[00402] . 38. A method of treating a disease selected from Cystic fibrosis, COPD (Chronic Obstructive Pulmonary Disease), Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spiήocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob disease, Fabry disease, dry eye disease, Sjogren's Syndrome or Straussler-Scheinker syndrome comprising: administering to a mammal an effective amount of a composition comprising a compound according to claim 1.
39. The method according to claim 34, wherein said disease is cystic fibrosis.
40. A method of modulating activity of an anion channel in vitro or in vivo, comprising the step of contacting said channel with a compound according to claim 1.
41. The method according to claim 40, wherein said anion channel is a chloride channel or a bicarbonate channel.
42. The method according to claim 40 wherein said anion channel is a chloride channel.
43. A method of treating an anion channel mediated disease in a mammal, comprising the step of administering to said mammal a composition comprising a compound according to claim 1.
44. The method according to claim 43, wherein said disease is cystic fibrosis.
5. A compound of formula I:
Figure imgf000403_0001
I or a pharmaceutically acceptable salt thereof, wherein:
G1 is =0, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-CO alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR7SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RA and RB, or any ring formed by RA and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, - NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, -NR5SO2NR'-, and each occurrence of Ru is independently R', halogen, NO2, or CN;
R1 is absent or is Y-Rγ; wherein Y is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -O-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR', SR', N(R')2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R5 is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is 0- 5;
T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R', halogen, NO2, or CN;
Q is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of Q are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of R is independently R', halogen, NO2, or CN;
Figure imgf000404_0001
wherein G2 is absent, an optionally substituted C1-C6 alkylidene chain, or a C3-C6 spirocycloalkylidene ring, wherein one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-,
N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; G3 is absent or an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO2-, -NR'-, N(SO2R')-, N(COR')-, -O-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R';
B is absent or is an optionally substituted C6-1O aryl> a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C1-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rwis independently R', halogen, NO2, or CN; provided that: i) when B is piperazinyl, G1 is =O, G2 is CHMe, and G3 is -CONH-, then R1 is not benzyl or ethyl; ii) when R2 and R3, taken together form a fused thieno ring, then G1 is not NH2 or optionally substituted phenyl; iii) when G1 is hydrogen, R2 and R3, taken together form a fused benzene ring, and x is 3, then each occurrence of Q-Rx is not OMe; iv) G1, R2 and R3 are not each simultaneously hydrogen; v) if G1 is hydrogen, then G2 is not CO; and vi) 2H Indol-2-one, l,3-dihydro-3,3,7-trimethyl-4-[3-[4-(2-quinazolinylmethyl)- l-piperazinyl]propoxy] and 2(1H)-Quinoline, 3,4-dihydro-8-methyl-5-[3-4-(2- quinazolinyl methyl)- l-piperazinyl]propoxy are excluded.
46. The compound of claim 45, wherein compounds have one of the following general structures I-A, I-B, I-C, I-D and I-E, as depicted below.
Figure imgf000406_0001
I-A I-B I C
Figure imgf000406_0002
I D I E
47. The compound of claim 45, wherein RΛ and RB are each independently hydrogen, an optionally substituted Q-Cgalkyl group, or V-Rv, where V is as defined generally above, and Rv is an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
48. The compound of claim 45, wherein RΛ and RB, taken together with the nitrogen atom, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring.
49. The compound of claim 45, wherein RA and RB are each independently hydrogen; an optionally substituted group selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or pentyl; an optionally substituted ring selected from:
Figure imgf000407_0001
u Ul IV
Figure imgf000407_0002
Vl VII VUl
Figure imgf000407_0003
IX X Xl XU
Figure imgf000407_0004
XlU xiv xv XVl
Figure imgf000407_0005
xvu XVlH XlX XX
Figure imgf000407_0006
XXl XXH XXlH XXIV
Figure imgf000408_0001
XXV XXVI XXVH XXVUl
Figure imgf000408_0002
xxix XXX xxxi xxxii
Figure imgf000408_0003
xxxiii xxxiv xxxv
H vA(uR",q vώiwi.
Figure imgf000408_0004
xxxvi xxxvii xxxviii xxxix
Figure imgf000408_0005
xL xLi xLii xLiii
Figure imgf000408_0006
xLiv XLV XLvi
nd RB, taken together are optionally substituted group selected from:
Figure imgf000408_0007
a b c d e
Figure imgf000409_0001
g h
Figure imgf000409_0002
m n or o
50. The compound of claim 45, wherein q is 0, 1, 2, or 3, and each occurrence of U-R is independently hydrogen, R', -CH2R', halogen, CN, NO2, -N(R')2, -CH2N(R')2, -OR', -CH2OR', -SR', -CH2SR', -COOR', -NR'COR', -NR'COOR', -CON(R')2, -SO2N(R')2, - CONR'(CH2)2N(R')2, -CONR(CH2)3N(R')2,-CONR'(CH2)4N(R')2, -O(CH2)2OR', O(CH2)3OR', O(CH2)4OR\ -O(CH2)2N(R')2, -O(CH2)3N(R')2, -0(CHz)4N(R' )2, -NR5CH(CH2OH)R', -
NR' CH(CH2CH2OH)R', -NR'(CH2)R', -NR'(CH2)2R', -NR'(CH2)3R', -NR'(CH2)4R\ - NR'(CH2)N(R')2, -NR'(CH2)2N(R')2, -NR'(CH2)3N(R')2, -NR' (CTt)4N(R' )2, -NR' (CH2)OR', - NR' (CH2)2OR' , -NR' (CH2)3OR' , or -NR' (CH2)4OR' .
51. The compound of claim 50, wherein q is 1, 2, or 3 and each occurrence of U-Ru is independently F, Cl, Br, CN, -OH, -NH2, -CH2OH, -CrC6alkyl, -O(Ci-C6alkyl), -CH2O(C1- C6alkyl), -COtQ-Cealkyl), -COOtQ-Cealkyl), -NHSO2(C rCealkyl), -SO2NH2, -CONH2, - CON(C rCealkyl), -SO2(C1-C6alkyl), -S02ρhenyl, phenyl, benzyl, ^(d-Cealkyl^, or -S(C1- C6alkyl), wherein each of the foregoing phenyl, benzyl, and C],-C6alkyl groups is independently and optionally substituted, and wherein each of the foregoing Cj-C6alkyl groups is linear, branched, or cyclic.
52. The compound of claim 45, wherein R1 is Y-Rγ, wherein Y is a C1-C4alkylidene chain, wherein one or two non-adjacent methylene units of Y are optionally replaced by CO, CONR, SO2, NRSO2, SO2NR, O, S, or NR; and each occurrence of Rγ is independently selected from R\ OR', SR', or N(R')2.
53. The compound of claim 52, wherein R1 is optionally substituted C1-C4alkyl.
54. The compound of claim 53, wherein R1 is -CH3, -CH2CH3, -CH2CH2CH3, - CH2CH2CH2CH3, -(CH2)2OR\ -(CH2)3OR\ -(CH2)2N(R')2, -(CH2)3N(R')2, -(CH2)2NRCOR\ or -(CH2)3NRCOR\
55. The compound of claim 45, wherein R2 and R3 are each independently hydrogen, halogen, or an optionally substituted group selected from C1-6alkyl, aryl, aryl(C1-6)alkyl, -N(R')2, -CH2N(R')2, OR', -CH2OR', SR', -CH2SR', COOR', -NRCOR', -(CH2)2N(R')2, -(CH2)2OR\ - (CH2)2SR\ -COR', -C0N(R')2, SO2R', or -SO2N(R')2.
56. The compound of claim 55, wherein R2 and R3 are each independently H, Cl, Br, F, CF3, Me, Et, -COOH, NH2, -N(CH3)2, -N(Et)2, -N(iPr)2, -O(CH2)2OCH3, -CO(C1-C4alkyl), -CONH2, -COOCH3, -OH, -CH2OH, -NHCOCH3, -SO2(CrC4alkyl), -SO2NH2, -SO2N(CH3)2, or an optionally substituted group selected from C1-4alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.
57. The compound of claim 45, wherein R2 and R3 taken togeiher form a ring selected from:
Figure imgf000410_0001
a
Figure imgf000410_0002
g
Figure imgf000411_0001
k
Figure imgf000411_0002
m n o
Figure imgf000411_0003
Figure imgf000411_0004
U W
Figure imgf000411_0005
aa bb
Figure imgf000411_0006
CC dd ee ff 004/017673
Figure imgf000412_0001
gg hh
wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom may optionally be substituted with one or more independent occurrences of Q-Rx.
58. The compound of claim 57, wherein R2 and R3, taken together form an optionally substituted phenyl group and compounds have the formula II:
Figure imgf000412_0002
II
59. The compound of claim 45, wherein compounds have one of formulas H-A, H-B, H-C, II-D, or II-E:
Figure imgf000412_0003
II-A H-B II-C
Figure imgf000412_0004
17673
60. The compound of claim 59, wherein x is 0-4, and each occurrence of Q-Rx, when present, is independently halogen, CN, NO2, or an optionally substituted group selected from C1- 4alkyl, aryl, aralkyl, heteroaryl, a cycloalkyl or heterocycloalkyl group having 3-10 atoms, - N(R')2, -CH2N(IO2, -OR', -CH2OR', -SR', -SO2R', -CH2SR', -COOR', -NRCOR', -C0N(R')2, Or -S(O)2N(R')*
61. The method of claim 59. wherein each occurrence of Q-Rx, when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, -N(CH3)2, -N(Et)2, -N(IPr)2, -O(CH2)2OCH3, - CONH2, -COOCH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, - NHCOCH3, -SO2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole.
62. The compound of claim 45, wherein G2 is a Q-Csalkylidene chain or a C3-C6 spiroalkylidene ring, wherein one or two methylene units are optionally replaced by -NR'-, - N(SO2R')-, N(COR')-, -0-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the Cr C3alkylidene chain is optionally and independently substituted with R', and G3 is a C1- C3alkylidene chain wherein one or two methylene units are optionally replaced by -NR'-, - N(SO2R')-, N(COR')-, -0-, -S-, -CO-, -CS, or -SO2-, and wherein any hydrogen atom in the C1- C3alkylidene chain is optionally and independently substituted with R' .
63. The compound of claim 62, wherein G2 is-CHR', wherein R' is hydrogen, or optionally substituted d-Qalkyl and G3 is -(C(R')2)1-3-, -NR'-, -CO-, -SO2-, or -CONR-.
64. The compound of claim 45, wherein B is -NR'C(R')2NR'-, -NR'(C(R')2)2NR'-, -
NR'(C(R')2)3NR'-, -NR'(C(R')2)4NR'-, or is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure
Figure imgf000413_0001
wherein n is O, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R')2, -O-, -NR-, S, C=O, or C=S.
65. The compound of claim 64, wherein at least one of X1, X2, X3, X4, X5 or X6 is a nitrogen atom.
66. The compound of claim 64, wherein at least one of X or X is a nitrogen atom, and X , when present, X3, X4, and X6 are each C(R'>2.
67. The compound of claim 45, wherein B is an optionally substituted 5-, 6- or 7-membered
saturated, partially unsaturated or fully unsaturated ring having the structure
Figure imgf000414_0001
and compounds have the structure of formula III:
Figure imgf000414_0002
III wherein n is 0, 1, or 2; X2 and X5 are each independently CR' or N; and each occurrence of X1, when present, and X3, X4 and X6 are each independently, as valency and stability permit, C(R')2, -O-, -NR-, S, C=O, or C=S.
68. The compound of claim 67, wherein compounds have one of the structures HI-A, III-B, III-C, III-D or III-E:
Figure imgf000414_0003
III-A III-B
Figure imgf000415_0001
m e m-D
Figure imgf000415_0002
iπ-E
69. The compound of claim 67, wherein compounds have one of the structures IV-A, IV-B, IV-C, IV-D, or IV-E..
Figure imgf000415_0003
IV-A IV-B
Figure imgf000415_0004
IV-C IV-D
Figure imgf000415_0005
IV-E
70. The compound of claim 67, wherein compounds have one of the structures V-A, V-B, V- C, V-D, orV-E:
Figure imgf000416_0001
V-A V-B
Figure imgf000416_0002
V-E
The compound of claim 45, wherein Ar1 is selected from:
Figure imgf000416_0003
ii IU IV
Figure imgf000416_0004
Vl vii
Figure imgf000416_0005
VIU IX X Xl (WRw)m
Figure imgf000417_0002
Figure imgf000417_0001
XU xiii XlV XV
Figure imgf000417_0003
xvi XVH XVUl XlX
Figure imgf000417_0004
XX XXl XXU XXUl
Figure imgf000417_0005
XXVl XXVU
XXlV XXV
Figure imgf000417_0006
XXVlH XXlX XXX XXXl
Figure imgf000417_0007
XXXU xxxϋi XXXlV XXXV 004/017673
H
O N ,
\4^^ -(WRw)π Vi. Ti T -(WRw)n i 41 (WRW)
XXXVl XXXVU xxxviii
Figure imgf000418_0001
XXXlX XL XLi XLlI
Figure imgf000418_0002
xLiii XLlV XLV XLVl
wherein m is 0, 1, 2, 3, 4 or 5, and wherein any Ar1 is bonded to G3 through any substitutable nitrogen or carbon atom, and wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom is substituted with one or more independent occurrences of W-Rw.
72. The compound of claim 71 , wherein Ar1 is an optionally substituted group selected from i, ii, v, vi, vii, x, xLii, xLiii, xLiv, XLv, or xLvi.
73. The compound of claim 71, wherein Ar1 is an optionally substituted phenyl group (i).
74. The compound of claim 71, wherein W is a bond or is an optionally substituted C1-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by O, NR, S, SO2, or COO, CO, and Rw is R' or halogen.
75. The compound of claim 74, wherein each occurrence of WRW is independently -C1- 3alkyl, -O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), - US2004/017673
0(CH2)N(R)(R'), -CON(R)(R'), -(CHa)2OR', -(CH2)OR', optionally substituted phenyl, - N(R)(R'), -(CHa)2N(R)(R'), or -(CH2)N(R)(R').
76. The compound of claim 70 wherein:
R and RB are each independently hydrogen, an optionally substituted group selected from Q-Gzalkyl, C3-C7 cycloalkyl, or C3-C7 heterocyclyl, or RA and RB, taken together, form an optionally substituted 5-, 6-, or 7-membered heterocyclyl ring;
R1 is -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -(CH2)2OR\ -(CH2)3OR\ - (CH2)2N(R')2, -(CH2)3N(R')2, -(CH2)2NRCOR' , or -(CH2)3NRCOR\ x is 0, 1, or 2, and each occurrence of -Q-R , when present, is Cl, Br, F, CF3, methyl, ethyl, propyl, butyl, CN, -COOH, -N(CHs)2, -N(Et)2, -N(IPr)2, -O(CH2)2OCH3, -CONH2, - COOCH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -CH2OH, - NHCOCH3, -SO2NH2, or an optionally substituted group selected from piperidinyl, piperizinyl, morpholino, phenyl, phenyloxy, benzyl, benzyloxy, pyridyl, pyrimidinyl, pyridazinyl, thiophene, furan, thiazole, oxazole, thiadiazole, oxadiazole, pyrazole, or pyrrole; n is 1 and X1, X3, X4, and X6 are each CHR;
G2 is -(C(R')2)1-3-, -NR'-, -C(R')2NR\ or -NR'C(R')2-;
G3 is -(COEO2)L3-, -NR'-, -CO-, -SO2-, or -(C=O)NR'-;
Ar1 is selected from one of rings a-i through a-xLVi; and each occurrence of WRW is independently -C1-3alkyl, -O(Ci-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -C(O)N(R)(R'), - (CH2)2OR\ -(CH2)OR', optionally substituted phenyl, -N(R)(R'), -(CH2)2N(R)(R'), or - (CH2)N(R)(R').
77. The compound of claim 76, wherein G2 is CH(Ci-3alkyl) or spirocyclopropyl; G3 is -CO-, -SO2-, or -CONR-; and Ar1 is phenyl optionally substituted with -WRW.
78. A pharmaceutical composition comprising:
(i) a compound according to claim 45; and (ii) a pharmaceutically acceptable carrier.
79. The composition of claim 78, optionally further comprising an additional agent selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an antiinflammatory agent, CFTR modulator, or a nutritional agent.
80. A method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (I):
Figure imgf000420_0001
or a pharmaceutically acceptable salt thereof, wherein:
G1 is =0, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR' NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR' CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR5SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RA and RB, or any ring formed by RA and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR1CO2-, -O-, - NR'CONR'-, -OCONR'-, -NR'NR5, -NR5NR5CO-, -NR5CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR1SO2-, -NR5SO2NR5-, and each occurrence of Ru is independently R5, halogen, NO2, or CN,
R1 is absent or is Y-Rγ;
Y is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently 004/017673
R', OR', SR', N(R')2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is 0- 5;
T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -0C0NR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R' , halogen, NO2, or CN;
Q is a bond or is an optionally substituted Cj-C6 alkylidene chain wherein up to two methylene units of Q are optionally and independnetly replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rx is independently R' , halogen, NO2, or CN;
Figure imgf000421_0001
wherein G2 is absent, an optionally substituted C1-C6 alkylidene chain, or a C3-C6 spirocycloalkylidene ring, wherein one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -O-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
G3 is absent or an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO2., -NR'-, N(SO2R')-, N(COR')-, -O-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
B is absent or is an optionally substituted C6-1O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C1-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rw is independently R', halogen, NO2, or CN; provided that G2, B, G3, and Ar1 are not simultaneously absent.
The method of claim 80, wherein the ABC transporter is CFTR.
82. A kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo, comprising:
(i) a composition comprising a compound of formula (I):
RVVR1
I or a pharmaceutically acceptable salt thereof, wherein:
G1 is =O, -RA, -ORA, SRA, or NRARB, wherein RA and RB are each independently V-Rv, or RA and RB, taken together with the nitrogen atom, form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein V is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of V are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR7CO2-, -0-, -NR' CONR'-, -OCONR'-, -NR'NR', -NR'NR'CO-, -NR' CO-, - S-, -SO, -SO2-, -NR'-, -SO2NR'-, NR5SO2-, -NR5SO2NR'-, and each occurrence of Rv is independently R', halogen, NO2, or CN, and wherein RA and RB, or any ring formed by RΛ and RB taken together with the nitrogen atom, are optionally and independently substituted by q occurrences of U-Ru, wherein q is 0-5, U is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of U are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, - NR'CONR5-, -OCONR5-, -NR'NR', -NR'NR'CO-, -NR5CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, -NR5SO2NR'-, and each occurrence of Ru is independently R5, halogen, NO2, or CN,
R1 is absent or is Y-Rγ;
Y is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Y are optionally and independently replaced by -CO-, -CONR-, -0-, -NRCO-, -S-, -SO2-, -NR-, -SO2NR-, or -NRSO2-, and each occurrence of Rγ is independently R', OR5, SR', N(R')2, halogen, NO2, or CN, provided that when R1 is present, it is always bonded to the nitrogen atom through a carbon atom; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; and each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8- membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R , or two occurrences of R, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 and R3 are each independently halogen or -T-Rz, or R2 and R3, taken together, form an optionally substituted 5- or 6-membered monocyclic aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 5-, 6-, or 7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein any ring formed by R2 and R3 taken together is optionally substituted at one or more carbon atoms with x independent occurrences of Q-Rx, wherein x is 0- 5;
T is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rz is independently R', halogen, NO2, or CN;
Q is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of Q are optionally and independnetly replaced by -CO-, -CS-, -COCO-, - CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, - NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rx is independently R', halogen, NO2, or CN;
Figure imgf000424_0001
wherein G2 is absent, an optionally substituted Ci-C6 alkylidene chain, or a C3-C6 spirocycloalkylidene ring, wherein one or two methylene units in said alkylidene are optionally and independently replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, N(SO2R')-, N(COR')-, -O-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
G3 is absent or an optionally substituted C1-C6 alkylidene chain, wherein one or two methylene units are optionally and independently replaced with -CO-, -CS-, -SO-, - SO2-, -NR'-, N(SO2R')-, N(COR')-, -0-, or -S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R' ;
B is absent or is an optionally substituted C6-1O aryl, a heteroaryl ring having 5-10 ring atoms, a cycloalkyl or heterocyclyl ring having 3-10 ring atoms, or a C1-C6 alkylidene chain, wherein one or two methylene units in the alkylidene chain are optionally replaced with -CO-, -CS-, -SO-, -SO2-, -NR'-, -N(SO2R'), -N(COR')-, -O, or - S-, and wherein one or two hydrogen atoms of one or more methylene units are optionally substituted with R'; and
Ar1 is absent or is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar1 is optionally substituted with m independent occurrences of WRW, wherein m is 0-5 and W is a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, - NR-, -SO2NR-, -NRSO2-, -NRSO2NR-, and each occurrence of Rwis independently R', halogen, NO2, or CN; provided that G2, B, G3, and( Ar1 are not simultaneously absent; and (ii) instructions for: a) contacting the composition with the biological sample; b) measuring activity of said ABC transporter or a fragment thereof.
The kit of claim 82, further comprising instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said ABC transporter or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the ABC transporter in the presence of the additional compound with the density of the ABC transporter in the presence of a composition of formula (I).
The kit of claim 82, wherein the kit is used to measure the density of CFTR.
PCT/US2004/017673 2003-06-06 2004-06-04 Pyrimidine derivatives as modulators of atp-binding cassette transporters WO2004111014A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT04754303T ATE440825T1 (en) 2003-06-06 2004-06-04 PYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
DE602004022819T DE602004022819D1 (en) 2003-06-06 2004-06-04 TRANSPORTER OF ATP-BINDING CASSETTE
EP04754303A EP1646615B1 (en) 2003-06-06 2004-06-04 Pyrimidine derivatives as modulators of atp-binding cassette transporters
US10/862,909 US8642609B2 (en) 2003-06-06 2004-06-07 Modulators of ATP-binding cassette transporters

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47669803P 2003-06-06 2003-06-06
US60/476,698 2003-06-06
US50013203P 2003-09-04 2003-09-04
US60/500,132 2003-09-04
US52018103P 2003-11-14 2003-11-14
US60/520,181 2003-11-14

Publications (1)

Publication Number Publication Date
WO2004111014A1 true WO2004111014A1 (en) 2004-12-23

Family

ID=33556391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017673 WO2004111014A1 (en) 2003-06-06 2004-06-04 Pyrimidine derivatives as modulators of atp-binding cassette transporters

Country Status (5)

Country Link
US (1) US8642609B2 (en)
EP (1) EP1646615B1 (en)
AT (1) ATE440825T1 (en)
DE (1) DE602004022819D1 (en)
WO (1) WO2004111014A1 (en)

Cited By (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011623A1 (en) * 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
WO2007111921A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
JP2008534600A (en) * 2005-03-31 2008-08-28 タケダ サン ディエゴ インコーポレイテッド Hydroxysteroid dehydrogenase inhibitor
DE102007061756A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 4-aminopyrimidine-5-carboxylic acids and their use
DE102007061757A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 2-phenylpyrimidine-5-carboxylic acids and their use
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
JP2010509373A (en) * 2006-11-13 2010-03-25 イーライ リリー アンド カンパニー Thienopyrimidinone for the treatment of inflammatory diseases and cancer
CN101157645B (en) * 2007-11-27 2010-06-02 江南大学 Method for synthesizing saffron acid
JP2010521513A (en) * 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Aza-pyridopyrimidinone derivatives
US7863220B2 (en) 2003-12-19 2011-01-04 David Alan Clark Herbicidal pyrimidines
WO2011019737A1 (en) 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
WO2011119984A1 (en) 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
WO2012035158A1 (en) 2010-09-17 2012-03-22 Novartis Ag Pyrazine derivatives as enac blockers
EP2444120A1 (en) 2007-12-10 2012-04-25 Novartis AG Spirocyclic amiloride analogues as ENac blockers
US8198442B2 (en) 2005-05-06 2012-06-12 E.I. Du Pont De Nemours And Company Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
WO2012170061A1 (en) 2011-06-08 2012-12-13 Vertex Pharmaceuticals Incorporated Formulations of (r)-1-(2,2-diflurobenzo[d][1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methyl propan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2578571A1 (en) 2007-11-16 2013-04-10 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2013093812A2 (en) 2011-12-19 2013-06-27 Umc Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2615085A1 (en) 2008-03-31 2013-07-17 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2013112788A1 (en) 2012-01-26 2013-08-01 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
EP2627178A1 (en) * 2010-10-11 2013-08-21 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2013140319A1 (en) 2012-03-19 2013-09-26 Novartis Ag Crystalline form of a succinate salt
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8623905B2 (en) 2006-04-07 2014-01-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2014071122A1 (en) 2012-11-02 2014-05-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014086687A1 (en) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova A cftr corrector for the teatment of genetic disorders affecting striated muscle
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9062073B2 (en) 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
JP2015143249A (en) * 2008-12-24 2015-08-06 プラナ バイオテクノロジー リミティッド Quinazolinone compounds
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2016517895A (en) * 2013-05-07 2016-06-20 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Novel compounds for treating cystic fibrosis and pharmaceutical compositions thereof
WO2016113205A1 (en) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituted pentafluoroethyl pyrimidinones and use thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
EP3170818A1 (en) 2007-12-07 2017-05-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10208017B2 (en) 2012-06-01 2019-02-19 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same
US10214519B2 (en) 2016-09-23 2019-02-26 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10227350B2 (en) 2016-09-23 2019-03-12 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2019089693A1 (en) * 2017-10-31 2019-05-09 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors
CN110023289A (en) * 2015-10-05 2019-07-16 纽约市哥伦比亚大学理事会 The removing of the activator and the protein masses including TAU of autophagy tide and phospholipase D and the treatment of protein sickness
WO2019138012A1 (en) 2018-01-11 2019-07-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of sarcoglycanopathies
US10479770B2 (en) 2016-09-23 2019-11-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
EP3753932A1 (en) * 2019-06-17 2020-12-23 Esteve Pharmaceuticals, S.A. Substituted bicyclic derivatives having multimodal activity against pain
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN114502549A (en) * 2019-10-10 2022-05-13 埃斯特韦制药股份公司 Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264819C (en) * 1996-09-04 2010-03-23 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2007504136A (en) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
RU2006111093A (en) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
US7407976B2 (en) * 2003-11-14 2008-08-05 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
LT2489659T (en) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2597463A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
JP2008533031A (en) * 2005-03-09 2008-08-21 ニトロメッド インコーポレーティッド Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists
EP1888536B1 (en) 2005-05-16 2010-04-28 E.I. Du Pont De Nemours And Company Process for preparing substituted pyrimidines
MX2008002019A (en) * 2005-08-11 2008-04-16 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator.
SI2404919T1 (en) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocyclic compound useful as a modulator of ATP-binding cassette transporters.
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
RS60205B1 (en) 2005-12-28 2020-06-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2635760C (en) 2005-12-28 2014-07-15 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8003651B2 (en) * 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2049546B1 (en) 2006-07-06 2010-12-29 Array Biopharma, Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
SI2054418T1 (en) 2006-07-06 2012-02-29 Array Biopharma Inc Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8377937B2 (en) * 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ583420A (en) 2007-08-24 2012-06-29 Vertex Pharma Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PT2639222T (en) * 2007-12-07 2016-11-01 Vertex Pharma Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
CA2708146A1 (en) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
RU2504542C2 (en) * 2008-01-09 2014-01-20 Эррэй Биофарма Инк. Hydroxylated pyrimidylcyclopentanes as protein kinase (akt) inhibitors
ES2647531T3 (en) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
MX2011001196A (en) * 2008-07-31 2011-05-30 Genentech Inc Pyrimidine compounds, compositions and methods of use.
CN102164587A (en) 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 Dosage units of 3-(6-(1-(2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
PT2349263E (en) * 2008-10-23 2014-07-28 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
KR101955863B1 (en) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
RU2607635C2 (en) * 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-substituted purine compounds, compositions and methods of use
WO2011058025A1 (en) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
KR20140025434A (en) 2011-04-01 2014-03-04 제넨테크, 인크. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
EP2694073B1 (en) 2011-04-01 2018-08-08 Genentech, Inc. Combinations of akt and mek inhibitors for treating cancer
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PE20150776A1 (en) 2012-09-10 2015-05-21 Hoffmann La Roche 6-AMINO ACID-HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
PL3068392T3 (en) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
RU2749213C2 (en) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Co-crystals of transmembrane conduction regulator modulators in cystic fibrosis
JP6494757B2 (en) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Process for high-throughput high performance liquid chromatography
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
JP6896715B2 (en) 2015-09-30 2021-06-30 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング Heteroaryl derivative as sepiapterin reductase
BR112023005189A2 (en) 2020-09-21 2023-04-25 Landos Biopharma Inc NLRX1 LIGANDS

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624084A (en) * 1967-01-25 1971-11-30 Ucb Sa 2,4,6-trisubstituted derivatives of pyrimidine
US3984555A (en) * 1970-06-05 1976-10-05 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung Therapeutic piperazinylalkyl-quinazolone-(4)-derivatives
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO2000064424A2 (en) * 1999-04-22 2000-11-02 University Of Wales College Of Medicine Cystic fibrosis medicaments
WO2001021598A1 (en) * 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
WO2002048117A1 (en) * 2000-12-11 2002-06-20 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6479499B1 (en) * 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
WO2003020280A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer
WO2003039460A2 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003059884A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
WO2003076418A1 (en) * 2002-03-07 2003-09-18 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
WO2003084544A2 (en) * 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
WO2004024162A1 (en) * 2002-09-10 2004-03-25 Phenex Pharmaceuticals Ag 2-amino-4-quinazolinones as lxr nuclear receptor binding compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127401A (en) * 1964-03-31 Z-benzyl-j
TW294595B (en) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
ES2231992T3 (en) * 1997-07-07 2005-05-16 Kowa Co., Ltd. DIAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
BR0113585A (en) * 2000-08-31 2003-07-29 Hoffmann La Roche Quinazoline derivatives as alpha-1 adrenergic antagonists
US6632810B2 (en) * 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624084A (en) * 1967-01-25 1971-11-30 Ucb Sa 2,4,6-trisubstituted derivatives of pyrimidine
US3984555A (en) * 1970-06-05 1976-10-05 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung Therapeutic piperazinylalkyl-quinazolone-(4)-derivatives
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO2000064424A2 (en) * 1999-04-22 2000-11-02 University Of Wales College Of Medicine Cystic fibrosis medicaments
WO2001021598A1 (en) * 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
US6479499B1 (en) * 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
WO2002048117A1 (en) * 2000-12-11 2002-06-20 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
WO2003020280A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer
WO2003039460A2 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003059884A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
WO2003076418A1 (en) * 2002-03-07 2003-09-18 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
WO2003084544A2 (en) * 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
WO2004024162A1 (en) * 2002-09-10 2004-03-25 Phenex Pharmaceuticals Ag 2-amino-4-quinazolinones as lxr nuclear receptor binding compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"ComGenex Product List", 23 June 2003, COMGENEX INTERNATIONAL INC., MONMOUTH, NJ, 08852, US *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2000, XP002298957 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2001, XP002298958 *

Cited By (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863220B2 (en) 2003-12-19 2011-01-04 David Alan Clark Herbicidal pyrimidines
US8802597B2 (en) 2003-12-19 2014-08-12 E I Du Pont De Nemours And Company Herbicidal pyrimidines
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JP2008534600A (en) * 2005-03-31 2008-08-28 タケダ サン ディエゴ インコーポレイテッド Hydroxysteroid dehydrogenase inhibitor
JP2012255004A (en) * 2005-03-31 2012-12-27 Takeda California Inc Hydroxysteroid dehydrogenase inhibitor
US8198442B2 (en) 2005-05-06 2012-06-12 E.I. Du Pont De Nemours And Company Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids
WO2007011623A1 (en) * 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
US7524848B2 (en) 2006-03-23 2009-04-28 Amgen Inc. Diaza heterocyclic amide compounds and their uses
WO2007111921A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
US8138190B2 (en) 2006-03-23 2012-03-20 Amgen Inc. Diaza heterocyclic amide compounds and their uses
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US10987348B2 (en) 2006-04-07 2021-04-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8952050B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8623905B2 (en) 2006-04-07 2014-01-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10239867B2 (en) 2006-04-07 2019-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8952049B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP2010509373A (en) * 2006-11-13 2010-03-25 イーライ リリー アンド カンパニー Thienopyrimidinone for the treatment of inflammatory diseases and cancer
JP2010521513A (en) * 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Aza-pyridopyrimidinone derivatives
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
EP2578571A1 (en) 2007-11-16 2013-04-10 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
EP3012250A1 (en) 2007-11-16 2016-04-27 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
CN101157645B (en) * 2007-11-27 2010-06-02 江南大学 Method for synthesizing saffron acid
EP3170818A1 (en) 2007-12-07 2017-05-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP3683218A1 (en) 2007-12-07 2020-07-22 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2444120A1 (en) 2007-12-10 2012-04-25 Novartis AG Spirocyclic amiloride analogues as ENac blockers
EP2520574A1 (en) 2007-12-10 2012-11-07 Novartis AG Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases
DE102007061756A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 4-aminopyrimidine-5-carboxylic acids and their use
DE102007061757A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 2-phenylpyrimidine-5-carboxylic acids and their use
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2615085A1 (en) 2008-03-31 2013-07-17 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
EP2980077A1 (en) 2008-03-31 2016-02-03 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP2015143249A (en) * 2008-12-24 2015-08-06 プラナ バイオテクノロジー リミティッド Quinazolinone compounds
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
WO2011019737A1 (en) 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2464354A1 (en) * 2009-08-10 2012-06-20 The Regents of the University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US8609661B2 (en) 2009-08-10 2013-12-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
CN102695510A (en) * 2009-08-10 2012-09-26 加利福尼亚大学董事会 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2464354A4 (en) * 2009-08-10 2013-03-27 Univ California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8933069B2 (en) 2010-02-17 2015-01-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9388195B2 (en) 2010-02-17 2016-07-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8921354B2 (en) 2010-02-17 2014-12-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9655900B2 (en) 2010-02-17 2017-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP3835297A1 (en) 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthesis and intermediates of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
EP3181561A1 (en) 2010-03-25 2017-06-21 Vertex Pharmaceuticals Incorporated Synthetic intermediate of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
WO2011119984A1 (en) 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP4253381A2 (en) 2010-03-25 2023-10-04 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2826776A1 (en) 2010-03-25 2015-01-21 Vertex Pharmaceuticals Incorporated Solid amorphous form of (R)-1(2,2-difluorobenzo(D)(1,3)dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)-cyclopropanecarboxamide
EP4005559A1 (en) 2010-04-07 2022-06-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP3150198A1 (en) 2010-04-07 2017-04-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
EP3381899A1 (en) 2010-04-22 2018-10-03 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
WO2012035158A1 (en) 2010-09-17 2012-03-22 Novartis Ag Pyrazine derivatives as enac blockers
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
EP2627178A1 (en) * 2010-10-11 2013-08-21 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2627178A4 (en) * 2010-10-11 2014-08-20 Merck Sharp & Dohme Quinazolinone-type compounds as crth2 antagonists
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9062073B2 (en) 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012170061A1 (en) 2011-06-08 2012-12-13 Vertex Pharmaceuticals Incorporated Formulations of (r)-1-(2,2-diflurobenzo[d][1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methyl propan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
USRE46942E1 (en) 2011-07-13 2018-07-10 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2013093812A2 (en) 2011-12-19 2013-06-27 Umc Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US11035852B2 (en) 2011-12-19 2021-06-15 Umc Utrecht Holding, B.V. Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells
US10006904B2 (en) 2011-12-19 2018-06-26 Umc Utrecht Holding B.V. Rapid quantitative assay to measure CFTR function in a primary intestinal culture model
EP3045912A1 (en) 2011-12-19 2016-07-20 UMC Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2013112788A1 (en) 2012-01-26 2013-08-01 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
JP2015511224A (en) * 2012-01-26 2015-04-16 ピーティーシー セラピューティクス， インコーポレイテッド Compounds for treating spinal muscular atrophy
US9399649B2 (en) 2012-01-26 2016-07-26 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP2809322A4 (en) * 2012-01-26 2015-12-23 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
EP2809322A1 (en) * 2012-01-26 2014-12-10 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2013140319A1 (en) 2012-03-19 2013-09-26 Novartis Ag Crystalline form of a succinate salt
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10562883B2 (en) 2012-06-01 2020-02-18 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same
US10208017B2 (en) 2012-06-01 2019-02-19 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
WO2014071122A1 (en) 2012-11-02 2014-05-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
EP3470063A1 (en) 2012-11-02 2019-04-17 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
WO2014086687A1 (en) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova A cftr corrector for the teatment of genetic disorders affecting striated muscle
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP2016517895A (en) * 2013-05-07 2016-06-20 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Novel compounds for treating cystic fibrosis and pharmaceutical compositions thereof
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3925607A1 (en) 2014-04-15 2021-12-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP4223294A1 (en) 2014-04-15 2023-08-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3424534A1 (en) 2014-04-15 2019-01-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
WO2016113205A1 (en) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituted pentafluoroethyl pyrimidinones and use thereof
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
CN110023289A (en) * 2015-10-05 2019-07-16 纽约市哥伦比亚大学理事会 The removing of the activator and the protein masses including TAU of autophagy tide and phospholipase D and the treatment of protein sickness
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US10227350B2 (en) 2016-09-23 2019-03-12 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10214519B2 (en) 2016-09-23 2019-02-26 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10479770B2 (en) 2016-09-23 2019-11-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11103508B2 (en) 2017-10-31 2021-08-31 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
US11524010B2 (en) 2017-10-31 2022-12-13 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
AU2018357933B2 (en) * 2017-10-31 2019-11-21 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
US11752153B2 (en) 2017-10-31 2023-09-12 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
WO2019089693A1 (en) * 2017-10-31 2019-05-09 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019138012A1 (en) 2018-01-11 2019-07-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of sarcoglycanopathies
US11298348B2 (en) 2018-01-11 2022-04-12 Inserm (Institut National De La Sante Et De La Recherche Médicale) Combination treatment of sarcoglycanopathies
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3753932A1 (en) * 2019-06-17 2020-12-23 Esteve Pharmaceuticals, S.A. Substituted bicyclic derivatives having multimodal activity against pain
CN114502549A (en) * 2019-10-10 2022-05-13 埃斯特韦制药股份公司 Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain

Also Published As

Publication number Publication date
US8642609B2 (en) 2014-02-04
US20050059687A1 (en) 2005-03-17
DE602004022819D1 (en) 2009-10-08
ATE440825T1 (en) 2009-09-15
EP1646615B1 (en) 2009-08-26
EP1646615A1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
EP1646615B1 (en) Pyrimidine derivatives as modulators of atp-binding cassette transporters
AU2004290581B2 (en) Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
EP1865949B1 (en) Modulators of ATP-binding cassette transporters
JP6035259B2 (en) Heteroaryl derivatives as CFTR modifiers
AU2008256717B2 (en) Modulators of cystic fibrosis transmembrane conductance regulator
EP2615085B1 (en) Pyridyl derivatives as CFTR modulators
EP1716122B1 (en) Modulators of atp-binding cassette transporters
AU2015228930B2 (en) Heteroaryl derivatives as CFTR modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10862909

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004754303

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004754303

Country of ref document: EP